TOHOKU UNIVERSITY Researchers

Details of the Researcher

Home

日本語 English

Akira Inoue

Section

Graduate School of Medicine

Job title

Professor

Degree

博士（医学）（東北大学）

researchmap

https://researchmap.jp/ino4081

J-GLOBAL ID

200901056402122084

Committee Memberships 6

日本緩和医療学会　編集委員

2010/04 - Present
日本緩和医療学会　編集委員

2010/04 - Present
日本臨床腫瘍学会　評議員

2009/03 - Present
日本臨床腫瘍学会　評議員

2009/03 - Present
日本肺癌学会　評議員

2008/11 - Present
日本肺癌学会　評議員

2008/11 - Present

Show all ︎Show first 5

Professional Memberships 3

日本緩和医療学会(2010/04- 編集委員)
日本臨床腫瘍学会(2009/03- 評議員)
日本肺癌学会(2008/11- 評議員)

Research Areas 1

Life sciences / Tumor diagnostics and therapeutics /

Awards 4

第9回日本学術振興会賞

2013/02
東北医学会奨学賞Ａ

2011/01/14　東北医学会
奨励賞

2010/04/22　日本呼吸器学会
篠井・河合賞

2009/11　日本肺癌学会

Papers 187

Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database

Satoshi Ikeda, Takashi Ogura, Etsuo Miyaoka, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Masahiro Seike, Kazuhisa Takahashi, Nobuyuki Yamamoto, Masaya Yotsukura, Shun-ichi Watanabe, Yasushi Shintani

Lung Cancer　2025/02

DOI： 10.1016/j.lungcan.2025.108102 　
Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study

Yusuke Hiratsuka, Keita Tagami, Akira Inoue, Mamiko Sato, Yasufumi Matsuda, Kazuhiro Kosugi, Emi Kubo, Maika Natsume, Hiroto Ishiki, Sayaka Arakawa, Masaki Shimizu, Naosuke Yokomichi, Shih-Wei Chiu, Mayu Shimoda, Hideyuki Hirayama, Kaoru Nishijima, Kota Ouchi, Tatsunori Shimoi, Tomoko Shigeno, Takuhiro Yamaguchi, Mitsunori Miyashita, Tatsuya Morita, Eriko Satomi

Supportive Care in Cancer　31　(12)　2023/10/16
Publisher: Springer Science and Business Media LLC
DOI： 10.1007/s00520-023-08099-2 　

ISSN： 0941-4355

eISSN： 1433-7339

More details Close

Abstract Purpose Although opioids have been shown to be effective for cancer pain, opioid-induced adverse events (AEs) are common. To date, little is known about the differences in risks of AEs by opioid type. This study was performed to compare the prevalence of AEs across opioids commonly used for analgesic treatment in Japan. Methods This study was conducted as a preplanned secondary analysis of a multicenter prospective longitudinal study of inpatients with cancer pain who received specialized palliative care for cancer pain relief. We assessed daily AEs until termination of follow-up. We rated the severity of AEs based on the Common Terminology Criteria for Adverse Events version 5.0. We computed adjusted odds ratios for each AE (constipation, nausea and vomiting, delirium, and drowsiness) with the following variables: opioid, age, sex, renal dysfunction, and primary cancer site. Results In total, 465 patients were analyzed. Based on the descriptive analysis, the top four most commonly used opioids were included in the analysis: oxycodone, hydromorphone, fentanyl, and tramadol. With respect to the prevalence of AEs among all analyzed patients, delirium (n = 25, 6.3%) was the most frequent, followed by drowsiness (n = 21, 5.3%), nausea and vomiting (n = 19, 4.8%), and constipation (n = 28, 4.6%). The multivariate logistic analysis showed that no single opioid was identified as a statistically significant independent predictor of any AE. Conclusion There was no significant difference in the prevalence of AEs among oxycodone, fentanyl, hydromorphone, and tramadol, which are commonly used for analgesic treatment in Japan.
Cancer Pain Management in Patients Receiving Inpatient Specialized Palliative Care Services Peer-reviewed

Keita Tagami, Shih-Wei Chiu, Kazuhiro Kosugi, Hiroto Ishiki, Yusuke Hiratsuka, Masaki Shimizu, Masanori Mori, Emi Kubo, Tomoo Ikari, Sayaka Arakawa, Tetsuya Eto, Mayu Shimoda, Hideyuki Hirayama, Kaoru Nishijima, Kota Ouchi, Tatsunori Shimoi, Tomoko Shigeno, Takuhiro Yamaguchi, Mitsunori Miyashita, Tatsuya Morita, Akira Inoue, Eriko Satomi

Journal of Pain and Symptom Management　2023/09
Publisher: Elsevier BV
DOI： 10.1016/j.jpainsymman.2023.09.015 　

ISSN： 0885-3924
Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. International-journal

Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi, Tomohiro Sakakibara, Toshiyuki Harada, Kazuhiro Usui, Akira Inoue, Shunichi Sugawara

Thoracic cancer　2023/08/17

DOI： 10.1111/1759-7714.15076 　

More details Close

BACKGROUND: This phase II trial was designed to evaluate the efficacy and safety of S-1 combined with weekly irinotecan as a second- or third-line treatment for patients with advanced or recurrent squamous cell lung cancer. METHODS: Patients with a body surface area <1.25, 1.25-1.50, and >1.50 m2 received oral S-1 on days 1-14 at 80, 100, and 120 mg/day, respectively, and irinotecan on days 1 and 8 at 70 mg/m2 every 3 weeks. The primary endpoint was the overall response rate, and the secondary endpoints were progression-free survival, overall survival, and the incidence and severity of adverse effects. RESULTS: Between September 2011 and December 2014, 30 patients were enrolled in this study. The overall response rate was 6.7% (95% confidence interval [CI]: 0.8%-22.1%), and the disease control rate was 73.3%. The median progression-free survival was 3.0 months (95% CI: 2.5-3.4 months), and the median overall survival was 10.5 months (95% CI: 5.6-13.7 months). Grade 3/4 treatment-related adverse events were reported in ≥10% of the patients, including leukopenia (21%), neutropenia (21%), anemia (17%), anorexia (10%), and hypokalemia (10%). CONCLUSIONS: Although the treatment-related adverse events were manageable, the combination of weekly irinotecan and S-1 did not have the expected effect.
専門的緩和ケアサービスが提供する標準的がん疼痛治療による疼痛改善理由の探索多施設共同観察研究から得られた質的データの内容分析

菅原佑菜, 田上恵太, 升川研人, 倉橋美岬, 菊池里美, 小杉和博, 石木寛人, 平塚裕介, 清水正樹, 森雅紀, 邱士い, 下田真優, 平山英幸, 山口拓洋, 井上彰, 里見絵理子, 宮下光令

Palliative Care Research　18　(Suppl.)　S196-S196　2023/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
緩和ケア病棟に入院した終末期がん患者の家族の予期悲嘆と死別後反応への影響

宮下光令, 後藤玲凪, 清水陽一, 林章敏, 前田一石, 三浦智史, 井上彰, 高野真優子, 石垣和美, 升川研人, 青山真帆, 森田達也, 木澤義之, 恒藤暁, 志真靖夫

Palliative Care Research　18　(Suppl.)　S225-S225　2023/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
緩和ケア病棟に入院した終末期がん患者の家族の予期悲嘆と死別後反応への影響

宮下光令, 後藤玲凪, 清水陽一, 林章敏, 前田一石, 三浦智史, 井上彰, 高野真優子, 石垣和美, 升川研人, 青山真帆, 森田達也, 木澤義之, 恒藤暁, 志真靖夫

Palliative Care Research　18　(Suppl.)　S225-S225　2023/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
高齢者肺扁平上皮肺癌における2次治療のICIの検討 CAPITAL試験の事後解析

小暮啓人, 嘉田晃子, 橋本大哉, 安宅信二, 滝口裕一, 坂英雄, 海老規之, 井上彰, 倉田宝保, 藤田結花, 西井洋一, 井谷英敏, 遠藤健夫, 柴山卓夫, 山本信之, 弦間昭彦

肺癌　62　(6)　650-650　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
高齢者肺扁平上皮肺癌における2次治療のICIの検討 CAPITAL試験の事後解析

小暮啓人, 嘉田晃子, 橋本大哉, 安宅信二, 滝口裕一, 坂英雄, 海老規之, 井上彰, 倉田宝保, 藤田結花, 西井洋一, 井谷英敏, 遠藤健夫, 柴山卓夫, 山本信之, 弦間昭彦

肺癌　62　(6)　650-650　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
進行非小細胞肺癌(NSCLC)に対する化学療法の実施状況に関する多施設調査

井上彰, 川嶋庸介, 守田亮, 中川拓, 鶴見恭士, 田中寿志, 野川ひとみ, 長島広相, 柳澤悟, 菊池創, 木村望, 千葉茂樹, 菊池崇史, 宮内栄作

肺癌　62　(6)　778-778　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR. International-journal

Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, Yukio Hosomi, Kana Watanabe, Satoshi Ikeda, Masahiro Seike, Yuka Fujita, Koichi Minato, Ryo Ko, Toshiyuki Harada, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue

Journal of clinical oncology : official journal of the American Society of Clinical Oncology　40　(31)　JCO2102911-3592　2022/08/12

DOI： 10.1200/JCO.21.02911 　

More details Close

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In a randomized, open-label, phase III NEJ009 study, gefitinib plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared with gefitinib-alone in patients with untreated non-small-cell lung cancer harboring mutations in epidermal growth factor receptor. Herein, we report the updated survival outcome and long-term tolerability. Patients were randomly assigned to gefitinib (gefitinib 250 mg orally, once daily) and gefitinib combined with carboplatin plus pemetrexed (GCP in a 3-week cycle for six cycles followed by concurrent gefitinib and pemetrexed maintenance) groups. At the data cutoff (May 22, 2020), GCP demonstrated significantly better PFS2 (hazard ratio, 0.77; 95% CI, 0.62 to 0.97; P = .027) than gefitinib. However, the updated median OS was 38.5 months (95% CI, 31.1 to 47.1) and 49.0 months (95% CI, 41.8 to 56.7) in the gefitinib and GCP groups, respectively (hazard ratio, 0.82; 95% CI, 0.64 to 1.06; P = .127). The OS in both groups was similar for the overall patient population. No severe adverse events occurred since the first report. This updated analysis revealed that the GCP regimen improved PFS and PFS2 with an acceptable safety profile compared with gefitinib-alone. GCP is more efficient than gefitinib monotherapy as a first-line treatment for non-small-cell lung cancer with epidermal growth factor receptor mutations.
本邦におけるがん疼痛への鎮痛補助薬の選択基準、使用方法の調査日本緩和医療学会専門医へのアンケート調査

田上恵太, 松岡弘道, 有吉恵介, 小山田隼佑, 井上彰

Palliative Care Research　17　(Suppl.)　S.243-S.243　2022/07
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
Development and Validation of the Death Pronouncement Burden Scale for Oncology Practice International-journal Peer-reviewed

Yusuke Hiratsuka, Mitsunori Miyashita, Yu Uneno, Kiyohumi Oya, Soichiro Okamoto, Takaomi Kessoku, Hironori Mawatari, Shunsuke Oyamada, Junko Nozato, Keita Tagami, Akira Inoue

Palliative Medicine Reports　3　(1)　39-46　2022/04/08
Publisher: Mary Ann Liebert Inc
DOI： 10.1089/pmr.2021.0082 　

eISSN： 2689-2820

More details Close

Background: Informing families of a patient's death is one of the most challenging responsibilities of clinicians who provide care for terminally ill patients. Although death pronouncement can be a highly stressful event for clinicians, no previous study has reported qualitative characteristics of the burden experienced by clinicians related to death pronouncements. Moreover, no scale has been developed to assess this burden. Objective: This study sought to develop a scale to evaluate clinicians' burden related to death pronouncement (Death Pronouncement Burden Scale for oncology practice [DPBS-oncol]) and examine its reliability and validity in Japan. Methods: We presented the DPBS-oncol to clinicians involved in oncology practice and examined its reliability and discriminant validity. To investigate the test-retest reliability of the scale, the DPBS-oncol was presented a second time to a subsample of the clinicians. Results: Factor analysis required a grouping of the 15 DPBS-oncol items into one factor. Cronbach's α coefficient of the total score of DPBS-oncol was 0.94, and the intraclass correlation coefficient of the total score of DPBS-oncol was 0.89. Regarding discriminant validity, DPBS-oncol total score was moderately correlated with other available scales for assessing clinicians' attitudes to end-of-life care. Conclusion: This study was the first to develop a scale to evaluate clinicians' burden related to death pronouncement. The DPBS-oncol, which includes 15 items, was validated and shown to have sufficient reliability.
Epidemiology of Respiration with Mandibular Movement in Advanced Cancer Patients: A Multicenter Prospective Cohort Study

Keisuke Kaneishi, Tatsuya Morita, Hiroyuki Kohara, Tetsuya Ito, Jun Nakagawa, Tomohiro Nishi, Akira Inoue, Shunsuke Oyamada, Masanori Mori

Journal of Palliative Medicine　2021/12/29
Publisher: Mary Ann Liebert Inc
DOI： 10.1089/jpm.2021.0328 　

ISSN： 1096-6218

eISSN： 1557-7740
Factors related to specialized palliative care use and aggressive care at end of life in Japanese patients with advanced solid cancers: a cohort study. International-journal

Yusuke Hiratsuka, Takayuki Oishi, Mitsunori Miyashita, Tatsuya Morita, Jennifer W Mack, Yuko Sato, Masahiro Takahashi, Keigo Komine, Ken Saijo, Chikashi Ishioka, Akira Inoue

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　29　(12)　7805-7813　2021/12

DOI： 10.1007/s00520-021-06364-w 　

More details Close

PURPOSE: This study aimed to (1) describe characteristics of aggressive care at the end of life (EOL) and (2) identify factors associated with specialized palliative care use (SPC) and aggressive care at the EOL among Japanese patients with advanced cancer. METHODS: This single-center, follow-up cohort study involved patients with advanced cancer who received chemotherapy at Tohoku University Hospital. Patients were surveyed at enrollment, and we followed clinical events for 5 years from enrollment in the study. We performed multivariate logistic regression analysis to identify independent factors related to SPC use and chemotherapy in the last month before death. RESULTS: We analyzed a total of 135 patients enrolled between January 2015 and January 2016. No patients were admitted to the intensive care unit, and few received resuscitation or ventilation. We identified no factors significantly associated with SPC use. Meanwhile, younger age (20-59 years, odds ratio [OR] 4.10; 95% confidence interval [CI] 1.30-12.91; p = 0.02) and no receipt of SPC (OR 4.32; 95% CI 1.07-17.37; p = 0.04) were associated with chemotherapy in the last month before death. CONCLUSION: Younger age and a lack of SPC were associated with chemotherapy at the EOL in patients with advanced cancer in Japan. These findings suggest that Japanese patients with advanced cancer may benefit from access to SPC.
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial

Yoshihito Kogure, Shunichiro Iwasawa, Hideo Saka, Yoichiro Hamamoto, Akiko Kada, Hiroya Hashimoto, Shinji Atagi, Yuichi Takiguchi, Noriyuki Ebi, Akira Inoue, Takayasu Kurata, Isamu Okamoto, Masafumi Yamaguchi, Toshiyuki Harada, Masahiro Seike, Masahiko Ando, Akiko M Saito, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Nobuyuki Yamamoto, Akihiko Gemma

The Lancet Healthy Longevity　2　(12)　e791-e800　2021/12
Publisher: Elsevier BV
DOI： 10.1016/s2666-7568(21)00255-5 　

ISSN： 2666-7568
Is the 1-day surprise question a useful screening tool for predicting prognosis in patients with advanced cancer?-a multicenter prospective observational study. International-journal

Tomoo Ikari, Yusuke Hiratsuka, Takuhiro Yamaguchi, Masanori Mori, Yu Uneno, Tomohiko Taniyama, Yosuke Matsuda, Kiyofumi Oya, Koji Amano, Keita Tagami, Akira Inoue

Annals of palliative medicine　10　(11)　11278-11287　2021/11

DOI： 10.21037/apm-21-1718 　

More details Close

BACKGROUND: For cancer patients nearing death, the prediction of their prognosis by physicians is crucial. This study examined the usefulness of the 1-Day Surprise Question (1DSQ). METHODS: This study was conducted as part of a multicenter prospective observational study. The physicians answered the 1DSQ "Would I be surprised if this patient died in the next 1 day?" when patients have palliative performance scale (PPS) ≤20. We calculated the sensitivity and specificity of the 1DSQ. Moreover, using multivariate analysis, we evaluated the characteristics of patients who died among those whose physicians answered the 1DSQ as "not surprised". RESULTS: Overall, 1,896 patients were enrolled, and 1,411 (74.4%) were analyzed between January and December 2017. Among these, 847 (60.0%) patients were placed in the "not surprised" group. The sensitivity, specificity, and positive and negative predictive values of the 1DSQ were 82.0% [95% confidence interval (CI): 77.5-85.8%], 45.5% (95% CI: 44.4-46.4%), 27.4% (95% CI: 25.9-28.7%), and 91.0% (95% CI: 88.9-92.9%), respectively. Multivariate analysis revealed that urine output over last 12 hours <100 mL, decreased response to visual stimuli, respiration with mandibular movement, pulselessness of radial artery, and saturation of percutaneous oxygen <90% were characteristics of patients who died as predicted by the physicians. CONCLUSIONS: The 1DSQ is a helpful screening tool for identifying cancer patients with impending death.
Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402. International-journal

Eisaku Miyauchi, Hisashi Tanaka, Atsushi Nakamura, Toshiyuki Harada, Taku Nakagawa, Mami Morita, Daisuke Jingu, Tomoya Kuda, Shunichi Gamou, Ryota Saito, Akira Inoue

Thoracic cancer　2021/09/14

DOI： 10.1111/1759-7714.14149 　

More details Close

BACKGROUND: NJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin-bound paclitaxel (nab-PTX) in patients with advanced non-small cell lung cancer (NSCLC). METHODS: The study included patients aged ≥20 years with previously treated NSCLC. Nab-PTX (100-150 mg/m2 ) was administered biweekly in a 28-day cycle. The phase I portion was performed to determine the recommended phase II dose of nab-PTX. In the phase II portion, the primary endpoint was the objective response rate. Secondary endpoints were disease control rate, progression-free survival, overall survival, and safety. RESULTS: A total of 15 patients received biweekly nab-PTX (100-150 mg/m2 ) and 12 patients in phase II were treated with 150 mg/m2 . In the phase I portion, 150 mg/m2 was determined as the recommended dose. Among those treated with 150 mg/m2 , the objective response rate was 22%, and the median progression-free and overall survival was 3.6 and 11.2 months, respectively. Adverse events grade ≥3 were observed in 39% of patients. CONCLUSIONS: Biweekly nab-PTX monotherapy was well tolerated and exhibited favorable antitumor activity in patients with previously treated NSCLC.
Appropriate referral timing to specialized palliative care service: survey of bereaved families of cancer patients who died in palliative care units. International-journal

Keita Tagami, Kento Masukawa, Akira Inoue, Tatsuya Morita, Yusuke Hiratsuka, Mamiko Sato, Katsura Kohata, Noriaki Satake, Yoshiyuki Kizawa, Satoru Tsuneto, Yasuo Shima, Mitsunori Miyashita

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　30　(1)　931-940　2021/08/21

DOI： 10.1007/s00520-021-06493-2 　

More details Close

Few studies have investigated appropriate referral timing of specialized palliative care (SPC) from the perspective of cancer patients' and families' experiences. We aimed to clarify appropriate SPC referral timing for patients with advanced cancer and their families. We used data from a nationwide bereaved family survey in Japan. We sent a questionnaire to 999 bereaved families of cancer patients who died in 164 palliative care units (PCUs) and analyzed the first SPC referral timing and how patients evaluated it. We defined SPC as outpatient or inpatient palliative care service comprising certified palliative care physicians, advanced-practice nurses, and multidisciplinary practitioners. Finally, 51.6% (n = 515) of all responses were analyzed. The SPC referral timing was evaluated as appropriate (26.1%), late or too late (20.2%), early or too early (1.2%), or none of these (52.5%). Of these, 32.3% reported that they were referred to an SPC when diagnosed with advanced or incurable cancer or during anti-cancer treatment, and 62.6% reported they were referred after anti-cancer treatment. Patient-perceived appropriateness of SPC referral timing was associated with their good death process. After excluding "none of these" responses, a significantly higher proportion of respondents who reported being referred to SPC at diagnosis and during anti-cancer treatment evaluated the response timing as appropriate, compared to those who reported being referred after anti-cancer treatment. Appropriate timing for SPC referrals relates to quality of death; findings suggest that appropriate timing is at the time of diagnosis or during anti-cancer treatment.
Changes in depressive symptoms among family caregivers of patients with cancer after bereavement and their association with resilience: A prospective cohort study. International-journal

Yoichi Shimizu, Akitoshi Hayashi, Isseki Maeda, Tomofumi Miura, Akira Inoue, Mayuko Takano, Maho Aoyama, Yutaka J Matsuoka, Tatsuya Morita, Yoshiyuki Kizawa, Satoru Tsuneto, Yasuo Shima, Kento Masukawa, Mitsunori Miyashita

Psycho-oncology　31　(1)　86-97　2021/08/03

DOI： 10.1002/pon.5783 　

More details Close

OBJECTIVES: To elucidate changes in depressive symptoms after bereavement and the impact of pre-loss resilience on such changes and on the extent of complicated grief and posttraumatic growth. METHODS: Prospective cohort surveys were provided to family caregivers of patients with cancer in four palliative care units (PCUs) before and after bereavement. Pre-loss Connor-Davidson Resilience Scale scores, pre- and post-loss Patient Health Questionnaire-9 scores, post-loss Brief Grief Questionnaire scores, and the expanded Posttraumatic Growth Inventory scores were determined. RESULTS: Out of 186 bereaved family caregivers, 71 (38.2%) responses were analyzed, among which 47% pre-loss and 15% post-loss responses suggested to be a high risk for major depressive disorder (MDD). Approximately 90% of family caregivers at a high risk for post-loss MDD were already at a high risk for pre-loss MDD. Even after adjustment of the background variables as covariates, the interaction effect between family caregivers' pre-loss depressive symptoms and resilience on post-loss depressive symptoms was observed (F = 7.29; p < 0.01). Moreover, pre-loss resilience was not associated with other bereavement outcome measures. CONCLUSIONS: Among family caregivers of patients with cancer in PCUs, 47% and 15% had high risk for MDD before and after bereavement, respectively. Moreover, pre-loss resilience mitigated post-loss depressive symptoms among family caregivers who had high risk for MDD before bereavement. However, considering the study's small sample size, further research is needed.
Prognostic model for patients with advanced cancer using a combination of routine blood test values. International-journal

Taeko Miyagi, Satoshi Miyata, Keita Tagami, Yusuke Hiratsuka, Mamiko Sato, Ikuo Takeda, Katsura Kohata, Noriaki Satake, Hiroaki Shimokawa, Akira Inoue

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　29　(8)　4431-4437　2021/08

DOI： 10.1007/s00520-020-05937-5 　

More details Close

PURPOSE: The purpose of this study was to develop a simple prognostic model based on objective indicators alone, i.e., routine blood test data, without using any subjective variables such as patient's symptoms and physician's prediction. METHODS: The subjects of this retrospective study were patients at the palliative care unit of Tohoku University Hospital, Japan. Eligible patients were over 20 years old and had advanced cancer (n = 225). The model for predicting survival was developed based on Cox proportional hazards regression models for univariable and multivariable analyses of 20 items selected from routine blood test data. All the analyses were performed according to the TRIPOD statement ( https://www.tripod-statement.org/ ). RESULTS: The univariable and multivariable regression analyses identified total bilirubin, creatinine, urea/creatinine ratio, aspartate aminotransferase, albumin, total leukocyte count, differential lymphocyte count, and platelet/lymphocyte ratio as significant risk factors for mortality. Based on the hazard ratios, the area under the curve for the new risk model was 0.87 for accuracy, 0.83 for sensitivity, and 0.74 for specificity. Diagnostic accuracy was higher than provided by the Palliative Prognostic Score and the Palliative Prognostic Index. The Kaplan-Meier analysis demonstrated a survival significance of classifying patients according to their score into low-, medium-, and high-mortality risk groups having median survival times of 67 days, 34 days, and 11 days, respectively (p < 0.001). CONCLUSIONS: We developed a simple and accurate prognostic model for predicting the survival of patients with advanced cancer based on routine blood test values alone that may be useful for appropriate advanced care planning in a palliative care setting.
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401). International-journal

Hisashi Tanaka, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, Naomi Watanabe, Hiroshi Yokouchi, Kazuhiro Usui, Ryota Saito, Hiroshi Watanabe, Tomomi Masuda, Tatsuro Fukuhara, Keita Kudo, Ryoichi Honda, Satoshi Oizimi, Makoto Maemondo, Akira Inoue, Naoto Morikawa

Thoracic cancer　12　(14)　2113-2121　2021/07

DOI： 10.1111/1759-7714.14048 　

More details Close

BACKGROUND: A cisplatin plus irinotecan (CPT-11) regimen is used for patients with extensive disease small cell lung cancer (ED-SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open-label randomized phase II trial, was designed to assess the benefit of maintenance therapy in patients with ED-SCLC who responded to induction therapy. METHODS: Patients with histologically- or cytologically-confirmed ED-SCLC were included and were treated with an induction therapy of four cycles of cisplatin (60 mg/m2 on day 1) plus CPT-11 (60 mg/m2 on days 1, 8, and 15) every four weeks. After induction therapy, patients who had nonprogressive disease were randomized to receive either maintenance CPT-11 (60 mg/m2 on days 1 and 8) every three weeks, or AMR (35 mg/m2 on days 1-3) every three weeks. RESULTS: A total of 34 patients were enrolled; 20 patients had progressive disease or received incomplete induction chemotherapy. Finally, 14 patients were randomly assigned to receive CPT-11 (n = 7) or AMR (n = 7). This study was terminated prematurely because of low patient accrual. The overall objective response rate was 73%, the median PFS was 5.7 months (95% confidence interval [CI]: 3.6-11.8), and the median overall survival was 20.1 months (95% CI: 13.7-not reached). No statistically significant difference in progression-free survival (PFS) were noted between patients treated with CPT-11 and those treated with AMR. There were no treatment-related deaths in this study. CONCLUSIONS: Maintenance therapy with CPT-11 or AMR after induction therapy might be effective in some patients.
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR). International-journal

Hibiki Udagawa, Eri Sugiyama, Toshiyuki Harada, Shinji Atagi, Ryo Koyama, Satoshi Watanabe, Yukiko Nakamura, Daijiro Harada, Osamu Hataji, Fumihiro Tanaka, Hiroshi Kida, Miyako Satouchi, Ken Maeno, Akira Inoue, Kiyotaka Yoh, Yuki Yamane, Yoshiko Urata, Hiroshige Yoshioka, Takeharu Yamanaka, Koichi Goto

Translational lung cancer research　10　(7)　3059-3070　2021/07

DOI： 10.21037/tlcr-21-240 　

More details Close

Background: Atezolizumab combined with bevacizumab plus platinum-based chemotherapy is a standard treatment for advanced non-squamous non-small-cell lung cancer (nsNSCLC). We aimed to determine the most effective platinum-based combination, such that future studies with atezolizumab can be conducted to further improve patient outcomes. Methods: This phase 2 study enrolled treatment-naïve patients with advanced or recurrent nsNSCLC who were randomly assigned to either cisplatin (75 mg/m2) + pemetrexed (500 mg/m2) + bevacizumab (15 mg/kg) (CisPemBev) followed by maintenance PemBev (N=132) or carboplatin (area under the concentration-time curve of 6 mg/mL/min) + paclitaxel (200 mg/m2) + bevacizumab (15 mg/kg) (CarPacBev) followed by maintenance Bev (N=67). The primary endpoint was progression-free survival (PFS, by central review). Secondary endpoints included overall survival (OS) and overall response rate (ORR). Adverse events (AEs) were evaluated for safety. This study was designed with the point estimate of the hazard ratio (HR) for PFS calculated based on an expected HR <0.830 with a probability ≥80%. Results: The HR for PFS (CisPemBev/CarPacBev) was 0.825 [95% confidence interval (CI), 0.600-1.134, median PFS, 7.6 vs. 7.0 months]. Because the observed point estimate of the HR for PFS was <0.830, the primary endpoint was met, and CisPem doublet therapy was deemed to be more effective than CarPac in terms of PFS. Median OS was 23.4 months for CisPemBev and 21.6 months for CarPacBev (HR 0.845; 95% CI, 0.583-1.242). The ORR was 57% for CisPemBev and 55% for CarPacBev. Both CisPemBev and CarPacBev were well tolerated; grade ≥3 AEs were reported in 67% and 82% of patients, respectively. Conclusions: CisPem combined with Bev was more effective in improving PFS compared with CarPacBev in patients with advanced nsNSCLC. CisPemBev was also well tolerated by this patient population. A study to evaluate the efficacy of atezolizumab plus CisPemBev is warranted. Trial Registration: University hospital Medical Information Network Clinical Trial Registry (ID: UMIN000013354).
日本緩和医療学会緩和ケアの質評価WPGによる専門的緩和ケアの質評価のための患者登録システムの開発状況

宮下光令, 平山英幸, 中條庸子, 金澤麻衣子, 田上恵太, 井上彰, 加藤雅志

Palliative Care Research　16　(Suppl.)　S167-S167　2021/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
苦痛スクリーニングは入院時のみで良いのか?東北大学病院のSTAS-Jを用いた苦痛スクリーニングデータの分析

宮下光令, 斎木花称子, 佐藤祐里, 金澤麻衣子, 中條庸子, 齋藤明美, 田上恵太, 井上彰

Palliative Care Research　16　(Suppl.)　S362-S362　2021/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
専門的な緩和ケアサービスの適切な受診・相談時期に関する遺族調査(J-HOPE4研究)

田上恵太, 升川研人, 井上彰, 森田達也, 平塚裕介, 佐藤麻美子, 木幡桂, 佐竹宣明, 木澤義之, 恒藤暁, 志真泰夫, 宮下光令

Palliative Care Research　16　(Suppl.)　S362-S362　2021/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
日本緩和医療学会緩和ケアの質評価WPGによる専門的緩和ケアの質評価のための患者登録システムの開発状況

宮下光令, 平山英幸, 中條庸子, 金澤麻衣子, 田上恵太, 井上彰, 加藤雅志

Palliative Care Research　16　(Suppl.)　S167-S167　2021/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
専門的な緩和ケアサービスの適切な受診・相談時期に関する遺族調査(J-HOPE4研究)

田上恵太, 升川研人, 井上彰, 森田達也, 平塚裕介, 佐藤麻美子, 木幡桂, 佐竹宣明, 木澤義之, 恒藤暁, 志真泰夫, 宮下光令

Palliative Care Research　16　(Suppl.)　S362-S362　2021/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
苦痛スクリーニングは入院時のみで良いのか?東北大学病院のSTAS-Jを用いた苦痛スクリーニングデータの分析

宮下光令, 斎木花称子, 佐藤祐里, 金澤麻衣子, 中條庸子, 齋藤明美, 田上恵太, 井上彰

Palliative Care Research　16　(Suppl.)　S362-S362　2021/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
訪問看護師のアンケート調査による、緩和ケアの専門家が不在の地域における緩和ケアアウトリーチの有効性

佐藤麻美子, 田上恵太, 猪狩智生, 佐竹宣明, 田上佑輔, 井上彰

Palliative Care Research　16　(Suppl.)　S435-S435　2021/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
【消化器癌;診断と治療のすべて】転移性腫瘍の治療・緩和ケアがん疼痛の薬物療法

佐藤麻美子, 田上恵太, 井上彰

消化器外科　44　(6)　1116-1119　2021/05
Publisher: (株)へるす出版
ISSN： 0387-2645
Factors influencing spiritual well-being in terminally ill cancer inpatients in Japan. International-journal

Yusuke Hiratsuka, Sang-Yeon Suh, Isseki Maeda, Tatsuya Morita, Masanori Mori, Satoko Ito, Tomohiro Nishi, Takayuki Hisanaga, Tetsuji Iriyama, Keisuke Kaneishi, Tomoo Ikari, Keita Tagami, Akira Inoue

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　29　(5)　2795-2802　2021/05

DOI： 10.1007/s00520-020-05802-5 　

More details Close

PURPOSE: Spiritual well-being is very important in patients undergoing palliative care. Although psychosocial factors have been suggested to be associated with spiritual well-being, the relationship between physical signs and spiritual well-being has not been fully elucidated. The aim of this study was to explore diverse factors associated with spiritual well-being among palliative care patients in Japan. METHODS: This study is a secondary analysis of a multicenter prospective cohort study involving patients admitted to palliative care units in Japan. Physicians recorded all data prospectively on a structured sheet designed for the study. The spiritual well-being score was measured using the Integrated Palliative Outcome Scale after patients' death in regard to symptoms over the previous 3 days. We classified each patient into "better" score (0-1) and "worse" score (2-4) groups and examined diverse factors associated with spiritual well-being. RESULTS: Among the 1896 patients enrolled, 1313 were evaluated. In the multivariate analysis, seven variables were significantly associated with "worse" score: worse spiritual well-being on admission (2-4) (p < 0.0001), younger age (< 80) (p = 0.0001), hyperactive delirium over 3 days before death (mild/moderate/severe) (p = 0.0001), expressed wish for hastened death (yes) (p = 0.0006), worse communication among patients and families (Support Team Assessment Schedule score 2-4) (p = 0.0008), pleural effusion (present) (p = 0.037), and marital status (unmarried) (p = 0.0408). CONCLUSION: Recognizing factors associated with spiritual well-being is potentially useful for identifying high-risk groups with lower spiritual well-being at the end of life. Further study is required to investigate factors associated with patient-reported spiritual well-being.
当院におけるIMRTによる根治的放射線化学療法後のデュルバルマブ投与症例の検討

木村望, 突田容子, 斎藤良太, 佐藤輝幸, 宮内栄作, 井上彰, 杉浦久敏

日本呼吸器学会誌　10　(増刊)　139-139　2021/04
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302

Yosuke Kawashima, Toshiyuki Harada, Yuka Fujita, Taku Nakagawa, Kana Watanabe, Naoto Morikawa, Kei Takamura, Kenya Kanazawa, Tomoya Kuda, Kazuhiro Usui, Akimasa Sekine, Akira Inoue, Shunichi Sugawara

International Journal of Clinical Oncology　26　(3)　515-522　2021/03/01
Publisher: Springer Japan
DOI： 10.1007/s10147-020-01828-1 　

ISSN： 1437-7772 1341-9625
Patients' understanding of communication about palliative care and health condition in Japanese patients with unresectable or recurrent cancer: a cross-sectional survey. International-journal

Yusuke Hiratsuka, Takayuki Oishi, Mitsunori Miyashita, Tatsuya Morita, Jennifer W Mack, Masahiro Takahashi, Hidekazu Shirota, Kazunori Otsuka, Chikashi Ishioka, Akira Inoue

Annals of palliative medicine　10　(3)　2650-2661　2021/03

DOI： 10.21037/apm-20-2045 　

More details Close

BACKGROUND: Understanding treatment goal is essential for decision-making among patients with unresectable/recurrent solid cancers. However, no previous studies in Japan have examined the association between patients' understanding and physicians' explanations. We aimed to examine agreement between patients' and physicians' reports of communication about palliative care and current health condition among patients with unresectable/recurrent cancer and explore factors associated with optimistic understanding in Japan. METHODS: In this cross-sectional, multicenter, observational survey in Japan, 178 patients with unresectable/ recurrent solid cancers and 16 physicians responded to questionnaires. The primary outcome was agreement between patients' and physicians' reports of communication about palliative care and current health condition. RESULTS: Of 56 patients who reported their communication about palliative care, 25/56 (44.6%) agreed with physician reports, and 31/56 (55.4%) were more optimistic than their physicians. Regarding current overall health condition, 45/122 (36.9%) patients gave reports that agreed with physicians' reports, and 77/122 (63.1%) were optimistic relative to physicians. Physicians' general approach about disclosure were not associated with patients' understanding. CONCLUSIONS: Fewer than 50% of Japanese patients with unresectable/recurrent cancer agreed with their physicians, whereas most others were more optimistic about palliative care communication and their health condition as compared to physicians. Effective communication is essential to ensure informed decisionmaking.
"3-Day Surprise Question" to predict prognosis of advanced cancer patients with impending death: Multicenter prospective observational study. International-journal

Tomoo Ikari, Yusuke Hiratsuka, Takuhiro Yamaguchi, Isseki Maeda, Masanori Mori, Yu Uneno, Tomohiko Taniyama, Yosuke Matsuda, Kiyofumi Oya, Keita Tagami, Akira Inoue

Cancer medicine　10　(3)　1018-1026　2021/02

DOI： 10.1002/cam4.3689 　

More details Close

BACKGROUND: The study aimed to clarify the efficacy of the "3-Day Surprise Question (3DSQ)" in predicting the prognosis for advanced cancer patients with impending death. PATIENTS AND METHODS: This study was a part of multicenter prospective observational study which investigated the dying process in advanced cancer patients in Japan. For patients with a Palliative Performance Scale ≤20, the 3DSQ "Would I be surprised if this patient died in the next 3 days?" was answered by their physicians. In addition to the sensitivity and specificity of the 3DSQ, the characteristics of patients who survived longer than expected were examined via multivariate analysis. RESULTS: Among the 1896 patients enrolled, 1411 were evaluated. Among 1179 (83.6%) patients who were classified into the "Not surprised" group, 636 patients died within 3 days. Among 232 (16.4%) patients of "Yes surprised" group, 194 patients lived longer than 3 days. The sensitivity, specificity, positive predictive value, and negative predictive value of the 3DSQ were 94.3% (95% confidence interval [CI]: 92.7% to 95.8%), 26.3% (95% CI: 24.8% to 27.6%), 53.9% (95% CI: 53.0% to 54.7%), and 83.6% (95% CI: 78.7% to 87.7%), respectively. Multivariate analysis showed palpable radial artery, absent respiration with mandibular movement, SpO2 ≥ 90%, opioid administration, and no continuous deep sedation as characteristics of patients who lived longer than expected. CONCLUSIONS: The 3-Day Surprise Question can be a useful screening tool to identify advanced cancer patients with impending death.
METex14 skipping testing guidance for lung cancer patients: The guidance from the biomarker committee, the Japan lung cancer society

Yasushi Yatabe, Koichi Goto, Shingo Matsumoto, Yutaka Hatanaka, Naoko Arakane, Sadakatsu Ikeda, Akira Inoue, Ichiro Kinoshita, Hideharu Kimura, Tomohiro Sakamoto, Miyako Satouchi, Junichi Shimizu, Kuniko Sunami, Koji Tsuta, Shinichi Toyooka, Kazuto Nishio, Kazumi Nishino, Masashi Mikubo, Tomoyuki Yokose, Hirotoshi Dosaka-Akita

Japanese Journal of Lung Cancer　61　(5)　361-370　2021
Publisher: Japan Lung Cancer Society
DOI： 10.2482/haigan.61.361 　

ISSN： 0386-9628
High Feasibility and Safety, but Negligible Efficacy of Acupressure for Treating Nausea in Cancer Patients Admitted to the Palliative Care Unit: A Pilot Study.

Hiroyuki Tsugita, Maho Aoyama, Noriaki Satake, Makoto Saito, Yusuke Hiratsuka, Akira Inoue, Shin Takayama, Mitsunori Miyashita

The Tohoku journal of experimental medicine　254　(3)　155-161　2021

DOI： 10.1620/tjem.254.155 　

More details Close

Management of nausea is an important dimension of palliative care. The first choice for treating nausea is antiemetics, but their efficacy is inadequate. Acupressure intervention for nausea in cancer patients has been studied as a non-pharmacological therapy, and appears to have had some effect. However, such a therapy has not been well reviewed in patients with terminal cancer. The purpose of this study was to clarify the feasibility of acupressure intervention and examine its safety and preliminary efficacy. We recruited cancer patients that fulfilled the eligibility criteria and were admitted to the palliative care unit, from August 2018 to February 2019, in Tohoku University Hospital, Japan. We conducted a longitudinal assessment of acupressure intervention in a single arm. We identified the patient's research accomplishments and evaluated possible fainting due to the vagal reflex and symptom severity. Descriptive statistics were used to calculate the completion rate for the feasibility and Wilcoxon signed-rank tests to compare the average of continuous variables for the safety and efficacy. Twelve patients participated in this study and completed the procedure. Their average age was 70 years (SD = 9.3), and the most common primary cancer sites were the rectum and pancreas. The blood pressure and pulse rate did not drop sharply. Four patients exhibited decreased nausea but there was no statistically significant difference (P = 0.5). We suggested that acupressure has high feasibility and safety, as an intervention for patients with terminal cancer. However, no significant differences were observed regarding its effect on nausea.
The current clinical use of adjuvant analgesics for refractory cancer pain in Japan: a nationwide cross-sectional survey. International-journal

Keita Tagami, Hiromichi Matsuoka, Keisuke Ariyoshi, Shunsuke Oyamada, Yusuke Hiratsuka, Yoshiyuki Kizawa, Atsuko Koyama, Akira Inoue

Japanese journal of clinical oncology　50　(12)　1434-1441　2020/12/16

DOI： 10.1093/jjco/hyaa147 　

More details Close

BACKGROUND: Although adjuvant analgesics are used to treat opioid-refractory cancer pain, there is insufficient evidence to support this practice and limited data to guide the choice depending on cancer pain pathophysiology, dose titration and starting dose. This survey aimed to clarify the current use of adjuvant analgesics for treating opioid-refractory cancer pain. METHODS: In this cross-sectional study, we sent an online survey questionnaire to 208 certified palliative care specialists. Primary outcomes were (i) effective pathophysiological mechanism of cancer pain and (ii) initiating doses and time period to the first response to each adjuvant analgesic therapy. RESULTS: In total, 87 (42%) palliative care specialists responded. Of all patients with cancer pain, 40% of patients (median) with refractory cancer pain were prescribed adjuvant analgesics. Additionally, 94.3, 93.1 and 86.2% of palliative care specialists found dexamethasone/betamethasone effective for neuropathic pain caused by tumor-related spinal cord compression, pregabalin effective for malignant painful radiculopathy and dexamethasone/betamethasone effective for brain tumor or leptomeningeal metastases-related headache, respectively. The median starting dose of pregabalin, dexamethasone/betamethasone, lidocaine and ketamine were 75, 4, 200, and 50 mg/day, respectively, and the median time to the first response of those medications were 5, 3, 2 and 3 days, respectively. CONCLUSIONS: Many palliative care specialists select adjuvant analgesics depending on the pathophysiological mechanism of cancer pain in each case. They used such adjuvant analgesics in low doses for cancer pain with short first-response periods.
Multiplex gene-panel testing for lung cancer patients. International-journal

Yasushi Yatabe, Kuniko Sunami, Koichi Goto, Kazuto Nishio, Naoko Aragane, Sadakatsu Ikeda, Akira Inoue, Ichiro Kinoshita, Hideharu Kimura, Tomohiro Sakamoto, Miyako Satouchi, Junichi Shimizu, Koji Tsuta, Shinichi Toyooka, Kazumi Nishino, Yutaka Hatanaka, Shingo Matsumoto, Masashi Mikubo, Tomoyuki Yokose, Hirotoshi Dosaka-Akita

Pathology international　70　(12)　921-931　2020/12

DOI： 10.1111/pin.13023 　

More details Close

The year 2019 was considered to be the first year of cancer genome medicine in Japan, with three gene-panel tests using next-generation sequencing (NGS) techniques being introduced into clinical practice. Among the three tests, the Oncomine CDx Target test was approved under the category of regular molecular testing for lung cancer, which meant that this test could be used to select patients for molecularly targeted drugs. Conversely, the other two tests, NCC OncoPanel and FoundationOne CDx, were assigned to be used under the National Cancer Genome Medicine Network, and implementation was restricted to patients for whom standard treatment was completed or expected to be completed. These NGS tests can detect a series of genetic alterations in individual tumors, which further promotes the development of therapeutic agents and elucidates molecular pathways. The NGS tests require appropriate tissue size and tumor cell content, which can be accessed only by pathologists. In this report, we review the current reimbursement schema in our national healthcare policy and the requirements of the specimens for NGS testing based on the recently published 'Guidance of Gene-panel Testing Using Next-Generation Sequencers for Lung Cancer', by the Japanese Society of Lung Cancer.
EGFR遺伝子陽性肺癌の治療戦略:最強な治療法は何か EGFR-TKIと化学療法の併用

朝比奈肇, 田中謙太郎, 井上彰, 大泉聡史, 前門戸任, 岡本勇, 清家正博, 杉尾賢二, 小林国彦

肺癌　60　(6)　489-489　2020/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. International-journal

Satoshi Igawa, Katsuhiko Naoki, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino

Lung cancer (Amsterdam, Netherlands)　146　160-164　2020/08

DOI： 10.1016/j.lungcan.2020.05.038 　

More details Close

OBJECTIVES: Most patients with small-cell lung cancer (SCLC) experience relapse because of the emergence of drug-resistant tumor cells. Therefore, second-line therapy is subsequently required to prolong their survival. However, it is unclear whether second-line chemotherapy can provide a survival benefit to elderly patients with relapsed SCLC. Therefore, this study aimed to evaluate survival and identify prognostic factors in an elderly population. MATERIALS AND METHODS: Based on a nationwide registry database of patients with SCLC (the Japanese Joint Committee of Lung Cancer Registry), we retrospectively reviewed medical records of patients aged ≥ 75 years with relapsed SCLC who subsequently received second-line chemotherapy. Survival time since the initiation of second-line chemotherapy was evaluated. RESULTS: Among 731 patients aged ≥ 75 years with SCLC who were accumulated by the nationwide registry database, this study included 228 patients, comprising 190 men and 38 women with a median age of 78 years. The number of patients with performance status (PS) of 0-1 and 2-4 was 196 and 32, respectively. The overall survival (OS) and 1-year survival rates were 7.5 months and 24 %, respectively. A multivariate analysis identified PS, clinical stage at the time of starting first-line therapy, and the interval from the start of first-line therapy to that of second-line therapy as independent prognostic factors. CONCLUSION: This study with the nationwide registry database showed that among the relapsed elderly SCLC patients who received second-line chemotherapy, a substantial OS may be expected in patients with good PS, at an early clinical stage at the time of starting first-line therapy, and with a longer interval from the start of first-line therapy to that of second-line chemotherapy.
Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. International-journal

Keigo Kobayashi, Kenzo Soejima, Koichi Fukunaga, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino

Lung cancer (Amsterdam, Netherlands)　146　236-243　2020/08

DOI： 10.1016/j.lungcan.2020.06.015 　

More details Close

INTRODUCTION: The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for EGFR-mutated non-adenocarcinoma (ADC) non-small cell lung cancer patients is not well established. Herein, we investigated key prognostic factors influencing the efficacy of EGFR-TKIs in these patients. METHODS: A total of 12,320 lung cancer patients pathologically diagnosed in 2012 at teaching hospitals in Japan were retrospectively selected. The follow-up survey was closed in 2016. RESULTS: EGFR-mutated non-ADC patients were more prone to malignant pleural effusion (MPE) and distant metastasis than ADC patients (P = 0.071 and 0.022, respectively). EGFR-mutated ADC patients were likely to have a longer median overall survival (OS) than non-ADC patients [hazard ratio (HR) 1.3 (95 % CI, 0.97-1.8, P = 0.072)-29.5 months (95 % CI, 27.9-31.1 months) versus 19.5 months (95 % CI, 10.8-28.2 months) (P = 0.068)]. There was no significant difference in median OS between EGFR-positive ADC and non-ADC patients receiving treatment with first-generation EGFR-TKI. Among EGFR-positive non-ADC patients, the median OS was significantly longer for patients receiving EGFR-TKI treatment than for those who did not [HR 4.5 (95 % CI, 2.1-9.8, P < 0.001)-25.5 months (95 % CI, 8.1-42.9 months) versus 7.5 months (95 % CI, 3.4-11.6 months) (P < 0.001)]. While there was no significant difference in the median OS for ADC patients with either 19 del or L858R mutations, the median OS was significantly longer for EGFR-mutated non-ADC patients with 19 del than for those with L858R mutation (HR 3.2 [95 % CI, 1.5-6.9, P = 0.004]; it was not reached for 19 del and was 15.5 months for L858R [95 % CI, 6.6-24.4 months], P = 0.002). DISCUSSION: EGFR-mutated non-ADC patients were more prone to MPE and distant metastasis. Both ADC and EGFR del19-positive non-ADC patients can benefit from EGFR-TKI treatment, whereas EGFR L858R-positive non-ADC patients might require different therapeutic options.
宗教的背景をもたない緩和ケア病棟における臨床宗教師の活動「臨床宗教師活動記録」の分析を通した一考察

金田諦晃, 青山真帆, 平塚裕介, 田上恵太, 升川研人, 宮下光令, 井上彰

スピリチュアルケア研究　4　45-59　2020/08
Publisher: (一社)日本スピリチュアルケア学会
ISSN： 2433-1627
緩和ケア病棟入院中の進行がん患者における機能的予後予測指標の開発

平塚裕介, 山口拓洋, 前田一石, 森田達也, 森雅紀, 横道直佑, 平本秀二, 松田洋祐, 小原弘之, 鈴木梢, 田上恵太, 井上彰

Palliative Care Research　15　(Suppl.)　S271-S271　2020/08
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
緩和ケア病棟における進行がん患者の予後予測因子の探索

宮城妙子, 宮田敏, 田上恵太, 平塚裕介, 佐藤麻美子, 武田郁央, 木幡桂, 佐竹宣明, 下川宏明, 井上彰

Palliative Care Research　15　(Suppl.)　S1101-S1101　2020/08
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
がん患者の家族介護者のレジリエンスと死別後の抑うつとの関連(J-HOPE4付帯研究)

清水陽一, 前田一石, 林章敏, 三浦智史, 井上彰, 志真泰夫, 恒藤暁, 木澤義之, 森田達也, 升川研人, 石垣和美, 高野真優子, 宮下光令

Palliative Care Research　15　(Suppl.)　S645-S645　2020/08
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
【進行期肺癌治癒への道-がんゲノム医療と免疫プレシジョン医療の接点】分子標的治療薬最前線 EGFR-TKI世代ごとの特徴

宮内栄作, 井上彰

呼吸器ジャーナル　68　(3)　354-361　2020/08
Publisher: (株)医学書院
ISSN： 2432-3268
Effectiveness of Gabapentinoids for Cancer-related Rectal and Vesical Tenesmus: Report of Four Cases

Keita Tagami, Masaru Yoshizumi, Akira Inoue, Motohiro Matoba

INDIAN JOURNAL OF PALLIATIVE CARE　26　(3)　381-384　2020/07

DOI： 10.4103/IJPC.IJPC_203_19 　

ISSN： 0973-1075

eISSN： 1998-3735
Impressions of Interfaith Chaplain's Activities among Patients in a Palliative Care Unit: A Semi-Structured Interview-Based Qualitative Study.

Yusuke Hiratsuka, Maho Aoyama, Taiko Kaneta, Kento Masukawa, Keita Tagami, Mitsunori Miyashita, Akira Inoue

The Tohoku journal of experimental medicine　251　(2)　91-96　2020/06

DOI： 10.1620/tjem.251.91 　

More details Close

Providing spiritual care in light of a patient's religious and/or spiritual background can help improve the quality of end-of-life care. Rinsho-shukyo-shi is a Japanese interfaith chaplain who provides religious and spiritual care to patients. In this study, we qualitatively explore the impressions of patients in a palliative care unit of the activities of an interfaith chaplain in a hospital in Japan. The authors used semi-structured interviews carried out by a male nurse experienced in qualitative and quantitative research in palliative care. The male nurse asked only a few predetermined questions in the interviews, which were conducted from January 19 to December 26, 2018. The interviewees were 15 patients diagnosed with advanced cancer (five men and 10 women; aged 53-81 years), and they were admitted to the palliative care unit of Tohoku University Hospital (the hospital has no religious affiliation). Patients who had spoken to the interfaith chaplain at the hospital at least twice were included in the study. The interviews were digitally audio-recorded, transcribed verbatim, and analyzed. Three main themes were identified through thematic analysis. Resistance varied across patients; no patient felt resistance to the intervention by, or to the presence of, the interfaith chaplain once he/she had spoken with him. Opinions about the interfaith chaplain also varied, with 10 patients claiming that his role was necessary for end-of-life care and beneficial for the chaplain himself. Finally, the patients' religious beliefs varied widely. In conclusion, the interfaith chaplain is deemed helpful by the interviewed patients in relieving their anxieties.
The Functional Palliative Prognostic Index: a scoring system for functional prognostication of patients with advanced cancer. International-journal Peer-reviewed

Yusuke Hiratsuka, Takuhiro Yamaguchi, Isseki Maeda, Tatsuya Morita, Masanori Mori, Naosuke Yokomichi, Shuji Hiramoto, Yosuke Matsuda, Hiroyuki Kohara, Kozue Suzuki, Keita Tagami, Takashi Yamaguchi, Akira Inoue

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　28　(12)　6067-6074　2020/04/17

DOI： 10.1007/s00520-020-05408-x 　

More details Close

PURPOSE: For appropriate advance care planning, functional prognostication is necessary. However, there are no studies of functional prognostication in patients with cancer. The aim of this study was to develop a functional prognostic scoring system for patients with advanced cancer. METHODS: In this multicenter prospective observational study, 1896 patients were enrolled. First, Cox regression analysis and the combination of forward and backward variable selection were used to identify the best subset of predictors. Second, the prognostic score value was defined from each regression coefficient of a significant prognostic factor. The Functional Palliative Prognostic Index (FPPI) was calculated by summing the prognostic scores. RESULTS: Patients were classified into three groups by the FPPI. For walking, the 14-day functional survival probability was > 72.8% for group A (score 0), 28.4-72.8% for group B (score 1), and < 28.4% for group C (score 2-3). For eating, the 14-day functional survival probability was > 71.8% for group A (score 0-3), 29.6-71.8% for group B (score 3.5-5.5), and < 29.6% for group C (score 6-9). For communicating, the 14-day functional survival probability was > 76.6% for group A (score 0-6.5), 22.6-76.6% for group B (score 7-10), and < 22.6% for group C (score 10.5-16). Regarding each item, group B functionally survived significantly longer than group C, and group A functionally survived significantly longer than either of the others. CONCLUSION: We firstly developed a functional prognostic scoring system for patients with advanced cancer. This FPPI system promises to be helpful in advance care planning.
The association between health-related quality of life and achievement of personalized symptom goal. International-journal Peer-reviewed

Keita Tagami, Takashi Kawaguchi, Tomofumi Miura, Takuhiro Yamaguchi, Yoshihisa Matsumoto, Yuki Sumazaki Watanabe, Yuko Uehara, Ayumi Okizaki, Akira Inoue, Tatsuya Morita, Hiroya Kinoshita

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　28　(10)　4737-4743　2020/01/22

DOI： 10.1007/s00520-020-05316-0 　

More details Close

PURPOSE: The aim of study was to explore the potential association between patient's self-reported physical symptom management goals as personalized symptom goal (PSGs) and health-related quality of life (HRQOL) in cancer patients. The secondary outcome was to investigate the relationship between number of physical symptoms not achieving the PSGs and HRQOL in cancer patients. METHODS: This single-center prospective observational study comprised 140 consecutive outpatients. We evaluated the PSGs and HRQOL using the Functional Assessment of Cancer Therapy-General (FACT-G). Patients were administered a self-report questionnaire, including reports on their physical symptom intensity and PSGs using Edmonton Symptom Assessment System-revised (ESAS-r) scores. We investigated the correlation between PSGs achievement (ESAS-r score ≤ PSG score) and FACT-G total scores, and relationship between and number of physical symptoms not achieving the PSGs (ESAS-r score > PSG score) and FACT-G total scores. RESULTS: The patients who did not achieve PSGs of pain, tiredness, lack of appetite, and shortness of breath had a lower FACT-G total score (p < 0.05). Multivariate linear regression showed that higher number of physical symptoms not achieving the PSGs correlated with lower FACT-G scores (decreasing by 1.826 points for each such symptom, p < 0.01). Predictors of increased number of physical symptoms not achieving the PSGs were younger age and a higher symptom intensity of anxiety. CONCLUSION: PSGs achievement was associated with HRQOL in cancer patients. Additionally, the number of unachieved PSGs were independent determinant of poor HRQOL, particularly in younger cancer patients and those with higher symptom intensity of anxiety.
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. International-journal

Yukio Hosomi, Satoshi Morita, Shunichi Sugawara, Terufumi Kato, Tatsuro Fukuhara, Akihiko Gemma, Kazuhisa Takahashi, Yuka Fujita, Toshiyuki Harada, Koichi Minato, Kei Takamura, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue

Journal of clinical oncology : official journal of the American Society of Clinical Oncology　38　(2)　115-123　2020/01/10

DOI： 10.1200/JCO.19.01488 　

More details Close

PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations; however, little is known about the efficacy and safety of this combination compared with that of standard therapy with EGFR- tyrosine kinase inhibitors alone. METHODS: We randomly assigned 345 patients with newly diagnosed metastatic NSCLC with EGFR mutations to gefitinib combined with carboplatin plus pemetrexed or gefitinib alone. Progression-free survival (PFS), PFS2, and overall survival (OS) were sequentially analyzed as primary end points according to a hierarchical sequential testing method. Secondary end points were objective response rate (ORR), safety, and quality of life. RESULTS: The combination group demonstrated a better ORR and PFS than the gefitinib group (ORR, 84% v 67% [P < .001]; PFS, 20.9 v 11.9 months; hazard ratio for death or disease progression, 0.490 [P < .001]), although PFS2 was not significantly different (20.9 v 18.0 months; P = .092). Median OS in the combination group was also significantly longer than in the gefitinib group (50.9 v 38.8 months; hazard ratio for death, 0.722; P = .021). The rate of grade ≥ 3 treatment-related adverse events, such as hematologic toxicities, in the combination group was higher than in the gefitinib group (65.3% v 31.0%); there were no differences in quality of life. One treatment-related death was observed in the combination group. CONCLUSION: Compared with gefitinib alone, gefitinib combined with carboplatin plus pemetrexed improved PFS in patients with untreated advanced NSCLC with EGFR mutations with an acceptable toxicity profile, although its OS benefit requires further validation.
切除不能III期NSCLCに対するUFT+CDDP+胸部放射線併用療法とPEM+CDDP+TRT併用療法のランダム化第II相試験

宮内栄作, 渡邉香奈, 戸井之裕, 中村敦, 福原達朗, 千葉亮祐, 秋山真親, 榊原純, 田中寿志, 吉村成央, 中川拓, 井草龍太郎, 峯村浩之, 守義明, 藤本圭介, 松下晴雄, 高橋史朗, 井上彰, 菅原俊一, 前門戸任

肺癌　59　(6)　672-672　2019/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
強度変調放射線治療による根治的化学放射線療法後のデュルバルマブ使用経験の報告

突田容子, 宮内栄作, 斎藤良太, 佐藤輝幸, 山本貴也, 片桐佑, 井上彰, 一ノ瀬正和

肺癌　59　(6)　674-674　2019/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
プラチナ製剤を含む2レジメン以上の治療歴を有する既治療NSCLCに対するnab-PTX単剤隔週投与の第I/II相試験

原田敏之, 宮内栄作, 田中寿志, 中村敦, 中川拓, 盛田麻美, 神宮大輔, 久田友哉, 蒲生俊一, 齊藤良太, 井上彰

肺癌　59　(6)　797-797　2019/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203. Peer-reviewed

Tsukita Y, Inoue A, Sugawara S, Kuyama S, Nakagawa T, Harada D, Tanaka H, Watanabe K, Mori Y, Harada T, Hino T, Fujii M, Ichinose M

Lung Cancer　18　(139)　89-93　2019/10
Explicit prognostic disclosure to Asian women with breast cancer: A randomized, scripted video-vignette study (J-SUPPORT1601). International-journal Peer-reviewed

Masanori Mori, Maiko Fujimori, Liesbeth M van Vliet, Takuhiro Yamaguchi, Chikako Shimizu, Takayuki Kinoshita, Miki Morishita-Kawahara, Akira Inoue, Hironobu Inoguchi, Yutaka Matsuoka, Eduardo Bruera, Tatsuya Morita, Yosuke Uchitomi

Cancer　125　(19)　3320-3329　2019/10/01

DOI： 10.1002/cncr.32327 　

ISSN： 0008-543X

More details Close

BACKGROUND: Nondisclosure of a poor prognosis to patients with advanced cancer remains a typical practice in Asia. Although the importance of prognostic communication has increasingly been recognized worldwide, little is known about whether explicit prognostic disclosure positively affects Asian patients with advanced cancer. The objective of this study was to examine the effects of explicit prognostic communication on patients with cancer recurrence. METHODS: In this randomized, video-vignette study, Japanese women with breast cancer who had undergone curative surgery viewed videos of prognostic communication between a patient with recurrent, incurable breast cancer and her oncologist. The videos differed only in the presence or absence of explicit prognostic disclosure. The primary outcome was participants' uncertainty (rated from 0 to 10), and the secondary outcomes included anxiety (measured on the State-Trait Anxiety Inventory-State: range, 20-80), satisfaction (Patient Satisfaction Questionnaire; range 0-10), self-efficacy (range, 0-10), and willingness to discuss advance care planning (range, 1-4). RESULTS: In total, 105 women participated (mean ± SD age, 53.8 ± 8.2 years). After viewing the video with more versus less explicit disclosure, participants showed significantly lower uncertainty (mean ± SE scores, 5.3 ±0.2 vs 5.7 ± 0.2, respectively; P = .032) and higher satisfaction (5.6 ± 0.2 vs 5.2 ± 0.2, respectively; P = .010) without increasing anxiety (changes in scores on the State-Trait Anxiety Inventory-State: 0.06 ± 0.5 vs 0.6 ± 0.5, respectively; P = .198). No significant differences were observed in self-efficacy (5.2 ± 0.2 vs 5.0 ± 0.2, respectively; P = .277) or willingness to discuss advance care planning (2.7 ± 0.1 vs 2.7 ± 0.1, respectively; P = .240). CONCLUSIONS: Explicit prognostic disclosure prompted better outcomes than nondisclosure in Japanese women with breast cancer. When asked about the prognosis by Asian patients with cancer, clinicians may be encouraged to respect their wishes and explicitly discuss the prognosis if deemed appropriate.
Bereavement risk assessment of family caregivers of patients with cancer: Japanese version of the Bereavement Risk Assessment Tool. Peer-reviewed

Uchida T, Satake N, Nakaho T, Inoue A, Saito H

Palliative & supportive care　17　(4)　448-452　2019/08

DOI： 10.1017/S1478951518000755 　

ISSN： 1478-9515
Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small-cell lung cancer: NJLCG1001. Peer-reviewed

Watanabe Kana, Toi Yukihiro, Nakamura Atsushi, Fukuhara Tatsuro, Chiba Ryosuke, Akiyama Masachika, Sakakibara-Konishi Jun, Tanaka Hisashi, Yoshimura Naruo, Miyauchi Eisaku, Nakagawa Taku, Igusa Ryotaro, Minemura Hiroyuki, Mori Yoshiaki, Fujimoto Keisuke, Matsushita Haruo, Takahashi Fumiaki, Inoue Akira, Sugawara Shunichi, Maemondo Makoto

JOURNAL OF CLINICAL ONCOLOGY　37　(15)　2019/05/20

ISSN： 0732-183X
Benefits of a Nationwide Palliative Care Education Program on Lung Cancer Physicians. Peer-reviewed

Inoue A, Yamaguchi T, Tanaka K, Sakashita A, Aoe K, Seki N, Hagiwara K

Internal medicine (Tokyo, Japan)　58　(10)　1399-1403　2019/05

DOI： 10.2169/internalmedicine.0872-18 　

ISSN： 0918-2918

More details Close

Objective The early integration of palliative care into standard cancer treatment has become a global standard. The Palliative care Emphasis program on symptom management and Assessment for Continuous medical Education (PEACE) has been conducted in Japan, and previous studies have reported that the PEACE workshop was able to improve various palliative care skills of participants. However, whether or not the effects of the program are long-lasting and if the program consequently changed physicians' practice with regard to lung cancer patients have been unclear. Methods Web-based surveys, including the palliative care knowledge test (PEACE-Q), the Palliative Care self-reported Practice Scale (PCPS), and the Palliative Care Difficulties Scale (PCDS), were conducted among lung cancer physicians in Japan. The differences in the survey results between participants and non-participants of the PEACE workshop were examined. Results Among 923 respondents (455 respiratory physicians, 345 pulmonary surgeons, and 123 others), 519 had participated in the PEACE workshop. The total PEACE-Q score was significantly higher in the PEACE workshop participants than in non-participants (28.0 versus 24.5, p<0.0001). The score was significantly higher in respiratory physicians than in pulmonary surgeons (27.4 versus 25.5). The total PCPS and PCDS scores were also significantly better in workshop participants than in non-participants (71.8 versus 67.1 and 34.3 versus 36.9, respectively), although some domains of PCDS were similar between the groups. Conclusion The PEACE program improved the knowledge and practices with regard to palliative care and resolved difficulties associated therewith among lung cancer physicians. In regions where palliative care specialists are insufficient, such educational programs may be effective.
Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: a nationwide cross-sectional survey. International-journal Peer-reviewed

Hiromichi Matsuoka, Keita Tagami, Keisuke Ariyoshi, Shunsuke Oyamada, Yoshiyuki Kizawa, Akira Inoue, Atsuko Koyama

Japanese journal of clinical oncology　49　(5)　486-490　2019/05/01

DOI： 10.1093/jjco/hyz002 　

ISSN： 0368-2811

More details Close

Cancer-related neuropathic pain (CNP) requires therapy involving multiple pharmaceuticals, including anticonvulsants and antidepressants; however, strong evidence to support this practice is limited. This study is a cross-sectional questionnaire-based survey. As the standard dose of adjuvant analgesics for CNP refractory to opioid therapy is not clear, the purpose of this study is to clarify the opinions of specialists about the usage of duloxetine and pregabalin for patients with CNP refractory to opioid therapy. Two hundred and eight certified palliative care specialists were surveyed and a total of 87 (42%) responses were analyzed. Twenty-five percent of specialists had considered increasing duloxetine doses up to 60 mg/day and 58% had considered increasing pregabalin doses up to 300 mg/day for CNP refractory to opioid therapy. However, 23% of the specialists succeeded in increasing duloxetine doses up to 60 mg/day and 17% in increasing pregabalin doses up to 300 mg/day, respectively.
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. Peer-reviewed

Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T

International journal of clinical oncology　24　(5)　485-493　2019/05

DOI： 10.1007/s10147-019-01396-z 　

ISSN： 1341-9625

More details Close

INTRODUCTION: The East Asia S-1 Trial in Lung Cancer (EAST-LC) was a randomized phase III study conducted in East Asia that demonstrated the non-inferiority of S-1 to docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Here, we reported the results of the Japanese subgroup treated with docetaxel 60 mg/m2, the standard dosage in Japan. PATIENTS AND METHODS: Patients were randomized 1:1 to receive either S-1 or docetaxel. The primary endpoint was overall survival (OS); the secondary endpoints included progression-free survival (PFS), response rate (RR), quality of life (QOL), and safety. RESULTS: Patient characteristics in the Japanese subgroup (n = 724) were similar to those in the overall EAST-LC population. Median OS was 13.4 months in the S-1 group and 12.6 months in the docetaxel group. In pemetrexed-pretreated patients, OS with S-1 was similar to that with docetaxel. Median PFS was 2.9 and 3.0 months in the S-1 and docetaxel groups, respectively. RR was 9.4% and 10.3% in the S-1 and docetaxel groups, respectively. The QOL of patients treated with S-1 was better compared with that of patients treated with docetaxel. Decreased appetite and diarrhea were more common in the S-1 group, whereas the frequency of neutropenia and febrile neutropenia was markedly higher in the docetaxel group. CONCLUSIONS: This Japanese subgroup analysis showed that S-1 had similar efficacy to docetaxel in patients with previously treated advanced NSCLC. These results are similar to those of the overall EAST-LC population.
Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer. Peer-reviewed

Hiramoto S, Tamaki T, Nagashima K, Hori T, Kikuchi A, Yoshioka A, Inoue A

International journal of clinical oncology　24　(4)　454-459　2019/04

DOI： 10.1007/s10147-018-1363-7 　

ISSN： 1341-9625
Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas Peer-reviewed

Yoko Tsukita, Naoya Fujino, Eisaku Miyauchi, Ryoko Saito, Fumiyoshi Fujishima, Koji Itakura, Yorihiko Kyogoku, Koji Okutomo, Mitsuhiro Yamada, Tatsuma Okazaki, Hisatoshi Sugiura, Akira Inoue, Yoshinori Okada, Masakazu Ichinose

Molecular Cancer　18　(1)　24　2019/02/11

DOI： 10.1186/s12943-019-0953-y 　

eISSN： 1476-4598
Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. Peer-reviewed

Kikuchi K, Nozawa K, Yamazaki N, Nakai Y, Higashiyama A, Asano M, Fujiwara Y, Kanda S, Ohe Y, Takashima A, Boku N, Inoue A, Takahashi M, Mori T, Taguchi O, Inoue Y, Mizutani H

The Journal of dermatology　46　(1)　18-25　2019/01

DOI： 10.1111/1346-8138.14691 　

ISSN： 0385-2407

eISSN： 1346-8138
Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey. Peer-reviewed

Oishi T, Sato K, Morita T, Mack JW, Shimodaira H, Takahashi M, Takahashi S, Inoue A, Murakawa Y, Kawahara M, Ishioka C, Miyashita M

Japanese journal of clinical oncology　48　(10)　913-919　2018/10

DOI： 10.1093/jjco/hyy112 　

ISSN： 0368-2811

eISSN： 1465-3621
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を促進する(Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas)

突田容子, 宮内栄作, 齊藤涼子, 岡崎達馬, 井上彰, 岡田克典, 一ノ瀬正和

日本癌学会総会記事　77回　1885-1885　2018/09
Publisher: (一社)日本癌学会
ISSN： 0546-0476
悪性消化管閉塞患者におけるデキサメタゾンによる経口摂取量改善効果の後方視的検討

平塚裕介, 佐藤麻美子, 小野寺克洋, 佐藤勝智, 木幡桂, 田上恵太, 宮城妙子, 佐竹宣明, 井上彰

Palliative Care Research　13　(3)　229-233　2018/09
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. International-journal Peer-reviewed

Yoshihito Kogure, Hideo Saka, Yuichi Takiguchi, Shinji Atagi, Takayasu Kurata, Noriyuki Ebi, Akira Inoue, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Akiko Kada, Takeharu Yamanaka, Masahiko Ando, Nobuyuki Yamamoto, Akihiko Gemma, Yukito Ichinose

Clinical lung cancer　19　(5)　e711-e715-e715　2018/09

DOI： 10.1016/j.cllc.2018.05.005 　

ISSN： 1525-7304

More details Close

BACKGROUND: Treatment with carboplatin (CBDCA) with weekly paclitaxel (PTX) has shown survival benefits compared with vinorelbine or gemcitabine in elderly patients with non-small-cell carcinoma (NSCLC). Docetaxel (DOC), however, remains a standard treatment in NSCLC. The 130-nm albumin-bound formulation of PTX (nab-PTX) has shown activity in NSCLC. Treatment with CBDCA with weekly nab-PTX showed significantly higher efficacy than CBDCA with PTX in patients with squamous histology and significantly increased overall survival (OS) in patients aged 70 years and older. PATIENTS AND METHODS: This randomized, multicenter, phase III trial (UMIN000019843) was designed to compare the efficacy and safety of CBDCA with nab-PTX with DOC in patients aged 70 years and older with advanced squamous NSCLC. Elderly patients who have received no previous chemotherapy for advanced/metastatic squamous NSCLC with Eastern Cooperative Oncology Group performance status of 0 or 1 will be randomized 1:1 to DOC (60 mg/m2 intravenous [I.V.] on day 1) or CBDCA (area under the blood concentration time curve 6 on day 1) with nab-PTX (100 mg/m2 I.V. on days 1, 8, and 15) of each 21-day cycle. The primary end point is OS. Recruitment began in December 2015 and planned enrollment is 250 patients. CONCLUSION: If OS is greater in patients treated with CBDCA with nab-PTX than with DOC, this study will provide a new standard of care for elderly patients with squamous NSCLC.
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. International-journal Peer-reviewed

Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K

Cancer science　109　(9)　2852-2862　2018/09

DOI： 10.1111/cas.13724 　

ISSN： 1347-9032

More details Close

Epidermal growth factor receptor (EGFR)-activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non-small-cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once-daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP8273 dose-escalation/dose-expansion study (NCT02192697) was undertaken in two phases. In phase I, Japanese patients (aged ≥20 years) with NSCLC previously treated with ≥1 EGFR TKI received escalating ASP8273 doses (25-600 mg) to assess safety/tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) by the Bayesian Continual Reassessment Method. In phase II, adult patients with T790M-positive NSCLC in Japan, Korea, and Taiwan received ASP8273 at RP2D to further assess safety/tolerability and determine antitumor activity, which was evaluated according to Simon's two-stage design (threshold response = 30%, expected response = 50%, α = 0.05, β = 0.1). Overall, 121 (n = 45 [33W/12M] phase I, n = 76 [48W/28M]) phase 2) patients received ≥1 dose of ASP8273. In phase I, RP2D and MTD were established as 300 and 400 mg, respectively. As 27 of the 63 patients treated with ASP8273 300 mg achieved a clinical response, ASP8273 was determined to have antitumor activity. The overall response rate at week 24 in all patients was 42% (n = 32/76; 95% confidence interval, 30.9-54.0). Median duration of progression-free survival was 8.1 months (95% confidence interval, 5.6, upper bound not reached). The most commonly reported treatment-related adverse event in phase II was diarrhea (57%, n = 43/76). ASP8273 300 mg was generally well tolerated and showed antitumor activity in Asian patients with both EGFR-activating and T790M mutations.
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. International-journal Peer-reviewed

Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K

Cancer science　109　(8)　2532-2538　2018/08

DOI： 10.1111/cas.13651 　

ISSN： 1347-9032

More details Close

Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of East Asian patients with non-small-cell lung cancer (NSCLC) and confer sensitivity to tyrosine kinase inhibitors (TKIs). ASP8273 is an irreversible EGFR-TKI, given orally, that inhibits EGFR activating mutations and has shown clinical activity in patients with EGFR mutation-positive NSCLC. Epidermal growth factor receptor-TKI-naïve Japanese adult patients (≥20 years) with NSCLC harboring EGFR mutations were enrolled in this open-label, single-arm, phase II study (ClinicalTrials.gov identifier NCT02500927). Patients received ASP8273 300 mg once daily until discontinuation criteria were met. The primary end-point was to determine the safety of ASP8273 300 mg; the secondary end-point was antitumor activity defined by RECIST version 1.1. Thirty-one patients (12 men and 19 women; median age, 64 years [range, 31-82 years]) with EGFR mutation-positive NSCLC were enrolled; as of 23 February 2016, 25 patients (81%) were still on study. Of the 31 patients, 27 (87%) had an exon 19 deletion (n = 13, 42%) or an L858R (n = 14, 45%) EGFR activating mutation, and two (7%) had an L861Q mutation. Five patients (16%) had other EGFR activating mutations, two had an activating mutation and the T790M resistance mutation. The most commonly reported treatment-emergent adverse event was diarrhea (n = 24, 77%). All patients had at least one post-baseline scan; one patient (3%) achieved a confirmed complete response, 13 (42%) had a confirmed partial response, and 15 (48%) had confirmed stable disease (disease control rate, 94% [n = 29/31]) per investigator assessment. Once-daily ASP8273 at 300 mg was generally well tolerated and showed antitumor activity in TKI-naïve Japanese patients with EGFR mutation-positive NSCLC.
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. International-journal Peer-reviewed

Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H

Expert opinion on pharmacotherapy　19　(10)　1049-1056　2018/07

DOI： 10.1080/14656566.2018.1484903 　

ISSN： 1465-6566

More details Close

BACKGROUND: This study aimed to analyze the characteristics and outcomes of patients suffering from non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor mutations (EGFRm+) receiving gefitinib who remained clinically stable following confirmation of progressive disease (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) (R-PD) and identify those who benefited from tyrosine kinase inhibitor therapy beyond PD. RESEARCH DESIGN AND METHODS: The clinical courses of patients with EGFRm+ advanced NSCLC who received first-line gefitinib were investigated. Clinical PD (C-PD) was defined as one or more of the following: (1) symptomatic PD, (2) worsening performance status resulting from PD, (3) threat to a major organ(s), or (4) unequivocal multiorgan PD. RESULTS: Of 529 patients, 258 experienced R-PD without C-PD. Among 258 patients, 91 received gefitinib beyond R-PD. Females were more likely to receive gefitinib beyond R-PD and exhibit a longer time from R-PD to C-PD than males (median days, 175 vs. 79.5). Survival beyond R-PD tended to be longer for elderly patients who received gefitinib beyond PD than for those who did not (median days, 458 vs. 336), but this was not the case for non-elderly patients (median days, 481 vs. 487). CONCLUSIONS: Some patients may benefit from continuation of gefitinib beyond PD.
悪性消化管閉塞に対するデキサメタゾンの後方視的検討

平塚裕介, 佐藤麻美子, 小野寺克洋, 佐藤勝智, 木幡桂, 田上恵太, 宮城妙子, 佐竹宣明, 井上彰

Palliative Care Research　13　(Suppl.)　S358-S358　2018/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. International-journal Peer-reviewed

Satoru Nihei, Junya Sato, Toshiyuki Harada, Shoichi Kuyama, Toshiro Suzuki, Nobutsugu Waga, Yoshitaka Saito, Shigeki Kisara, Atsuko Yokota, Kouji Okada, Masami Tsuchiya, Kazufumi Terui, Yumiko Tadokoro, Takeshi Chiba, Kenzo Kudo, Satoshi Oizumi, Akira Inoue, Naoto Morikawa

Cancer chemotherapy and pharmacology　81　(6)　1051-1059　2018/06

DOI： 10.1007/s00280-018-3580-1 　

ISSN： 0344-5704

More details Close

PURPOSE: The objective of this study was to investigate the effect of renin-angiotensin system inhibitors (RASIs) on bevacizumab (BV)-induced proteinuria in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: We retrospectively reviewed the medical records of NSCLC patients receiving BV between 2008 and 2014 at 11 hospitals. The patients were categorized into three groups according to their antihypertensive drug use: RASI user, non-RASI user, and non-user groups. The primary outcome was a proteinuria event of any grade during the first 6 cycles of BV treatment. RESULTS: A total of 211 patients were included, 89 of whom received antihypertensive drugs. Of these 89 patients, 49 were in the RASI user group, and 40 were in the non-RASI user group. The non-user group comprised 122 patients. The occurrence of proteinuria in the RASI user group was significantly lower than that in the non-RASI user group (P = 0.037) but was not significantly lower than that in the non-user group (P = 0.287). Patients using RASIs had a lower rate of proteinuria than those who did not use RASIs according to multivariate analysis (odds ratio 0.32; 95% confidence interval 0.12-0.86; P = 0.024). CONCLUSION: Our study suggests that RASI administration reduces the risk of proteinuria in patients receiving BV.
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort Peer-reviewed

Isamu Okamoto, Satoshi Morita, Naoki Tashiro, Fumio Imamura, Akira Inoue, Takashi Seto, Nobuyuki Yamamoto, Yuichiro Ohe, Kazuhiko Nakagawa, Masahiro Fukuoka

Lung Cancer　117　14-19　2018/03/01
Publisher: Elsevier Ireland Ltd
DOI： 10.1016/j.lungcan.2018.01.005 　

ISSN： 1872-8332 0169-5002
Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. International-journal Peer-reviewed

Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T

ESMO open　3　(2)　e000313　2018/02

DOI： 10.1136/esmoopen-2017-000313 　

ISSN： 2059-7029
Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naIve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901 Peer-reviewed

Naoto Morikawa, Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada, Yuka Fujita, Terufumi Katoh, Hiroshi Yokouchi, Hiroshi Watanabe, Kazuhiro Usui, Toshiro Suzuki, Jun Sakakibara-Konishi, Hiroki Nagai, Mariko Kanbe, Toshihiro Nukiwa

LUNG CANCER　111　38-42　2017/09

DOI： 10.1016/j.lungcan.2017.06.016 　

ISSN： 0169-5002

eISSN： 1872-8332
Overexpression of IL-38 protein in anticancer drug-induced lung injury and acute exacerbation of idiopathic pulmonary fibrosis Peer-reviewed

Masaki Tominaga, Masaki Okamoto, Tomotaka Kawayama, Masanobu Matsuoka, Shinjiro Kaieda, Yuki Sakazaki, Takashi Kinoshita, Daisuke Mori, Akira Inoue, Tomoaki Hoshino

Respiratory Investigation　55　(5)　293-299　2017/09/01
Publisher: Elsevier B.V.
DOI： 10.1016/j.resinv.2017.06.001 　

ISSN： 2212-5353 2212-5345
The “value” of immune-checkpoint inhibitors for advanced lung cancer Peer-reviewed

Akira Inoue

Respiratory Investigation　55　(4)　253-254　2017/07/01
Publisher: Elsevier B.V.
DOI： 10.1016/j.resinv.2017.04.001 　

ISSN： 2212-5353 2212-5345
Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer Peer-reviewed

Naoki Tode, Toshiaki Kikuchi, Tomohiro Sakakibara, Taizou Hirano, Akira Inoue, Shinya Ohkouchi, Tsutomu Tamada, Tatsuma Okazaki, Akira Koarai, Hisatoshi Sugiura, Tetsuya Niihori, Yoko Aoki, Keiko Nakayama, Kunio Matsumoto, Yoichi Matsubara, Masayuki Yamamoto, Akira Watanabe, Toshihiro Nukiwa, Masakazu Ichinose

CANCER SCIENCE　108　(6)　1263-1270　2017/06

DOI： 10.1111/cas.13233 　

ISSN： 1349-7006
Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. International-journal Peer-reviewed

Naoki Tode, Toshiaki Kikuchi, Tomohiro Sakakibara, Taizou Hirano, Akira Inoue, Shinya Ohkouchi, Tsutomu Tamada, Tatsuma Okazaki, Akira Koarai, Hisatoshi Sugiura, Tetsuya Niihori, Yoko Aoki, Keiko Nakayama, Kunio Matsumoto, Yoichi Matsubara, Masayuki Yamamoto, Akira Watanabe, Toshihiro Nukiwa, Masakazu Ichinose

Cancer science　108　(6)　1263-1270　2017/06

DOI： 10.1111/cas.13233 　

ISSN： 1347-9032

More details Close

Lung cancer accompanied by somatic activating mutations in the epidermal growth factor receptor (EGFR) gene, which is associated with a significant clinical response to the targeted therapy, is frequently found in never-smoking Asian women with adenocarcinoma. Although this implies genetic factors underlying the carcinogenesis, the etiology remains unclear. To gain insight into the pathogenic mechanisms, we sequenced the exomes in the peripheral-blood DNA from six siblings, four affected and two unaffected siblings, of a family with familial EGFR-mutant lung adenocarcinoma. We identified a heterozygous missense mutation in MET proto-oncogene, p.Asn375Lys, in all four affected siblings. Combined with somatic loss of heterozygosity for MET, the higher allele frequency in a Japanese sequencing database supports a causative role of the MET mutation in EGFR-mutant lung cancer. Functional assays showed that the mutation reduces the binding affinity of MET for its ligand, hepatocyte growth factor, and damages the subsequent cellular processes, including proliferation, clonogenicity, motility and tumorigenicity. The MET mutation was further observed to abrogate the ERBB3-mediated AKT signal transduction, which is shared downstream by EGFR. These findings provide an etiological view that the MET mutation is involved in the pathogenesis of EGFR-mutant lung cancer because it generates oncogenic stress that induces compensatory EGFR activation. The identification of MET in a family with familial EGFR-mutant lung cancer is insightful to explore the pathogenic mechanism of not only familial, but also sporadic EGFR-mutant lung cancer by underscoring MET-related signaling molecules.
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival Peer-reviewed

Chee Khoon Lee, Lucy Davies, Yi-Long Wu, Tetsuya Mitsudomi, Akira Inoue, Rafael Rosell, Caicun Zhou, Kazuhiko Nakagawa, Sumitra Thongprasert, Masahiro Fukuoka, Sally Lord, Ian Marschner, Yu-Kang Tu, Richard J. Gralla, Val Gebski, Tony Mok, James Chih-Hsin Yang

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE　109　(6)　2017/06

DOI： 10.1093/jnci/djw279 　

ISSN： 0027-8874

eISSN： 1460-2105
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301 Peer-reviewed

Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, Shunichi Sugawara, Makoto Maemondo, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Toshiyuki Harada, Hiroshi Watanabe, Taku Nakagawa, Masakazu Ichinose

ONCOLOGIST　22　(6)　640-E59　2017/06

DOI： 10.1634/theoncologist.2017-0059 　

ISSN： 1083-7159

eISSN： 1549-490X
自然崩壊型腫瘍崩壊症候群を合併した肺扁平上皮癌の1例

板倉康司, 平野泰三, 宮内栄作, 井上彰, 杉浦久敏, 一ノ瀬正和

日本呼吸器学会誌　6　(3)　200-204　2017/05
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP Peer-reviewed

Tomohide Tamura, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Hiroshige Yoshioka, Masao Harada, Yuichiro Ohe, Naoyuki Nogami, Haruyasu Murakami, Hiroshi Kuriki, Tadashi Shimada, Tomohiro Tanaka, Kengo Takeuchi, Makoto Nishio

JOURNAL OF CLINICAL ONCOLOGY　35　(14)　1515-+　2017/05

DOI： 10.1200/JCO.2016.70.5749 　

ISSN： 0732-183X

eISSN： 1527-7755
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Peer-reviewed

Eisaku Miyauchi, Masakazu Ichinose, Akira Inoue

Journal of Thoracic Oncology　12　(5)　e59-e61　2017/05/01
Publisher: Elsevier Inc
DOI： 10.1016/j.jtho.2017.01.027 　

ISSN： 1556-1380 1556-0864
Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations. Peer-reviewed

Satoshi Oizumi, Shunichi Sugawara, Koichi Minato, Toshiyuki Harada, Akira Inoue, Yuka Fujita, Makoto Maemondo, Satoshi Watanabe, Kazuhiko Ito, Akihiko Gemma

JOURNAL OF CLINICAL ONCOLOGY　35　(2)　e000313　2017/05

DOI： 10.1200/JCO.2017.35.15_suppl.9038 　

ISSN： 0732-183X

eISSN： 1527-7755
A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016) Peer-reviewed

Satoru Miura, Makoto Maemondo, Akira Iwashima, Toshiyuki Harada, Shunichi Sugawara, Kunihiko Kobayashi, Akira Inoue, Taku Nakagawa, Yuichi Takiguchi, Hiroshi Watanabe, Takashi Ishida, Masaki Terada, Hiroshi Kagamu, Akihiko Gemma, Hirohisa Yoshizawa

INVESTIGATIONAL NEW DRUGS　35　(2)　227-234　2017/04

DOI： 10.1007/s10637-017-0436-1 　

ISSN： 0167-6997

eISSN： 1573-0646
Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting Peer-reviewed

Kiyotaka Yoh, Yasushi Goto, Yoichi Naito, Kazuma Kishi, Kiyoshi Mori, Katsuyuki Hotta, Yukio Hosomi, Kazuhiko Yamada, Chiharu Tanai, Yoshio Tomizawa, Akira Inoue, Yoshinori Hasegawa, Makoto Nishio, Yasuo Ohashi, Hideo Kunitoh

ANTICANCER RESEARCH　37　(3)　1507-1513　2017/03

DOI： 10.21873/anticanres.11478 　

ISSN： 0250-7005

eISSN： 1791-7530
Randomized phase II trial of daily administration versus alternate-day administration of S-1 in patients with advanced non-small cell lung cancer Peer-reviewed

Aya Suzuki, Makoto Maemondo, Shunichi Sugawara, Taku Nakagawa, Kageaki Taima, Akira Inoue, Kazuhiko Matsuno, Kazuhiro Usui, Takashi Yokoi, Mariko Kanbe, Toshihiro Nukiwa

Cancer Treatment and Research Communications　12　56-61　2017
Publisher: Elsevier Ltd
DOI： 10.1016/j.ctarc.2017.05.004 　

ISSN： 2468-2942
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol. Peer-reviewed

Shinji Takeuchi, Kenichi Yoshimura, Tadami Fujiwara, Masahiko Ando, Shinobu Shimizu, Katsuhiko Nagase, Yoshinori Hasegawa, Toshiaki Takahashi, Nobuyuki Katakami, Akira Inoue, Seiji Yano

The journal of medical investigation : JMI　64　(3.4)　321-325　2017

DOI： 10.2152/jmi.64.321 　

ISSN： 1343-1420

More details Close

The BIM deletion polymorphism is reported to be associated with poor outcomes of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) treated with EGFR-TKIs, including gefitinib. We have shown that a histone deacetylase inhibitor, vorinostat, can epigenetically restore BIM function and apoptosis sensitivity to EGFR-TKIs in EGFR-mutant NSCLC cells with BIM deletion polymorphisms. The purpose of this study is to determine the feasibility of combined treatment of vorinostat with gefitinib in BIM deletion polymorphism positive EGFR-mutant NSCLC patients. BIM deletion polymorphism positive EGFR-mutant NSCLC patients treated with at least one EGFR-TKI and one regimen of chemotherapy are being recruited to this study. Vorinostat (200-400 mg) will be administered orally once daily on days 1-7, and gefitinib 250 mg orally once daily on days 1-14. With a fixed dose of gefitinib, the dose of vorinostat will be escalated following a conventional 3+3 design. The primary endpoint is to define the maximum tolerated dose (MTD) of vorinostat combined with 250 mg of gefitinib. This is the first phase I study of combined therapy with vorinostat and gefitinib for NSCLC patients double selected for an EGFR mutation and BIM deletion polymorphism. J. Med. Invest. 64: 321-325, August, 2017.
Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. Peer-reviewed

Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H

ESMO open　2　(4)　e000214　2017

DOI： 10.1136/esmoopen-2017-000214 　
Two cases of pseudo-achalasia with lung cancer: Case report and short literature review Peer-reviewed

Taizou Hirano, Eisaku Miyauchi, Akira Inoue, Ryotaro Igusa, Shigeki Chiba, Kazuhiro Sakamoto, Hisatoshi Sugiura, Toshiaki Kikuchi, Masakazu Ichinose

Respiratory Investigation　54　(6)　494-499　2016/11/01
Publisher: Elsevier B.V.
DOI： 10.1016/j.resinv.2016.04.006 　

ISSN： 2212-5353 2212-5345
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy Peer-reviewed

Giorgio Scagliotti, Makoto Nishio, Miyako Satouchi, Giuseppe Valmadre, Seiji Niho, Domenico Galetta, Diego Cortinovis, Fabio Benedetti, Eiji Yoshihara, Lukas Makris, Akira Inoue, Kaoru Kubota

LUNG CANCER　100　20-23　2016/10

DOI： 10.1016/j.lungcan.2016.06.023 　

ISSN： 0169-5002

eISSN： 1872-8332
An analysis of the relationship between metastases and cachexia in lung cancer patients Peer-reviewed

Masatoshi Shiono, Kan Huang, Robert J. Downey, Nikita Consul, Nicolas Villanueva, Kristen Beck, Kathleen Fenn, Donald Dietz, Takuhiro Yamaguchi, Shunsuke Kato, Chaitanya Divgi, Kevin Kalinsky, Ying Wei, Yuan Zhang, Alain C. Borczuk, Akira Inoue, Balazs Halmos, Swarnali Acharyya

CANCER MEDICINE　5　(9)　2641-2648　2016/09

DOI： 10.1002/cam4.841 　

ISSN： 2045-7634
A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A Peer-reviewed

Kazuhiro Usui, Shunichi Sugawara, Masaru Nishitsuji, Yuka Fujita, Akira Inoue, Atsuto Mouri, Hiroshi Watanabe, Hiroshi Sakai, Ichiro Kinoshita, Yoshihito Ohhara, Makoto Maemondo, Hiroshi Kagamu, Koichi Hagiwara, Kunihiko Kobayashi

LUNG CANCER　99　131-136　2016/09

DOI： 10.1016/j.lungcan.2016.07.003 　

ISSN： 0169-5002

eISSN： 1872-8332
【免疫チェックポイント制御阻害療法の新展開】非小細胞肺癌

宮内栄作, 井上彰

癌と化学療法　43　(6)　666-671　2016/06
Publisher: (株)癌と化学療法社
ISSN： 0385-0684
Immune checkpoint therapy for non-small-cell lung cancer Peer-reviewed

Eisaku Miyauchi, Akira Inoue

Japanese Journal of Cancer and Chemotherapy　43　(6)　666-671　2016/06/01
Publisher: Japanese Journal of Cancer and Chemotherapy Publishers Inc.
ISSN： 0385-0684
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients Peer-reviewed

Akira Inoue, Kazushi Yoshida, Satoshi Morita, Fumio Imamura, Takashi Seto, Isamu Okamoto, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Satoshi Muto, Masahiro Fukuoka

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　46　(5)　462-467　2016/05

DOI： 10.1093/jjco/hyw014 　

ISSN： 0368-2811

eISSN： 1465-3621
VII. Developments of Chemotherapy and Improvements of Prognosis in Lung Cancer

Inoue Akira

Nihon Naika Gakkai Zasshi　105　(6)　997-1003　2016
Publisher: The Japanese Society of Internal Medicine
DOI： 10.2169/naika.105.997 　

ISSN： 0021-5384
Prospective and clinical validation of ALK immunohistochemistry: Results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study) Peer-reviewed

Kengo Takeuchi, Y. Togashi, Y. Kamihara, T. Fukuyama, H. Yoshioka, A. Inoue, H. Katsuki, K. Kiura, K. Nakagawa, T. Seto, M. Maemondo, T. Hida, M. Harada, Y. Ohe, N. Nogami, N. Yamamoto, M. Nishio, T. Tamura

Annals of Oncology　27　(1)　185-192　2016/01/01
Publisher: Oxford University Press
DOI： 10.1093/annonc/mdv501 　

ISSN： 1569-8041 0923-7534
Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion Peer-reviewed

Satoshi Watanabe, Akira Inoue, Toshihiro Nukiwa, Kunihiko Kobayashi

ANTICANCER RESEARCH　35　(12)　6957-6961　2015/12

ISSN： 0250-7005

eISSN： 1791-7530
EGFR遺伝子変異を伴う肺がん患者の遺伝的機序の解明

東出直樹, 菊地利明, 平野泰三, 大河内眞也, 井上彰, 一ノ瀬正和

日本癌学会総会記事　74回　J-1013　2015/10
Publisher: (一社)日本癌学会
ISSN： 0546-0476
RAS Inhibitor Prevent Proteinuria of NSCLC Patients Who Received Bevasizumab Chemotherapy: NJLCG 1303 Peer-reviewed

Kuyama, Shoichi, Nihei, Satoru, Harada, Toshiyuki, Suzuki, Toshiro, Saito, Yoshitaka, Oizumi, Satoshi, Kisara, Shigeki, Inoue, Akira, Yokota, Atsuko, Yokouchi, Hiroshi, Okada, Koji, Mori, Yoshiaki, Tsuchiya, Masami, Maemondo, Makoto, Terui, Kazufumi, Taima, Kageaki, Tadokoro, Yumiko, Watanabe, Hiroshi, Sato, Junya, Morikawa, Naoto

JOURNAL OF THORACIC ONCOLOGY　10　(9)　S662-S662　2015/09

ISSN： 1556-0864

eISSN： 1556-1380
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial Peer-reviewed

K. Kubota, Tokyo Cooperative Oncology Group, H. Sakai, N. Katakami, M. Nishio, A. Inoue, H. Okamoto, H. Isobe, H. Kunitoh, Y. Takiguchi, K. Kobayashi, Y. Nakamura, H. Ohmatsu, S. Sugawara, K. Minato, M. Fukuda, A. Yokoyama, M. Takeuchi, H. Michimae, Akihiko Gemma, S. Kudoh

Annals of Oncology　26　(7)　1401-1408　2015/07/01
Publisher: Oxford University Press
DOI： 10.1093/annonc/mdv190 　

ISSN： 1569-8041 0923-7534
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002) Peer-reviewed

Eisaku Miyauchi, Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Yasuo Saijo, Hirohisa Yoshizawa, Koichi Hagiwara, Toshihiro Nukiwa

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　45　(7)　670-676　2015/07

DOI： 10.1093/jjco/hyv054 　

ISSN： 0368-2811

eISSN： 1465-3621
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702 Peer-reviewed

Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Yoshiaki Mori, Satoshi Oizumi, Masao Harada, Kageaki Taima, Naoto Morikawa, Takashi Ishida, Ichiro Kinoshita, Hiroshi Watanabe, Toshiro Suzuki, Taku Nakagawa, Ryota Saito, Toshihiro Nukiwa

LUNG CANCER　89　(1)　61-65　2015/07

DOI： 10.1016/j.lungcan.2015.04.012 　

ISSN： 0169-5002

eISSN： 1872-8332
Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study Peer-reviewed

Osamu Ishimoto, Shunichi Sugawara, Akira Inoue, Makoto Maemondo, Toshihiro Nukiwa

Respiratory Investigation　53　(4)　156-160　2015/07/01
Publisher: Elsevier B.V.
DOI： 10.1016/j.resinv.2015.02.006 　

ISSN： 2212-5353 2212-5345
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis Peer-reviewed

Chee Khoon Lee, Yi-Long Wu, Pei Ni Ding, Sarah J. Lord, Akira Inoue, Caicun Zhou, Tetsuya Mitsudomi, Rafael Rosell, Nick Pavlakis, Matthew Links, Val Gebski, Richard J. Gralla, James Chih-Hsin Yang

JOURNAL OF CLINICAL ONCOLOGY　33　(17)　1958-U142　2015/06

DOI： 10.1200/JCO.2014.58.1736 　

ISSN： 0732-183X

eISSN： 1527-7755
Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation Peer-reviewed

Tatsuro Fukuhara, Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita, Yuka Fujita, Yasuo Saijo, Koichi Hagiwara, Satoshi Morita, Toshihiro Nukiwa

LUNG CANCER　88　(2)　181-186　2015/05

DOI： 10.1016/j.lungcan.2015.02.004 　

ISSN： 0169-5002

eISSN： 1872-8332
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies Peer-reviewed

Naoto Morikawa, Yuji Minegishi, Akira Inoue, Makoto Maemondo, Kunihiko Kobayashi, Shunichi Sugawara, Masao Harada, Koichi Hagiwara, Shoji Okinaga, Satoshi Oizumi, Toshihiro Nukiwa, Akihiko Gemma

EXPERT OPINION ON PHARMACOTHERAPY　16　(4)　465-472　2015/03

DOI： 10.1517/14656566.2015.1002396 　

ISSN： 1465-6566

eISSN： 1744-7666
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Peer-reviewed

Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T, North East Japan, Study Group, Tokyo Cooperative, Oncology Group

Ann Oncol.　26　(5)　888-894　2015
Publisher: Oxford University Press
DOI： 10.1093/annonc/mdv063 　

ISSN： 0923-7534
Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues. Peer-reviewed

Narumi S, Miki Y, Hata S, Ebina M, Saito M, Mori K, Kobayashi M, Suzuki T, Iwabuchi E, Sato I, Maemondo M, Endo C, Inoue A, Kondo T, Yamada-Okabe H, Ichinose M, Sasano H

The International journal of biological markers　30　(2)　234-242　2015/01
Publisher: SAGE Publications
DOI： 10.5301/jbm.5000131 　

ISSN： 0393-6155

eISSN： 1724-6008
The burden of introducing the Japanese language version of the Liverpool Care Pathway(LCP-J)for dying patients in general wards and their families:experience of health care professionals in a university hospital

菅野雄介, 佐藤一樹, 早川陽子, 瀧田好恵, 我妻崇史, 千葉友子, 本田和子, 柴田弘子, 山内かず子, 高橋信, 井上彰, 宮下光令

Palliat Care Res (Web)　10　(1)　318-323 (J-STAGE)-323　2015
Publisher: Japanese Society for Palliative Medicine
DOI： 10.2512/jspm.10.318 　

ISSN： 1880-5302

More details Close

The purpose of this study was to explore the burden of introducing LCP-J in two wards（medical oncology and respiratory medicine）in Tohoku University Hospital. We administered audit evaluations about dying cancer patients and interviewed 2 doctors and 8 nurses regarding LCP-J intervention. LCP-J was used for 22 patients（38％）, and no significant difference in infusion, potent opioid analgesic and sedative medication within last 48 hours were seen between users and nonusers. Responses were categorized into［confirm directions about dying care among health care professionals］, and［training in dying care in a structured way］as usefulness facets of the LCP-J, and［difficulty in assessment of dying］,［burden of health care professionals］, and［difficulty using LCP-J without knowledge and training in dying care］as burdens of the LCP-J. We explored the burden of LCP-J in general wards, and found that use of the LCP-J could need education in dying care and backup of the palliative care team.
Treatment of advanced non-small-cell lung cancer in elderly patients Peer-reviewed

Eisaku Miyauchi, Akira Inoue

Japanese Journal of Cancer and Chemotherapy　42　(1)　6-11　2015/01/01
Publisher: Japanese Journal of Cancer and Chemotherapy Publishers Inc.
ISSN： 0385-0684
Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma North Japan Lung Cancer Group Study 0803 Peer-reviewed

Akira Inoue, Shunichi Sugawara, Masao Harada, Kunihiko Kobayashi, Toshiyuki Kozuki, Shoichi Kuyama, Makoto Maemondo, Hajime Asahina, Akiko Hisamoto, Taku Nakagawa, Katsuyuki Hotta, Toshihiro Nukiwa

JOURNAL OF THORACIC ONCOLOGY　9　(12)　1805-1809　2014/12

DOI： 10.1097/JTO.0000000000000362 　

ISSN： 1556-0864

eISSN： 1556-1380
GATA2 regulates differentiation of bone marrow-derived mesenchymal stem cells. Peer-reviewed

Kamata M, Okitsu Y, Fujiwara T, Kanehira M, Nakajima S, Takahashi T, Inoue A, Fukuhara N, Onishi Y, Ishizawa K, Shimizu R, Yamamoto M, Harigae H

Haematologica　99　(11)　1686-1696　2014/11

DOI： 10.3324/haematol.2014.105692 　

ISSN： 0390-6078
Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/TCOG0902. Peer-reviewed

Satoshi Oizumi, Shunichi Sugawara, Koichi Minato, Toshiyuki Harada, Akira Inoue, Yuka Fujita, Makoto Maemondo, Hirohisa Yoshizawa, Kazuhiko Ito, Akihiko Gemma, Masaru Nishitsuji, Masao Harada, Hiroshi Isobe, Ichiro Kinoshita, Satoshi Morita, Kunihiko Kobayashi, Koichi Hagiwara, Minoru Kurihara, Toshihiro Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　32　(15)　2014/05

DOI： 10.1200/jco.2014.32.15_suppl.8016 　

ISSN： 0732-183X

eISSN： 1527-7755
Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel and Docetaxel Alone in Elderly Patients With Advanced Non-Small Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801 Peer-reviewed

Makoto Maemondo, Akira Inoue, Shunichi Sugawara, Toshiyuki Harada, Yuji Minegishi, Kazuhiro Usui, Koji Miwa, Naoto Morikawa, Mariko Kambe, Kenji Ube, Kana Watanabe, Osamu Ishimoto, Tomohiro Sakakibara, Akihiko Gemma, Toshihiro Nukiwa

ONCOLOGIST　19　(4)　352-353　2014/04

DOI： 10.1634/theoncologist.2013-0411 　

ISSN： 1083-7159

eISSN： 1549-490X
肺癌のdriver mutationをめぐって

井上彰, 後藤功一, 萩原弘一, 光冨徹哉

呼吸　33　(2)　111-120　2014/02
Publisher: (一社)呼吸研究
ISSN： 0286-9314
Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q Peer-reviewed

Satoshi Watanabe, Yuji Minegishi, Hirohisa Yoshizawa, Makoto Maemondo, Akira Inoue, Shunichi Sugawara, Hiroshi Isobe, Masao Harada, Yoshiki Ishii, Akihiko Gemma, Koichi Hagiwara, Kunihiko Kobayashi

JOURNAL OF THORACIC ONCOLOGY　9　(2)　189-194　2014/02

DOI： 10.1097/JTO.0000000000000048 　

ISSN： 1556-0864

eISSN： 1556-1380
An effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer Peer-reviewed

Makoto Kobayashi, Tomohiro Sakakibara, Akira Inoue, Tatsuro Fukuhara, Hironobu Sasano, Masakazu Ichinose, Toshihiro Nukiwa

Respiratory Investigation　52　(1)　49-56　2014/01

DOI： 10.1016/j.resinv.2013.06.003 　

ISSN： 2212-5345
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802 Peer-reviewed

Yosuke Kawashima, Akira Inoue, Shunichi Sugawara, Satoshi Oizumi, Makoto Maemondo, Koichi Okudera, Toshiro Suzuki, Kazuhiro Usui, Masao Harada, Naoto Morikawa, Yukihiro Hasegawa, Ryota Saito, Osamu Ishimoto, Tomohiro Sakakibara, Hajime Asahina, Toshihiro Nukiwa

Respiratory Investigation　52　(3)　190-194　2014
Publisher: Elsevier
DOI： 10.1016/j.resinv.2013.12.005 　

ISSN： 2212-5353 2212-5345
LUX-lung 4: A phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both Peer-reviewed

Nobuyuki Katakami, Shinji Atagi, Koichi Goto, Toyoaki Hida, Takeshi Horai, Akira Inoue, Yukito Ichinose, Kunihiko Koboyashi, Koji Takeda, Katsuyuki Kiura, Kazuto Nishio, Yoko Seki, Ryuichi Ebisawa, Mehdi Shahidi, Nobuyuki Yamamoto

Journal of Clinical Oncology　31　(27)　3335-3342　2013/09/20

DOI： 10.1200/JCO.2012.45.0981 　

ISSN： 0732-183X 1527-7755
Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Peer-reviewed

Satoru Yanagisawa, Akira Inoue, Akira Koarai, Manabu Ono, Tokiwa Tamai, Masakazu Ichinose

JOURNAL OF THORACIC ONCOLOGY　8　(8)　E73-E74　2013/08

DOI： 10.1097/JTO.0b013e318293dfc1 　

ISSN： 1556-0864
Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601 Peer-reviewed

Shunichi Sugawara, Makoto Maemondo, Motoko Tachihara, Akira Inoue, Osamu Ishimoto, Tomohiro Sakakibara, Kazuhiro Usui, Hiroshi Watanabe, Nobumichi Matsubara, Kana Watanabe, Kenya Kanazawa, Takashi Ishida, Yasuo Saijo, Toshihiro Nukiwa

LUNG CANCER　81　(1)　91-96　2013/07

DOI： 10.1016/j.lungcan.2013.04.010 　

ISSN： 0169-5002
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). International-journal Peer-reviewed

Hiroaki Akamatsu, Akira Inoue, Tetsuya Mitsudomi, Kunihiko Kobayashi, Kazuhiko Nakagawa, Keita Mori, Toshihiro Nukiwa, Yoichi Nakanishi, Nobuyuki Yamamoto

Japanese journal of clinical oncology　43　(6)　664-8　2013/06

DOI： 10.1093/jjco/hyt049 　

ISSN： 0368-2811

More details Close

OBJECTIVE: Interstitial lung disease associated with gefitinib is a critical adverse reaction. When geftinib was administered to EGFR-unknown patients, the interstitial lung disease incidence rate was approximately 3-4% in Japan, and usually occurs during the first 4 weeks of treatment. However, it has not been fully investigated in EGFR-mutated patients. METHODS: We collected clinical records of participants of two Phase III trials (WJTOG 3405 and NEJ 002), which compared gefitinib with platinum doublet chemotherapy. All patients were EGFR mutated, chemo-naïve and had good performance status. RESULTS: A total of 402 patients were enrolled in this study. In the gefitinib arm, 10 (5.0%) of 201 patients developed interstitial lung disease, of whom five (2.5%) were Grade 3 or greater, with two deaths (1.0%). In contrast, only one patient developed interstitial lung disease (Grade 1) in the chemotherapy arm. With regard to gefitinib, smoking history was significantly associated with developing interstitial lung disease (odds ratio 0.18; 95% confidence interval: 0.05-0.74; P = 0.01). The cumulative incidence rate of interstitial lung disease was similar in the 0-4, 5-8 and 9-12 week time periods. However, between smokers and never-smokers, cumulative incidence rates in the first 4 weeks were significantly different (4.7% versus 0%, P = 0.03). Three of 10 patients developed interstitial lung disease after 8 weeks of gefitinib administration (days 135, 171 and 190, respectively). CONCLUSIONS: Among EGFR-mutated patients, the incidence of interstitial lung disease associated with gefitinib was not different from that in previous reports. Smoking history was associated with developing interstitial lung disease, and smokers had a higher incidence rate of interstitial lung disease in the first 4 weeks.
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study Peer-reviewed

Takashi Seto, Katsuyuki Kiura, Makoto Nishio, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Nobuyuki Yamamoto, Hiroshige Yoshioka, Masao Harada, Yuichiro Ohe, Naoyuki Nogami, Kengo Takeuchi, Tadashi Shimada, Tomohiro Tanaka, Tomohide Tamura

LANCET ONCOLOGY　14　(7)　590-598　2013/06

DOI： 10.1016/S1470-2045(13)70142-6 　

ISSN： 1470-2045
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis Peer-reviewed

Chee Khoon Lee, Chris Brown, Richard J. Gralla, Vera Hirsh, Sumitra Thongprasert, Chun-Ming Tsai, Eng Huat Tan, James Chung-Man Ho, Da Tong Chu, Adel Zaatar, Jemela Anne Osorio Sanchez, Vu Van Vu, Joseph Siu Kie Au, Akira Inoue, Siow Ming Lee, Val Gebski, James Chih-Hsin Yang

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE　105　(9)　595-605　2013/05

DOI： 10.1093/jnci/djt072 　

ISSN： 0027-8874

eISSN： 1460-2105
A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703 Peer-reviewed

Nobumichi Matsubara, Makoto Maemondo, Akira Inoue, Osamu Ishimoto, Kana Watanabe, Tomohiro Sakakibara, Tatsuro Fukuhara, Naoto Morikawa, Masashi Tanaka, Shunichi Sugawara, Toshihiro Nukiwa

Respiratory Investigation　51　(1)　28-34　2013/03

DOI： 10.1016/j.resinv.2012.09.004 　

ISSN： 2212-5345
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901. International-journal Peer-reviewed

Toshiyuki Harada, Satoshi Oizumi, Kenichiro Ito, Kei Takamura, Eiki Kikuchi, Tomoya Kuda, Shunichi Sugawara, Aya Suzuki, Makoto Maemondo, Yuka Fujita, Ichiro Kinoshita, Akira Inoue, Fumihiro Hommura, Yutaka Katsuura, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura

The oncologist　18　(4)　439-45　2013

DOI： 10.1634/theoncologist.2012-0308 　

ISSN： 1083-7159

More details Close

Amrubicin, a third-generation synthetic anthracycline agent, has favorable clinical activity and acceptable toxicity for the treatment of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer. We conducted this study to evaluate the efficacy and safety of amrubicin for advanced NSCLC patients as a third- or fourth-line therapy. Eligible patients had recurrent or refractory advanced NSCLC after second- or third-line therapy. Patients received amrubicin, 35 mg/m(2) i.v. on days 1-3 every 3 weeks. The primary endpoint was the disease control rate (DCR). Secondary endpoints were the overall survival (OS) time, progression-free survival (PFS) time, response rate, and toxicity profile. Of the 41 patients enrolled, 26 received amrubicin as a third-line and 15 received it as a fourth-line therapy. The median number of treatment cycles was two (range, 1-9). Objective responses were complete response (n = 0), partial response (n = 4), stable disease (n = 21), progressive disease (n = 15), and not evaluable (n = 1), resulting in a DCR of 61.0% (95% confidence interval, 46.0%-75.9%). The overall response rate was 9.8% (95% confidence interval, 0.6%-18.8%). The median PFS interval was 3.0 months, median OS time was 12.6 months, and 1-year survival rate was 53.7%. Grade 3 or 4 hematological toxicities were neutropenia (68%), anemia (12%), thrombocytopenia (12%), and febrile neutropenia (17%). Nonhematological toxicities were mild and reversible. No treatment-related deaths were observed. Amrubicin showed significant clinical activity with manageable toxicities as a third- or fourth-line therapy for patients with advanced NSCLC. This study provides relevant data for routine practice and future prospective trials evaluating third- or fourth-line treatment strategies for patients with advanced NSCLC.
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. Peer-reviewed

Kobayashi M, Miki Y, Ebina M, Abe K, Mori K, Narumi S, Suzuki T, Sato I, Maemondo M, Endo C, Inoue A, Kumamoto H, Kondo T, Yamada-Okabe H, Nukiwa T, Sasano H

British journal of cancer　107　(10)　1745-1753　2012/11
Publisher: 10
DOI： 10.1038/bjc.2012.422 　

ISSN： 0007-0920

eISSN： 1532-1827
A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer Peer-reviewed

Manabu Soda, Kazutoshi Isobe, Akira Inoue, Makoto Maemondo, Satoshi Oizumi, Yuka Fujita, Akihiko Gemma, Yoshihiro Yamashita, Toshihide Ueno, Kengo Takeuchi, Young Lim Choi, Hitoshi Miyazawa, Tomoaki Tanaka, Koichi Hagiwara, Hiroyuki Mano

CLINICAL CANCER RESEARCH　18　(20)　5682-5689　2012/10

DOI： 10.1158/1078-0432.CCR-11-2947 　

ISSN： 1078-0432
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study Peer-reviewed

Makoto Maemondo, Yuji Minegishi, Akira Inoue, Kunihiko Kobayashi, Masao Harada, Shoji Okinaga, Naoto Morikawa, Satoshi Oizumi, Tomoaki Tanaka, Hiroshi Isobe, Shoji Kudoh, Koichi Hagiwara, Toshihiro Nukiwa, Akihiko Gemma

JOURNAL OF THORACIC ONCOLOGY　7　(9)　1417-1422　2012/09

DOI： 10.1097/JTO.0b013e318260de8b 　

ISSN： 1556-0864
Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment Peer-reviewed

Sayaka Mochizuki, Naoki Nishimura, Akira Inoue, Koji Murakami, Toshihiro Nukiwa, Naohiko Chohnabayashi

Respiratory Investigation　50　(3)　117-121　2012/09

DOI： 10.1016/j.resinv.2012.06.002 　

ISSN： 2212-5345
EGFR遺伝子変異を伴う家族性肺腺癌患者におけるエクソーム解析(Whole-exome sequencing of familial non-small cell lung cancer patients with the EGFR gene mutations)

東出直樹, 菊地利明, 榊原智博, 福原達朗, 大河内眞也, 岡崎達馬, 井上彰, 貫和敏博

日本癌学会総会記事　71回　545-546　2012/08
Publisher: (一社)日本癌学会
ISSN： 0546-0476
Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial Peer-reviewed

Satoshi Oizumi, Kunihiko Kobayashi, Akira Inoue, Makoto Maemondo, Shunichi Sugawara, Hirohisa Yoshizawa, Hiroshi Isobe, Masao Harada, Ichiro Kinoshita, Shoji Okinaga, Terufumi Kato, Toshiyuki Harada, Akihiko Gemma, Yasuo Saijo, Yuki Yokomizo, Satoshi Morita, Koichi Hagiwara, Toshihiro Nukiwa

ONCOLOGIST　17　(6)　863-870　2012/06

DOI： 10.1634/theoncologist.2011-0426 　

ISSN： 1083-7159

eISSN： 1549-490X
First-line gefitinib for elderly patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: A combined analysis of NEJ studies. Peer-reviewed

Narumi Sodai, Inoue Akira, Morikawa Naoto, Minegishi Yuji, Maemondo Makoto, Okinaga Shoji, Kobayashi Kunihiko, Harada Toshiyuki, Hagiwara Koichi, Nukiwa Toshihiro, Gemma Akihiko

JOURNAL OF CLINICAL ONCOLOGY　30　(15)　2012/05/20

ISSN： 0732-183X
A case of small-cell lung carcinoma with EGFR gene mutation Peer-reviewed

Sodai Narumil, Akira Inoue, Taizo Shibahara, Ryotaro Igusa, Tomohiro Sakakibaral, Toshihiro Nukiwa

Japanese Journal of Lung Cancer　51　(7)　798-802　2011/12

DOI： 10.2482/haigan.51.798 　

ISSN： 0386-9628
悪性胸膜中皮腫(MPM)に対する当院でのペメトレキセド(PEM)化学療法の治療成績

綿貫善太, 井上彰, 福原達朗, 榊原智博, 太田洋充, 久田修, 佐々木陽彦, 大河内眞也, 海老名雅仁, 貫和敏博

肺癌　51　(5)　470-470　2011/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Peer-reviewed

Hironori Satoh, Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Yasuo Saijo, Hirohisa Yoshizawa, Koichi Hagiwara, Toshihiro Nukiwa

JOURNAL OF THORACIC ONCOLOGY　6　(8)　1413-1417　2011/08

DOI： 10.1097/JTO.0b013e31821d43a8 　

ISSN： 1556-0864
Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling Peer-reviewed

Juliann Chmielecki, Jasmine Foo, Geoffrey R. Oxnard, Katherine Hutchinson, Kadoaki Ohashi, Romel Somwar, Lu Wang, Katherine R. Amato, Maria Arcila, Martin L. Sos, Nicholas D. Socci, Agnes Viale, Elisa de Stanchina, Michelle S. Ginsberg, Roman K. Thomas, Mark G. Kris, Akira Inoue, Marc Ladanyi, Vincent A. Miller, Franziska Michor, William Pao

SCIENCE TRANSLATIONAL MEDICINE　3　(90)　90ra59-90ra59　2011/07

DOI： 10.1126/scitranslmed.3002356 　

ISSN： 1946-6234

eISSN： 1946-6242
悪性胸膜中皮腫(MPM)に対する当院でのペメトレキセド(PEM)化学療法の治療成績

綿貫善太, 井上彰, 福原達朗, 榊原智博, 太田洋充, 久田修, 佐々木陽彦, 大河内眞也, 海老名雅仁, 貫和敏博

日本呼吸器学会雑誌　49　(増刊)　322-322　2011/03
Publisher: (一社)日本呼吸器学会
ISSN： 1343-3490
Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study) Peer-reviewed

Fumio Imamura, Makoto Nishio, Rintaro Noro, Masahiro Tsuboi, Norihiko Ikeda, Akira Inoue, Yoshinobu Ohsaki, Yukio Kimura, Kazumi Nishino, Junji Uchida, Takeshi Horai

CHEMOTHERAPY　57　(4)　357-362　2011

DOI： 10.1159/000330481 　

ISSN： 0009-3157
FIRST-LINE GEFITINIB VS CARBOPLATIN/PACLITAXEL IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: PHASE III STUDY NEJ002 Peer-reviewed

Osamu Ishimoto, Kobayashi Kunihiko, Inoue Akira, Maemondo Makoto, Sugawara Shunichi, Oizumi Satoshi, Saijo Yasuo, Gemma Akihiko, Morita Satoshi, Hagiwara Koichi, Nukiwa Toshihiro

ANNALS OF ONCOLOGY　21　11　2010/11

DOI： 10.1093/annonc/mdq560 　

ISSN： 0923-7534
Lung cancer Peer-reviewed

Akira Inoue

Japanese Journal of Cancer and Chemotherapy　37　(7)　1224-1229　2010/07/15
Publisher: Japanese Journal of Cancer and Chemotherapy Publishers Inc.
ISSN： 0385-0684
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. Peer-reviewed

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita, Yuka Fujita, Shoji Okinaga, Haruto Hirano, Kozo Yoshimori, Toshiyuki Harada, Takashi Ogura, Masahiro Ando, Hitoshi Miyazawa, Tomoaki Tanaka, Yasuo Saijo, Koichi Hagiwara, Satoshi Morita, Toshihiro Nukiwa

NEW ENGLAND JOURNAL OF MEDICINE　362　(25)　2380-2388　2010/06

DOI： 10.1056/NEJMoa0909530 　

ISSN： 0028-4793
A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405 Peer-reviewed

A. Inoue, O. Ishimoto, S. Fukumoto, K. Usui, T. Suzuki, H. Yokouchi, M. Maemondo, M. Kanbe, S. Ogura, T. Harada, S. Oizumi, M. Harada, S. Sugawara, T. Fukuhara, T. Nukiwa

ANNALS OF ONCOLOGY　21　(4)　800-803　2010/04

DOI： 10.1093/annonc/mdp384 　

ISSN： 0923-7534
Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer Peer-reviewed

T. Sakakibara, A. Inoue, S. Sugawara, M. Maemondo, T. Ishida, K. Usui, T. Abe, M. Kanbe, H. Watanabe, Y. Saijo, T. Nukiwa

ANNALS OF ONCOLOGY　21　(4)　795-799　2010/04

DOI： 10.1093/annonc/mdp401 　

ISSN： 0923-7534
進行非小細胞肺癌で化学療法を施行した患者の予後調査に基づく、全生存期間、2年生存率の10年の変化

村松聡士, 佐々木陽彦, 井上彰, 福原達朗, 大河内眞也, 榊原智博, 千葉茂樹, 阿部恭子, 小山正平, 冲永壮治, 前門戸任, 大内譲, 安田浩康, 海老名雅仁, 貫和敏博

日本呼吸器学会雑誌　48　(増刊)　273-273　2010/03
Publisher: (一社)日本呼吸器学会
ISSN： 1343-3490
Frequency of and variables associated with the EGFR mutation and its subtypes Peer-reviewed

Tomoaki Tanaka, Masaru Matsuoka, Akihisa Sutani, Akihiko Gemma, Makoto Maemondo, Akira Inoue, Shoji Okinaga, Makoto Nagashima, Satoshi Oizumi, Kazutsugu Uematsu, Yoshiaki Nagai, Gaku Moriyama, Hitoshi Miyazawa, Kenji Ikebuchi, Satoshi Morita, Kunihiko Kobayashi, Koichi Hagiwara

INTERNATIONAL JOURNAL OF CANCER　126　(3)　651-655　2010/02

DOI： 10.1002/ijc.24746 　

ISSN： 0020-7136
Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib Peer-reviewed

Hajime Asahina, Satoshi Oizumi, Akira Inoue, Ichiro Kinoshita, Takashi Ishida, Yuka Fujita, Noriaki Sukoh, Masao Harada, Makoto Maemondo, Yasuo Saijo, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Toshihiro Nukiwa, Masaharu Nishimura

ONCOLOGY　79　(5-6)　423-429　2010

DOI： 10.1159/000326488 　

ISSN： 0030-2414
Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection Peer-reviewed

T. Kikuchi, A. Watanabe, K. Gomi, T. Sakakibara, K. Nishimori, H. Daito, S. Fujimura, R. Tazawa, A. Inoue, M. Ebina, Y. Tokue, M. Kaku, T. Nukiwa

THORAX　64　(10)　901-907　2009/10

DOI： 10.1136/thx.2009.114603 　

ISSN： 0040-6376
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations Peer-reviewed

Satoshi Morita, Isamu Okamoto, Kunihiko Kobayashi, Koichi Yamazaki, Hajime Asahina, Akira Inoue, Koichi Hagiwara, Noriaki Sunaga, Noriko Yanagitani, Toyoaki Hida, Kimihide Yoshida, Tomonori Hirashima, Kosei Yasumoto, Kenji Sugio, Tetsuya Mitsudomi, Masahiro Fukuoka, Toshihiro Nukiwa

CLINICAL CANCER RESEARCH　15　(13)　4493-4498　2009/07

DOI： 10.1158/1078-0432.CCR-09-0391 　

ISSN： 1078-0432
Retrospective analysis of acquired resistance during the treatment with gefitinib in non-small cell lung cancer patients with epidermal growth factor receptor mutations Peer-reviewed

Teruyuki Sato, Akira Inoue, Tatsuro Fukuhara, Tomohiro Sakakibara, Hiromitsu Ohta, Masahito Ebina, Yasuo Saijo, Toshihiro Nukiwa

Japanese Journal of Lung Cancer　49　(3)　257-261　2009/06/20

DOI： 10.2482/haigan.49.257 　

ISSN： 0386-9628
EGFR遺伝子変異陽性NSCLC症例に対するゲフィチニブ治療の第II相試験統合解析(I-CAMP study group)

杉尾賢二, 平島智徳, 樋田豊明, 萩原弘一, 砂長則明, 井上彰, 朝比奈肇, 森田智視, 光冨徹哉, 福岡正博, 貫和敏博, 安元公正

日本呼吸器学会雑誌　47　(増刊)　109-109　2009/05
Publisher: (一社)日本呼吸器学会
ISSN： 1343-3490
原発性肺癌での根治的放射線治療における重症放射線肺臓炎の検討

中村敦, 井上彰, 太田洋充, 大河内眞也, 海老名雅仁, 貫和敏博

日本呼吸器学会雑誌　47　(増刊)　207-207　2009/05
Publisher: (一社)日本呼吸器学会
ISSN： 1343-3490
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy Peer-reviewed

Akira Inoue, Kunihiko Kobayashi, Kazuhiro Usui, Makoto Maemondo, Shoji Okinaga, Iwao Mikami, Masahiro Ando, Koichi Yamazaki, Yasuo Saijo, Akihiko Gemma, Hitoshi Miyazawa, Tomoaki Tanaka, Kenji Ikebuchi, Toshihiro Nukiwa, Satoshi Morita, Koichi Hagiwara

JOURNAL OF CLINICAL ONCOLOGY　27　(9)　1394-1400　2009/03

DOI： 10.1200/JCO.2008.18.7658 　

ISSN： 0732-183X
Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402 Peer-reviewed

Akira Inoue, Shunichi Sugawara, Koichi Yamazaki, Makoto Maemondo, Toshiro Suzuki, Kazunori Gomi, Shingo Takanashi, Chieko Inoue, Minoru Inage, Hiroshi Yokouchi, Hiroshi Watanabe, Toumei Tsukamoto, Yasuo Saijo, Osamu Ishimoto, Fumihiro Hommura, Toshihiro Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　26　(33)　5401-5406　2008/11

DOI： 10.1200/JCO.2008.18.1974 　

ISSN： 0732-183X
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer Peer-reviewed

Riichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura, Nobuyuki Yamamoto, Masahiro Tsuboi, Kazuhiko Nakagawa, Tetsu Shinkai, Shunichi Negoro, Fumio Imamura, Kenji Eguchi, Koji Takeda, Akira Inoue, Keisuke Tomii, Masao Harada, Noriyuki Masuda, Haiyi Jiang, Yohji Itoh, Yukito Ichinose, Nagahiro Saijo, Masahiro Fukuoka

JOURNAL OF CLINICAL ONCOLOGY　26　(26)　4244-4252　2008/09

DOI： 10.1200/JCO.2007.15.0185 　

ISSN： 0732-183X
Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation Peer-reviewed

Akira Inoue, Hong Xin, Takuji Suzuki, Masahiko Kanehira, Yoshio Kuroki, Tatsuro Fukuhara, Toshiaki Kikuchi, Makoto Maemondo, Toshihiro Nukiwa, Yasuo Saijo

CANCER SCIENCE　99　(8)　1679-1684　2008/08

DOI： 10.1111/j.1349-7006.2008.00857.x 　

ISSN： 1347-9032
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene Peer-reviewed

Tatsuro Fukuhara, Yasuo Saijo, Tomohiro Sakakibara, Akira Inoue, Naoto Morikawa, Masayuki Kanamori, Ichiro Nakashima, Toshihiro Nukiwa

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　214　(4)　359-363　2008/04

DOI： 10.1620/tjem.214.359 　

ISSN： 0040-8727

eISSN： 1349-3329
Adenocarcinoma with epidermal growth factor receptor gene mutations in three siblings Peer-reviewed

Tomohiro Sakakibara, Yasuo Saijo, Tatsuro Fukuhara, Kazunori Gomi, Akira Inoue, Osamu Ishimoto, Shunichi Sugawara, Toshihiro Nukiwa

JOURNAL OF THORACIC ONCOLOGY　3　(3)　311-313　2008/03

DOI： 10.1097/JTO.0b013e3181653cce 　

ISSN： 1556-0864
Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/Mesothelin increases its potential as a useful serum tumor marker for mesothelioma Peer-reviewed

Kazu Shiomi, Yoshiaki Hagiwara, Kouji Sonoue, Tatsuya Segawa, Kazuya Miyashita, Masahiro Maeda, Hiroshi Izumi, Kimihiko Masuda, Masataka Hirabayashi, Takao Moroboshi, Takashi Yoshiyama, Atsuko Ishida, Yuji Natori, Akira Inoue, Masashi Kobayashi, Yukinori Sakao, Hideaki Miyamoto, Kazuhisa Takahashi, Okio Hino

CLINICAL CANCER RESEARCH　14　(5)　1431-1437　2008/03

DOI： 10.1158/1078-0432.CCR-07-1613 　

ISSN： 1078-0432
SiRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma Peer-reviewed

Sumitaka Yamanaka, Zhaodi Gu, Masami Sato, Rumi Fujisaki, Kenichi Inomata, Akira Sakurada, Akira Inoue, Toshihiro Nukiwa, Takashi Kondo, Akira Horii

PATHOBIOLOGY　75　(1)　2-8　2008

DOI： 10.1159/000113789 　

ISSN： 1015-2008
Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer Peer-reviewed

Osamu Ishimoto, Shunichi Sugawara, Akira Inoue, Takashi Ishida, Mitsuru Munakata, Sadahiro Koinumaru, Yukihiro Hasegawa, Toshiro Suzuki, Hiroshi Miki, Yasuo Saijo, Toshihiro Nukiwa

JOURNAL OF THORACIC ONCOLOGY　1　(9)　979-983　2006/11

DOI： 10.1097/01243894-200611000-00010 　

ISSN： 1556-0864
A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer Peer-reviewed

Akira Inoue, Koichi Yamazaki, Makoto Maemondo, Takuji Suzuki, Yuichiro Kimura, Mariko Kanbe, Hiroshi Isobe, Masaharu Nishimura, Yasuo Saijo, Toshihiro Nukiwa

JOURNAL OF THORACIC ONCOLOGY　1　(6)　551-555　2006/07

DOI： 10.1097/01243894-200607000-00009 　

ISSN： 1556-0864
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations Peer-reviewed

Akira Inoue, Takuji Suzuki, Tatsuro Fukuhara, Makoto Maemondo, Yuichiro Kimura, Naoto Morikawa, Hiroshi Watanabe, Yasuo Saijo, Toshihiro Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　24　(21)　3340-3346　2006/07

DOI： 10.1200/JCO.2005.05.4692 　

ISSN： 0732-183X
A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer Peer-reviewed

A Inoue, K Usui, O Ishimoto, N Matsubara, M Tanaka, M Kanbe, K Gomi, S Koinumaru, Y Saijo, T Nukiwa

LUNG CANCER　52　(1)　83-87　2006/04

DOI： 10.1016/j.lungcan.2005.11.014 　

ISSN： 0169-5002
Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients Peer-reviewed

H Watanabe, H Kunitoh, S Yamamoto, S Kawasaki, A Inoue, K Hotta, K Shiomi, M Kusumoto, K Sugimura, N Saijo

CANCER SCIENCE　97　(3)　214-218　2006/03

DOI： 10.1111/j.1349-7006.2006.00157.x 　

ISSN： 1347-9032
Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: Results from a prospective feasibility study Peer-reviewed

K Hotta, A Inoue, K Kiura, H Ueoka, M Tanimoto, T Nukiwa

LUNG CANCER　50　(3)　413-415　2005/12

DOI： 10.1016/j.lungcan.2005.07.006 　

ISSN： 0169-5002
【肺癌の制圧を目指して】ゲフィチニブの急性肺障害

大河内眞也, 井上彰, 貫和敏博

成人病と生活習慣病　35　(3)　328-333　2005/03
Publisher: (株)東京医学社
ISSN： 1347-0418
Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts Peer-reviewed

S Andarini, T Kikuchi, M Nukiwa, P Pradono, T Suzuki, S Ohkouchi, A Inoue, M Maemondo, N Ishii, Y Saijo, K Sugamura, T Nukiwa

CANCER RESEARCH　64　(9)　3281-3287　2004/05

DOI： 10.1158/0008-5472.CAN-03-3911 　

ISSN： 0008-5472
高齢者進行非小細胞肺癌に対するカルボプラチン,パクリタキセル(毎週投与)併用療法の第2相試験

井上彰, 臼井一裕, 西條康夫, 田中昌史, 石本修, 大河内眞也, 木村雄一郎, 小犬丸貞裕, 前門戸任, 貫和敏博

日本呼吸器学会雑誌　42　(増刊)　180-180　2004/03
Publisher: (一社)日本呼吸器学会
ISSN： 1343-3490
Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis Peer-reviewed

A Inoue, Y Saijo, T Kikuchi, K Gomi, T Suzuki, M Maemondo, M Miki, T Sato, T Nukiwa

ANNALS OF ONCOLOGY　15　(1)　51-54　2004/01

DOI： 10.1093/annonc/mdh008 　

ISSN： 0923-7534
Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer Peer-reviewed

H Watanabe, N Yamamoto, T Tamura, T Shimoyama, K Hotta, A Inoue, M Sawada, Y Akiyama, H Kusaba, H Nokihara, Sekine, I, H Kunitoh, Y Ohe, T Kodama, N Saijo

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　33　(12)　626-630　2003/12

DOI： 10.1093/jjco/hyg116 　

ISSN： 0368-2811
Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan Peer-reviewed

A Inoue, Y Yamada, Y Matsumura, Y Shimada, K Muro, M Gotoh, T Hamaguchi, T Mizuno, K Shirao

SUPPORTIVE CARE IN CANCER　11　(8)　528-532　2003/08

DOI： 10.1007/s00520-003-0488-y 　

ISSN： 0941-4355
Gefitinib(イレッサ)投与後に間質性肺炎を発症した進行非小細胞肺癌の4例

清水川稔, 井上彰, 海老名雅仁, 小西一央, 大河内眞也, 五味和紀, 前門戸任, 西條康夫, 貫和敏博

日本呼吸器学会雑誌　41　(増刊)　104-104　2003/03
Publisher: (一社)日本呼吸器学会
ISSN： 1343-3490
Severe acute interstitial pneumonia and gefitinib Peer-reviewed

A Inoue, Y Saijo, M Maemondo, K Gomi, Y Tokue, Y Kimura, M Ebina, T Kikuchi, T Moriya, T Nukiwa

LANCET　361　(9352)　137-139　2003/01

DOI： 10.1016/S0140-6736(03)12190-3 　

ISSN： 0140-6736
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer Peer-reviewed

A Inoue, H Kunitoh, K Mori, T Nukiwa, M Fukuoka, N Saijo

LUNG CANCER　38　(2)　205-209　2002/11

DOI： 10.1016/S0169-5002(02)00185-X 　

ISSN： 0169-5002
Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer Peer-reviewed

H Kusaba, T Tamura, T Shimoyama, K Hotta, A Inoue, H Nokihara, Y Ueda, Y Akiyama, N Yamamoto, Sekine, I, H Kunitoh, Y Ohe, T Kodama, N Saijo

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　32　(2)　43-47　2002/02

DOI： 10.1093/jjco/hyf013 　

ISSN： 0368-2811
A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer Peer-reviewed

K Hotta, Sekine, I, T Tamura, M Sawada, H Watanabe, H Kusaba, Y Akiyama, A Inoue, T Shimoyama, H Nokihara, Y Ueda, N Yamamoto, H Kunitoh, Y Ohe, T Kodama, N Saijo

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　31　(12)　596-600　2001/12

DOI： 10.1093/jjco/hye129 　

ISSN： 0368-2811
A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer Peer-reviewed

Y Akiyama, Y Ohe, T Tamura, M Sawada, A Inoue, H Kusaba, N Yamamoto, Sekine, I, H Kunitoh, T Kodama, N Saijo

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　31　(10)　482-487　2001/10

DOI： 10.1093/jjco/hye111 　

ISSN： 0368-2811
Radiation pneumonitis in lung cancer patients: A retrospective study of risk factors and the long-term prognosis Peer-reviewed

A Inoue, H Kunitoh, Sekine, I, M Sumi, K Tokuuye, N Saijo

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　49　(3)　649-655　2001/03

DOI： 10.1016/S0360-3016(00)00783-5 　

ISSN： 0360-3016
Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene Peer-reviewed

A Inoue, K Narumi, N Matsubara, S Sugawara, Y Saijo, K Satoh, T Nukiwa

CANCER LETTERS　157　(1)　105-112　2000/08

DOI： 10.1016/S0304-3835(00)00480-8 　

ISSN： 0304-3835
Inhibition of experimental metastasis of human fibrosarcoma cells by anti-recombinant 37-kDa laminin binding protein antibody Peer-reviewed

K Narumi, A Inoue, H Tanaka, M Isemura, T Shimo-Oka, T Abe, T Nukiwa, K Satoh

JAPANESE JOURNAL OF CANCER RESEARCH　90　(4)　425-431　1999/04

ISSN： 0910-5050

Show all ︎Show first 5

Misc. 149

A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: Capital study.

Yoichiro Hamamoto, Yoshihito Kogure, Akiko Kada, Hiroya Hashimoto, Shinji Atagi, Yuichi Takiguchi, Hideo Saka, Noriyuki Ebi, Akira Inoue, Takayasu Kurata, Takeharu Yamanaka, Masahiko Ando, Shunichiro Iwasawa, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Nobuyuki Yamamoto, Akihiko Gemma

JOURNAL OF CLINICAL ONCOLOGY　39　(15)　2021/05

DOI： 10.1200/JCO.2021.39.15_suppl.9031 　

ISSN： 0732-183X

eISSN： 1527-7755
A Questionnaire Survey of Home Care Nurses’ Attitudes, Difficulties, and Self-reported Practices for Palliative Care in a Community without Specialists to Identify Interventional Targets of Palliative Care Outreach

佐藤麻美子, 佐藤麻美子, 田上恵太, 田上恵太, 田上佑輔, 青山真帆, 井上彰

Palliative Care Research (Web)　16　(1)　2021

ISSN： 1880-5302
EGFR-TKIと化学療法の併用

朝比奈肇, 田中謙太郎, 井上彰, 大泉聡史, 前門戸任, 岡本勇, 清家正博, 杉尾賢二, 小林国彦

日本肺癌学会総会号　61st　2020

ISSN： 0386-9628
A Japanese Lung Cancer Registry Study of Medically Treated Patients

肺癌　59　(6)　734-734　2019/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Refractory Chest Pain Induced by Implantable Cardioverter-Defibrillator in a Patient with Advanced Cancer: What Is the Best Timing for Deactivation of an ICD? International-journal

Yusuke Hiratsuka, Keita Tagami, Akira Inoue

Journal of palliative medicine　22　(7)　745-746　2019/07

DOI： 10.1089/jpm.2019.0126 　
大学病院緩和ケア病棟における臨床宗教師の役割入院患者の語りの主題分析結果を通して

金田諦晃, 青山真帆, 平塚裕介, 田上恵太, 宮下光令, 井上彰

Palliative Care Research　14　(Suppl.)　S229-S229　2019/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
臨床宗教師介入による心理的影響に対するインタビュー調査

平塚裕介, 青山真帆, 金田諦晃, 升川研人, 田上恵太, 宮下光令, 井上彰

Palliative Care Research　14　(Suppl.)　S342-S342　2019/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
緩和ケア病棟に入院中の終末期がん患者の家族介護者のレジリエンスと精神的健康の関連の検討

清水陽一, 前田一石, 林章敏, 松本禎久, 井上彰, 高野真優子, 石垣和美, 升川研人, 宮下光令

Palliative Care Research　14　(Suppl.)　S332-S332　2019/06
Publisher: (NPO)日本緩和医療学会
eISSN： 1880-5302
【非小細胞肺癌薬物療法の選択と実際】遺伝子診断の結果に基づくIV期非小細胞肺癌への薬物療法 EGFR遺伝子変異陽性非小細胞肺癌(非扁平上皮癌)に対する治療戦略

宮内栄作, 井上彰

臨床腫瘍プラクティス　15　(2)　99-105　2019/05
Publisher: (株)ヴァンメディカル
ISSN： 1880-3083
がん臨床研究の今後 NEJSG(北東日本研究機構)の成果と展望

小林国彦, 前門戸任, 清家正博, 磯部宏, 大泉聡史, 井上彰, 石井芳樹, 萩原弘一, 各務博, 滝口裕一, 弦間昭彦, 久保田馨, 高橋和久, 西條康夫, 菊地利明, 吉澤弘久, 礒部威

月刊腫瘍内科　23　(2)　94‐100　2019/02/28

ISSN： 1881-6568
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を促進する(Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas)

突田容子, 宮内栄作, 齊藤涼子, 岡崎達馬, 井上彰, 岡田克典, 一ノ瀬正和

日本癌学会総会記事　77回　1885-1885　2018/09
Publisher: 日本癌学会
ISSN： 0546-0476
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を制御する

突田容子, 藤野直也, 宮内栄作, 井上彰, 板倉康司, 山田充啓, 岡崎達馬, 桜田晃, 杉浦久敏, 岡田克典, 一ノ瀬正和

日本呼吸器学会誌(Web)　7　(増刊)　267-267　2018/03/10
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5884
EGFR遺伝子変異陽性NSCLCのゲフィチニブ/化学療法併用の第二相試験(NEJ005/TCOG0902) 最新アップデート解析

宮林貴大, 大泉聡史, 菅原俊一, 湊浩一, 原田敏之, 井上彰, 藤田結花, 前門戸任, 渡部聡, 弦間昭彦, 出村芳樹, 原田眞雄, 磯部宏, 木下一郎, 森田智視, 小林国彦, 萩原弘一, 相羽惠介, 貫和敏博

日本呼吸器学会誌　7　(増刊)　128-128　2018/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を制御する

突田容子, 藤野直也, 宮内栄作, 井上彰, 板倉康司, 山田充啓, 岡崎達馬, 桜田晃, 杉浦久敏, 岡田克典, 一ノ瀬正和

日本呼吸器学会誌　7　(増刊)　267-267　2018/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を制御する

突田容子, 藤野直也, 宮内栄作, 井上彰, 板倉康司, 山田充啓, 岡崎達馬, 桜田晃, 杉浦久敏, 岡田克典, 一ノ瀬正和

日本呼吸器学会誌　7　(増刊)　267-267　2018/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876
EGFR遺伝子変異陽性NSCLCのゲフィチニブ/化学療法併用の第II相試験(NEJ005/TCOG0902)最新アップデート結果

渡部聡, 大泉聡史, 菅原俊一, 湊浩一, 原田敏之, 井上彰, 藤田結花, 前門戸任, 伊藤和彦, 弦間昭彦, 出村芳樹, 原田眞雄, 磯部宏, 木下一郎, 森田智視, 小林国彦, 萩原弘一, 栗原稔, 貫和敏博

肺癌　57　(5)　442-442　2017/09
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628
Effect of nationwide palliative care education program on lung cancer specialists.

Akira Inoue, Takuhiro Yamaguchi, Keiko Tanaka, Akihiro Sakashita, Keisuke Aoe, Kenji Eguchi

JOURNAL OF CLINICAL ONCOLOGY　35　2017/05

DOI： 10.1200/JCO.2017.35.15_suppl.e21715 　

ISSN： 0732-183X

eISSN： 1527-7755
Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutation positive non-small cell lung cancer.

Shunichi Sugawara, Koichi Azuma, Makoto Nishio, Hidetoshi Hayashi, Katsuyuki Kiura, Miyako Satouchi, Toyoaki Hida, Atsushi Nakamura, Yasuo Iwamoto, Akira Inoue, Koji Takeda, Satoshi Ikeda, Tomoki Nakagawa, Seitaro Asahina, Kanji Komatsu, Satoshi Morita, Masahiro Fukuoka, Kazuhiko Nakagawa

JOURNAL OF CLINICAL ONCOLOGY　35　2017/05

DOI： 10.1200/JCO.2017.35.15_suppl.9037 　

ISSN： 0732-183X

eISSN： 1527-7755
A case of spontaneous tumor lysis syndrome complicated with squamous cell carcinoma of the lung

板倉康司, 平野泰三, 宮内栄作, 井上彰, 井上彰, 杉浦久敏, 一ノ瀬正和

日本呼吸器学会誌(Web)　6　(3)　200‐204 (WEB ONLY)-204　2017/05
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5884
プラチナ既治療肺扁平上皮癌に対するTS‐1+CPT‐11併用療法のII相臨床試験(NJLCG1101)

原田敏之, 石本修, 宮内栄作, 榊原智博, 臼井一裕, 井上彰, 菅原俊一

日本呼吸器学会誌(Web)　6　140　2017/03/10

ISSN： 2186-5884
化学療法プラチナ既治療肺扁平上皮癌に対するTS-1+CPT-11併用療法のII相臨床試験(NJLCG1101)

原田敏之, 石本修, 宮内栄作, 榊原智博, 臼井一裕, 井上彰, 菅原俊一

日本呼吸器学会誌　6　(増刊)　140-140　2017/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
Overall Survival (OS) of EGFR Mutation Positive Non-Small Cell Lung Cancer Patients: Real-World Treatment Patterns of 1,660 Japanese Patients

Kazushi Yoshida, Yuichiro Ohe, Akira Inoue, Toru Kumagai, Masayuki Takeda, Nobuyuki Yamamoto, Takashi Seto, Isamu Okamoto, Naoki Tashiro, Satoshi Morita, Masahiro Fukuoka

JOURNAL OF THORACIC ONCOLOGY　12　(1)　S336-S337　2017/01

ISSN： 1556-0864

eISSN： 1556-1380
ASP8273 Tolerability and Antitumor Activity in TKI-Naive Japanese Subjects with EGFRmut plus NSCLC: Preliminary Results

Makoto Nishio, Koichi Azuma, Hidetoshi Hayashi, Toyoaki Hida, Akira Inoue, Yasuo Iwamoto, Satoshi Ikeda, Katsuyuki Kiura, Miyako Satouchi, Shunichi Sugawara, Koji Takeda, Desai Bhardwaj, Anne Keating, Kanji Komatsu, Maiko Morishita, Kentaro Takeda, Satoshi Morita, Masahiro Fulmoka, Kazuhiko Nakagawa

JOURNAL OF THORACIC ONCOLOGY　12　(1)　S1243-S1244　2017/01

DOI： 10.1016/j.jtho.2016.11.1753 　

ISSN： 1556-0864

eISSN： 1556-1380
プラチナ既治療肺扁平上皮癌に対するTS‐1+CPT‐11併用療法の第II相臨床試験(NJLCG1101)

宮内栄作, 石本修, 原田敏之, 榊原智博, 臼井一裕, 井上彰, 菅原俊一

日本肺癌学会総会号　57th　(6)　511-511　2016/11/05
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations

M. Maemondo, T. Fukuhara, S. Sugawara, Y. Takiguchi, A. Inoue, S. Oizumi, Y. Ishii, H. Yoshizawa, T. Isobe, A. Gemma, S. Morita, K. Hagiwara, K. Kobayashi, T. Nukiwa

ANNALS OF ONCOLOGY　27　2016/10

DOI： 10.1093/annonc/mdw383.86 　

ISSN： 0923-7534

eISSN： 1569-8041
Carboplatin (Cb) plus nab-paclitaxel (PTX) versus docetaxel (D) for elderly squamous (Sq) non-small cell lung cancer (NSCLC) (CAPITAL study)

Y. Kogure, H. Saka, Y. Takiguchi, S. Atagi, T. Kurata, N. Ebi, A. Inoue, K. Kubota, M. Takenoyama, T. Seto, A. Kada, T. Yamanaka, M. Ando, N. Yamamoto, A. Gemma, Y. Ichinose

ANNALS OF ONCOLOGY　27　2016/10

DOI： 10.1093/annonc/mdw383.99 　

ISSN： 0923-7534

eISSN： 1569-8041
尺骨動脈閉塞症を合併した肺腺癌の1例

山中駿, 宮内栄作, 平野泰三, 佐藤慶, 高橋秀徳, 村上康司, 玉井ときわ, 山田充啓, 岡崎達馬, 玉田勉, 杉浦久敏, 一ノ瀬正和, 井上彰

肺癌　56　(5)　404-404　2016/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).

Yoshida Kazushi, Akira Inoue, Shunichi Sugawara, Shuji Murakami, Hideo Saka, Satoshi Morita, Young Hak Kim, Fumio Imamura, Koji Takeda, Kazuhiko Nakagawa, Masayuki Takeda, Shinji Atagi, Yoshikazu Hasegawa, Nobuyuki Yamamoto, Nobuyuki Katakami, Hiroshige Yoshioka, Yasuo Iwamoto, Isamu Okamoto, Takashi Seto, Yuichiro Ohe

JOURNAL OF CLINICAL ONCOLOGY　34　(15)　2016/05

DOI： 10.1200/JCO.2016.34.15_suppl.e20503 　

ISSN： 0732-183X

eISSN： 1527-7755
非小細胞肺癌(ALK遺伝子転座陽性非扁平上皮癌) (特集肺がん・胃がん・大腸がん : そのファーストラインを終えたら?) -- (セカンドライン以降の化学療法治療戦略は?)

齋藤良太, 井上彰

臨床腫瘍プラクティス　12　(1)　15-21　2016
Publisher: ヴァン・メディカル
ISSN： 1880-3083
終末期がん患者を介護する家族の不安と抑うつの実態とその関連要因の検証に関する研究

佐竹宣明, 佐藤一樹, 中保利通, 井上彰, 宮下光令

Palliative Care Research　11　(Suppl.)　315　2016
PHASE II STUDY OF CARBOPLATIN (CBDCA) PLUS WEEKLY NAB-PACLITAXEL (NAB-PTX) IN ELDERLY PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC): NORTH JAPAN LUNG CANCER STUDY GROUP TRIAL 1301

Naoto Morikawa, Shunichi Sugawara, Eisaku Miyauchi, Akira Inoue, Masakazu Ichinose

RESPIROLOGY　20　89-89　2015/12

ISSN： 1323-7799

eISSN： 1440-1843
Brain Metastases in NSCLC-are TKIs changing the treatment strategy?

Wolfram C.M. Dempke, Klaus Edvardsen, Shun Lu, Niels Reinmuth, Martin Reck, Akira Inoue

Anticancer Research　35　(11)　5797-5806　2015/11/01
Publisher: International Institute of Anticancer Research
ISSN： 0250-7005
Phase II study of carboplatin plus weekly nab-paclitaxel in elderly patients with NSCLC:NJLCG1301

Kazuhiro Usui, Eisaku Miyauchi, Shunichi Sugawara, Tatsuro Fukuhara, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Akira Inoue, Masakazu Ishinose

ANNALS OF ONCOLOGY　26　92-92　2015/11

ISSN： 0923-7534

eISSN： 1569-8041
Updates on PFS and safety results of a Phase I/II study (AF-001JP) of alectinib in ALK-rearranged advanced NSCLC

Toshiyuki Kozuki, Makoto Nishio, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Tomohiro Tanaka, Tomohide Tamura

ANNALS OF ONCOLOGY　26　73-73　2015/11

ISSN： 0923-7534

eISSN： 1569-8041
NEJ016: Phase II study of CBDCA and weekly PTX plus BEV for highly selected elderly non-squamous NSCLC patients

Ryo Ito, Satoru Miura, Makoto Maemondo, Toshiyuki Harada, Shunichi Sugawara, Kunihiko Kobayashi, Akira Inoue, Taku Nakagawa, Yuichi Takiguchi, Hirohisa Yoshizawa

ANNALS OF ONCOLOGY　26　91-91　2015/11

ISSN： 0923-7534

eISSN： 1569-8041
Phase I/II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations

Toshio Shimizu, Hiroshi Nokihara, Haruyasu Murakami, Takashi Seto, Makoto Nishio, Koji Takeda, Akira Inoue, Katsuyuki Kiura, Koichi Azuma, Anne Keating, Andrew Krivoshik, Koichi Uegaki, Kentaro Takeda, Kanji Komatsu, Satoshi Morita, Masahiro Fukuoka, Kazuhiko Nakagawa

ANNALS OF ONCOLOGY　26　82-82　2015/11

ISSN： 0923-7534

eISSN： 1569-8041
高齢者肺癌高齢者非小細胞肺癌に対するCarboplatin+少量分割nab-Paclitaxelの第II相臨床試験(NJLCG1301)

福原達朗, 齋藤平佐, 菅原俊一, 臼井一裕, 宮内栄作, 藤田結花, 加藤晃史, 鈴木俊郎, 中川拓, 原田敏之, 三浦弘之, 渡辺洋, 井上彰, 一ノ瀬正和

肺癌　55　(5)　394-394　2015/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
NEJ016: Phase II study of carboplatin and weekly paclitaxel plus bevacizumab followed by bevacizumab for highly selected elderly non-squamous non-small cell lung cancer patients

T. Harada, S. Miura, M. Maemondo, A. Iwashima, S. Sugawara, K. Kobayashi, A. Inoue, T. Nakagawa, Y. Takiguchi, H. Watanabe, M. Seike, T. Ishida, M. Terada, A. Gemma, H. Yoshizawa

EUROPEAN JOURNAL OF CANCER　51　S617-S617　2015/09

ISSN： 0959-8049

eISSN： 1879-0852
Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy

K. Kasahara, K. Kiura, N. Nogami, K. Takayama, Y. Takiguchi, T. Hirashima, K. Aoe, H. Hayashi, H. Saka, K. Takahashi, F. Imamura, S. Oizumi, A. Inoue, M. Satouchi, M. Tatsumi, T. Nakamura, S. Enatsu, T. Tamura, K. Nakagawa

EUROPEAN JOURNAL OF CANCER　51　S620-S620　2015/09

ISSN： 0959-8049

eISSN： 1879-0852
NEJ016: Phase II Study of CBDCA and Weekly PTX plus BEV Followed by BEV for Highly Selected Elderly Non-Squamous NSCLC Patients

Ou Yamaguchi, Satoru Miura, Makoto Maemondo, Akira Iwashima, Toshiyuki Harada, Shunichi Sugawara, Kunihiko Kobayashi, Akira Inoue, Taku Nakagawa, Yuichi Takiguchi, Hiroshi Watanabe, Masahiro Seike, Takashi Ishida, Masaki Terada, Akihiko Gemma, Hirohisa Yoshizawa

JOURNAL OF THORACIC ONCOLOGY　10　(9)　S315-S315　2015/09

ISSN： 1556-0864

eISSN： 1556-1380
Phase II Study of Carboplatin plus Weekly Nab-Paclitaxel in Elderly Patients with NSCLC: North Japan Lung Cancer Study Group Trial 1301

Osamu Ishimoto, Kazuhiro Usui, Makoto Maemondo, Eisaku Miyauchi, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Taku Nakagawa, Toshiyuki Harada, Hiroyuki Miura, Hiroshi Watanabe, Akira Inoue, Masakazu Ichinose

JOURNAL OF THORACIC ONCOLOGY　10　(9)　S657-S658　2015/09

ISSN： 1556-0864

eISSN： 1556-1380
Final Results of Randomized Phase II Study of Carboplatin plus Irinotecan vs. Carboplatin plus Amrubicin for ED-SCLC

Yuka Fujita, Naoto Morikawa, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada, Akira Inoue, Terufumi Katoh, Hiroshi Yokouchi, Toshihiro Nukiwa

JOURNAL OF THORACIC ONCOLOGY　10　(9)　S498-S498　2015/09

ISSN： 1556-0864

eISSN： 1556-1380
Bevacizumab投与の非小細胞肺癌におけるRenin-Angiotensin系阻害薬の蛋白尿低減効果

木皿重樹, 佐藤淳也, 二瓶哲, 八島一史, 伊原大輔, 森川直人, 井上彰, 眞野成康

日本癌治療学会誌　50　(3)　1576-1576　2015/09
Publisher: (一社)日本癌治療学会
ISSN： 0021-4671
治療小細胞肺癌の化学療法 (特集最新の肺がん治療)

齋藤良太, 井上彰

臨牀と研究　92　(7)　855-860　2015/07
Publisher: 大道学館出版部
ISSN： 0021-4965
The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.

Chee Lee, Lucy Claire Davies, Yi-Long Wu, Tetsuya Mitsudomi, Akira Inoue, Rafael Rosell, Caicun Zhou, Kazuhiko Nakagawa, Sumitra Throngprasert, Masahiro Fukuoka, Richard J. Gralla, Val Gebski, Tony Mok, James Chih-Hsin Yang

JOURNAL OF CLINICAL ONCOLOGY　33　(15)　2015/05

ISSN： 0732-183X

eISSN： 1527-7755
A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK plus NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.

Yuichiro Ohe, Makoto Nishio, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Hiroshige Yoshioka, Masao Harada, Naoyuki Nogami, Haruyasu Murakami, Kengo Takeuchi, Tadashi Shimada, Hiroshi Kuriki, Tomohiro Tanaka, Tomohide Tamura

JOURNAL OF CLINICAL ONCOLOGY　33　(15)　2015/05

ISSN： 0732-183X

eISSN： 1527-7755
東北大学病院呼吸器バイオバンクの現状と課題

宮内栄作, 光石陽一郎, 東出直樹, 椎原淳, 三橋善哉, 村松聡士, 小林誠, 佐藤輝幸, 玉井ときわ, 山田充啓, 小荒井晃, 井上彰, 岡崎達馬, 大河内眞也, 玉田勉, 杉浦久敏, 菊地利明, 一ノ瀬正和

日本呼吸器学会誌　4　(増刊)　151-151　2015/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
【高齢者のがん治療】高齢者の肺癌治療

宮内栄作, 井上彰

癌と化学療法　42　(1)　6-11　2015/01
Publisher: (株)癌と化学療法社
ISSN： 0385-0684
Phase I/II study of alectinib (CH5424802/RO5424802) in patients with alk-rearranged non-small cell lung cancer (NSCLC): Updated results from the AF-001JP trial

Hiroshige Yoshioka, Makoto Nishio, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Tomohiro Tanaka, Tomohide Tamura

Japanese Journal of Lung Cancer　54　(7)　892-897　2014/12/20
Publisher: Japan Lung Cancer Society
DOI： 10.2482/haigan.54.892 　

ISSN： 0386-9628
Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC

T. Tamura, T. Seto, K. Nakagawa, M. Maemondo, A. Inoue, T. Hida, H. Yoshioka, M. Harada, Y. Ohe, N. Nogami, H. Murakami, K. Takeuchi, T. Asakawa, K. Kikuchi, T. Tanaka, M. Nishio

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　90　S6-S6　2014/11

ISSN： 0360-3016

eISSN： 1879-355X
RANDOMIZED PHASE 2 OF AMRUBICIN(A) VS RE-CHALLENGE OF PLATINUM(P) IN SENSITIVE-RELAPSED SMALL-CELL LUNG CANCER (SCLC)

Satoshi Oizumi, Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Yoshiaki Mori, Masao Harada, Kageaki Taima, Naoto Morikawa, Takashi Ishida, Ichiro Kinoshita

ANNALS OF ONCOLOGY　25　2014/10

DOI： 10.1093/annonc/mdu435.88 　

ISSN： 0923-7534

eISSN： 1569-8041
RANDOMIZED PII OF CONCURRENT VS SEQUENTIAL ALTERNATING GEFITINIB AND CHEMOTHERAPY IN EGFR-MUTANT NSCLC: NEJ005/TCOG0902

Koichi Minato, Satoshi Oizumi, Shunichi Sugawara, Toshiyuki Harada, Akira Inoue, Yuka Fujita, Makoto Maemondo, Hirohisa Yoshizawa, Minoru Kurihara, Toshihiro Nukiwa

ANNALS OF ONCOLOGY　25　2014/10

DOI： 10.1093/annonc/mdu435.52 　

ISSN： 0923-7534

eISSN： 1569-8041
未治療進行EGFR遺伝子変異陽性肺がんに対するゲフィチニブ治療後のプラチナ併用化学療法の有効性の検討

宮内栄作, 井上彰, 小林国彦, 前門戸任, 菅原俊一, 大泉聡史, 磯部宏, 弦間昭彦, 西條康夫, 吉澤弘久, 森田智視, 萩原弘一, 貫和敏博

肺癌　54　(5)　397-397　2014/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
EGFR遺伝子変異を伴う家族性肺腺癌患者におけるエクソーム解析(Whole-exome sequencing of familial non-small cell lung cancer patients with the EGFR gene mutations)

東出直樹, 菊地利明, 榊原智博, 光石陽一郎, 大河内眞也, 井上彰, 一ノ瀬正和

日本癌学会総会記事　73回　P-2150　2014/09
Publisher: 日本癌学会
ISSN： 0546-0476
FINAL RESULT OF RANDOMIZED PHASE 2 TRIAL COMPARING AMRUBICIN (A) WITH RE-CHALLENGE OF PLATINUM DOUBLET (P) IN PATIENTS (PTS) WITH SENSITIVE-RELAPSED SMALL-CELL LUNG CANCER (SCLC): NJLCG0702

M. Maemondo, A. Inoue, S. Sugawara, Y. Mori, S. Oizumi, M. Harada, K. Taima, N. Morikawa, T. Ishida, I. Kinoshita, H. Watanabe, T. Suzuki, T. Nakagawa, R. Saito, T. Nukiwa

ANNALS OF ONCOLOGY　25　2014/09

DOI： 10.1093/annonc/mdu355.9 　

ISSN： 0923-7534

eISSN： 1569-8041
Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC).

Atsushi Nakamura, Akira Inoue, Makoto Maemondo, Yoshiaki Mori, Satoshi Oizumi, Masao Harada, Shingo Takanashi, Naoto Morikawa, Takashi Ishida, Ichiro Kinoshita, Hiroshi Watanabe, Toshiro Suzuki, Taku Nakagawa, Ryota Saito, Toshihiro Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　32　(15)　2014/05

ISSN： 0732-183X

eISSN： 1527-7755
NEJ009 trial: A randomized phase III study of gefitinib (G) on combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation

Akira Inoue, Yukio Hosomi, Makoto Maemondo, Shunichi Sugawara, Terufumi Kato, Kazuhlsa Takahashi, Yuka Fujita, Aklhlko Gamma, Toshiyuki Harada, Satoshi Oizumi, Koichi Minato, Satoshi Morita, Toshihiro Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　32　(15)　2014/05

ISSN： 0732-183X

eISSN： 1527-7755
Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.

Yosuke Kawashima, Naoto Morikawa, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada, Akira Inoue, Yuka Fujita, Terufumi Kato, Hiroshi Yokouchi, Hiroshi Watanabe, Kazuhiro Usui, Toshiro Suzuki, Satoshi Oizumi, Hiroki Nagai, Mariko Kanbe, Toshihiro Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　32　(15)　2014/05

ISSN： 0732-183X

eISSN： 1527-7755
クリゾチニブ (特集進行・再発非小細胞肺癌への個別化薬物治療) -- (分子標的治療薬の使いどころ)

齋藤良太, 井上彰

臨床腫瘍プラクティス　10　(2)　181-185　2014
Publisher: ヴァン・メディカル
ISSN： 1880-3083
【新薬展望2014】 (第III部)治療における最近の新薬の位置付け<薬効別> 新薬の広場肺癌治療薬

宮内栄作, 井上彰

医薬ジャーナル　50　(増刊)　352-360　2014/01
Publisher: (株)医薬ジャーナル社
ISSN： 0287-4741
RANDOMIZED PHASE III TRIAL OF S-1 PLUS CISPLATIN VERSUS DOCETAXEL PLUS CISPLATIN FOR ADVANCED NON-SMALL-CELL LUNG CANCER (TCOG0701): SUBGROUP ANALYSIS

Osamu Ishimoto, Akihiko Gemma, Hiroshi Sakai, Nobuyuki Katakami, Kaoru Kubota, Makoto Nishio, Akira Inoue, Hiroaki Okamoto, Hiroshi Isobe, Hideo Kunitoh, Yuichi Takiguchi, Kunihiko Kobayashi, Yoichi Nakamura, Hironobu Ohmatsu, Kouichi Minato, Masaaki Fukuda, Akira Yokoyama, Masahiro Takeuchi, Hirofumi Michimae, Shoji Kudoh

JOURNAL OF THORACIC ONCOLOGY　8　S193-S193　2013/11

ISSN： 1556-0864

eISSN： 1556-1380
ONE-YEAR FOLLOW-UP OF A PHASE I/II STUDY OF A HIGHLY SELECTIVE ALK INHIBITOR CH5424802/RO5424802 IN ALK-REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

Akira Inoue, Makoto Nishio, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Toyoaki Hida, Hiroshige Yoshioka, Masao Harada, Yuichiro Ohe, Naoyuki Nogami, Haruyasu Murakami, Kengo Takeuchi, Kazue Kikuchi, Takashi Asakawa, Shumpei Yokoyama, Tomohide Tamura

JOURNAL OF THORACIC ONCOLOGY　8　S1204-S1204　2013/11

ISSN： 1556-0864

eISSN： 1556-1380
PHASE II STUDY OF AMRUBICIN FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER AS THIRD-LINE OR FOURTH-LINE CHEMOTHERAPY: UPDATED RESULTS

Satoshi Oizumi, Toshiyuki Harada, Kenichiro Ito, Kei Takamura, Tomoya Kuda, Shunichi Sugawara, Kana Watanabe, Makoto Maemondo, Yuka Fujita, Ichiro Kinoshita, Akira Inoue, Fumihiro Hommura, Yutaka Katsuura, Hirotoshi Akita, Hiroshi Isobe, Masaharu Nishimura

RESPIROLOGY　18　8-8　2013/11

ISSN： 1323-7799

eISSN： 1440-1843
PHASE II STUDY OF AMRUBICIN (AMR) AND CARBOPLATIN (CBDCA) FOR INVASIVE THYMOMA (IT) AND THYMIC CARCINOMA (TC) : NORTH JAPAN LUNG CANCER GROUP 0803

Shoichi Kuyama, Akira Inoue, Masamoto Nakanishi, Yosuke Kawashima, Masao Harada, Kunihiko Kobayashi, Toshiyuki Kozuki, Tomohiro Sakakibara, Makoto Maemondo, Hajime Asahina, Akiko Hisamoto, Taku Nakagawa, Toshihiro Nukiwa

JOURNAL OF THORACIC ONCOLOGY　8　S647-S647　2013/11

ISSN： 1556-0864

eISSN： 1556-1380
EGFR遺伝子変異を伴う家族性肺腺癌患者におけるエクソーム解析(Whole-exome sequencing of familial non-small cell lung cancer patients with the EGFR gene mutations)

東出直樹, 菊地利明, 榊原智博, 齋藤良太, 光石陽一郎, 大河内眞也, 井上彰, 一ノ瀬正和

日本癌学会総会記事　72回　287-288　2013/10
Publisher: (一社)日本癌学会
ISSN： 0546-0476
A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP.

Kazuhiko Nakagawa, Katsuyuki Kiura, Makoto Nishio, Takashi Seto, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Nobuyuki Yamamoto, Hiroshige Yoshioka, Masao Harada, Yuichiro Ohe, Naoyuki Nogami, Kengo Takeuchi, Tadashi Shimada, Tomohiro Tanaka, Tomohide Tamura

JOURNAL OF CLINICAL ONCOLOGY　31　(15)　2013/05

ISSN： 0732-183X

eISSN： 1527-7755
Early History of Fee Tail (ESSAYS IN COMMEMORATION OF THE SEVENTIETH BIRTHDAY OF PROFESSOR OSANAI SATORU)

Inoue Akira

The Chuo law review　119　(9)　79-112　2013/03
Publisher: Chuo University
ISSN： 0009-6296
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T

Ann Oncol.　24　54-59　2013/01

DOI： 10.1093/annonc/mds214 　
非小細胞肺癌に対する3・4次治療としての塩酸アムルビシン単剤療法の第II相試験(HOT0901)

久田友哉, 原田敏之, 伊藤健一郎, 高村圭, 菊地英毅, 大泉聡史, 菅原俊一, 鈴木綾, 前門戸任, 藤兼俊明, 藤田結花, 田口純, 木下一郎, 井上彰, 本村文宏, 勝浦豊, 秋田弘俊, 磯部宏, 西村正治

肺癌　52　(5)　798　2012/10/05

ISSN： 0386-9628
Minor EGFR遺伝子変異陽性の非小細胞肺癌に対するGefitinibの治療効果

渡部聡, 吉澤弘久, 前門戸任, 井上彰, 菅原俊一, 磯部宏, 原田眞雄, 石井芳樹, 萩原弘一, 小林国彦

肺癌　52　(5)　557-557　2012/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628
RANDOMIZED PHASE II TRIAL OF CARBOPLATIN COMBINED WITH WEEKLY PACLITAXEL (CWP) AND DOCETAXEL ALONE (D) IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): NJLCG 0801

A. Inoue, M. Maemondo, S. Sugawara, T. Harada, Y. Minegishi, K. Usui, M. Ando, N. Morikawa, Y. Mori, O. Ishimoto, N. Matsubara, T. Sakakibara, K. Watanabe, A. Gemma, T. Nukiwa

ANNALS OF ONCOLOGY　23　31-31　2012/10

ISSN： 0923-7534
RANDOMIZED PHASE II STUDY OF CONCURRENT GEFITINIB PLUS CHEMOTHERAPY VERSUS ALTERNATION OF GEFITINIB AND CHEMOTHERAPY IN PREVIOUSLY UNTREATED NON-SMALL CELL LUNG CANCER (NSCLC) WITH SENSITIVE EGFR MUTATIONS: NEJ005/TCOG0902

S. Oizumi, J. Sakakibara-Konishi, A. Inoue, K. Kobayashi, A. Gemma, H. Yoshizawa, H. Isobe, Y. Saijyo, Y. Ishii, S. Morita, K. Hagiwara, T. Nukiwa

ANNALS OF ONCOLOGY　23　23-23　2012/10

ISSN： 0923-7534
PROGNOSTIC FACTORS IN NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: DATA FROM THE RANDOMIZED PHASE III STUDY COMPARED GEFITINIB WITH CARBOPLATIN PLUS PACLITAXEL (NEJ002)

Y. Minegishi, K. Kobayashi, M. Maemondo, A. Inoue, S. Sugawara, S. Ohizumi, H. Isobe, K. Hagiwara, S. Morita, T. Nukiwa, A. Gemma

ANNALS OF ONCOLOGY　23　116-116　2012/10

ISSN： 0923-7534
PHASE II STUDY OF AMRUBICIN (AMR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AS THIRD-LINE OR FOURTH-LINE CHEMOTHERAPY: HOKKAIDO LUNG CANCER CLINICAL STUDY GROUP TRIAL (HOT) 0901

K. Itoh, T. Harada, K. Takamura, E. Kikuchi, S. Ohizumi, S. Sugawara, M. Maemondo, Y. Fujita, I. Kinoshita, A. Inoue, F. Hommura, Y. Katsuura, H. Dosaka-Akita, H. Isobe, M. Nishimura

ANNALS OF ONCOLOGY　23　113-113　2012/10

ISSN： 0923-7534
S-1 PLUS CISPLATIN VERSUS DOCETAXEL PLUS CISPLATIN IN CHEMOTHERAPY-NAIVE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A RANDOMIZED, MULTICENTER PHASE III STUDY (TCOG0701)

S. Niho, A. Gemma, H. Sakai, K. Kubota, M. Nishio, A. Inoue, H. Okamoto, H. Isobe, H. Kunitoh, Y. Takiguchi, K. Kobayashi, Y. Nakamura, N. Katakami, M. Takeuchi, S. Kudoh

ANNALS OF ONCOLOGY　23　34-34　2012/10

ISSN： 0923-7534
【呼吸器内科:EVIDENCE UPDATE】肺癌

宮内栄作, 井上彰

呼吸器内科　22　(4)　285-294　2012/10
Publisher: (有)科学評論社
ISSN： 1884-2887
RANDOMIZED PHASE III TRIAL OF S-1 PLUS CISPLATIN VERSUS DOCETAXEL PLUS CISPLATIN FOR ADVANCED NON-SMALL-CELL LUNG CANCER (TCOG0701)

H. Sakai, A. Gemma, K. Kubota, M. Nishio, H. Okamoto, A. Inoue, H. Isobe, K. Kobayashi, M. Takeuchi, S. Kudoh

ANNALS OF ONCOLOGY　23　404-404　2012/09

ISSN： 0923-7534
LONG-TERM SURVIVORS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: DATA FROM A RANDOMIZED PHASE III STUDY COMPARING GEFITINIB WITH CARBOPLATIN PLUS PACLITAXEL (NEJ002)

Y. Minegishi, K. Kobayashi, M. Maemondo, A. Inoue, S. Sugawara, S. Oizumi, K. Hagiwara, T. Nukiwa, S. Morita, A. Gemma

ANNALS OF ONCOLOGY　23　412-412　2012/09

ISSN： 0923-7534
FINAL ANALYSIS OF RANDOMIZED PHASE II TRIAL OF CARBOPLATIN COMBINED WITH WEEKLY PACLITAXEL (CP) AND DOCETAXEL ALONE (D) IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): NJLCG 0801

T. Harada, M. Maemondo, S. Sugawara, A. Inoue, K. Usui, M. Ando, N. Morikawa, Y. Mori, A. Gemma, T. Nukiwa

ANNALS OF ONCOLOGY　23　427-427　2012/09

ISSN： 0923-7534
A PHASE I/II STUDY OF ALK INHIBITOR CH5424802 IN PATIENTS WITH ALK-POSITIVE NSCLC; SAFETY AND EFFICACY INTERIM RESULTS OF THE PHASE II PORTION

M. Nishio, K. Kiura, K. Nakagawa, T. Seto, A. Inoue, M. Maemondo, T. Hida, M. Harada, H. Yoshioka, T. Tamura

ANNALS OF ONCOLOGY　23　153-153　2012/09

ISSN： 0923-7534
【肺癌実地医家に不可欠の最新の臨床知識とその活用】治療/特定の肺癌の治療戦略とその有効性進行期非小細胞肺癌の治療戦略 EGFR遺伝子変異陽性の腺癌

宮内栄作, 井上彰

Medical Practice　29　(6)　996-1000　2012/06
Publisher: (株)文光堂
ISSN： 0910-1551
Phase II study of amrubicin (AMR) for patients (pts) with non-small cell lung cancer (NSCLC) as third-line or fourth-line chemotherapy: Hokkaido Lung Cancer Clinical Study Group trial (HOT) 0901.

Toshiyuki Harada, Kenichiro Ito, Kei Takamura, Eiki Kikuchi, Satoshi Oizumi, Tomoya Kuda, Shunichi Sugawara, Makoto Maemondo, Yuka Fujita, Ichiro Kinoshita, Akira Inoue, Fumihiro Hommura, Yutaka Katsuura, Hirotoshi Akita, Hiroshi Isobe, Masaharu Nishimura

JOURNAL OF CLINICAL ONCOLOGY　30　(15)　2012/05

ISSN： 0732-183X

eISSN： 1527-7755
Randomized phase II trial of carboplatin combined with weekly paclitaxel (CP) and docetaxel alone (D) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): NJLCG 0801.

Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Akira Inoue, Nobumichi Matsubara, Kana Watanabe, Osamu Ishimoto, Tomohiro Sakakibara, Yuji Minegishi, Kazuhiro Usui, Masahiro Ando, Naoto Morikawa, Yoshiaki Mori, Akihiko Gemma, Toshihiro Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　30　(15)　2012/05

ISSN： 0732-183X

eISSN： 1527-7755
Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802.

Ryota Saito, Akira Inoue, Shunichi Sugawara, Satoshi Oizumi, Makoto Maemondo, Koichi Okudera, Toshiro Suzuki, Kazuhiro Usui, Masao Harada, Naoto Morikawa, YUkihiro Hasegawa, Osamu Ishimoto, Tomohiro Sakakibara, Hajime Asahina, Toshihiro Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　30　(15)　2012/05

ISSN： 0732-183X

eISSN： 1527-7755
Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701)

Nobuyuki Katakami, Akihiko Gemma, Hiroshi Sakai, Kaoru Kubota, Makoto Nishio, Akira Inoue, Hiroaki Okamoto, Hiroshi Isobe, Hideo Kunitoh, Yuichi Takiguchi, Kunihiko Kobayashi, Yoichi Nakamura, Hironobu Ohmatsu, Shunichi Sugawara, Koichi Minato, Masaaki Fukuda, Akira Yokoyama, Masahiro Takeuchi, Hirofumi Michimae, Shoji Kudoh

JOURNAL OF CLINICAL ONCOLOGY　30　(15)　2012/05

ISSN： 0732-183X

eISSN： 1527-7755
Imatinib treatment for gefitinib-resistant lung cancer harboring epidermal growth factor receptor mutation

Tatsuro Fukuhara, Cezary Jan Treda, Tomohiro Sakakibara, Akira Inoue, Masahito Ebina, Toshihiro Nukiwa

CANCER RESEARCH　72　2012/04

DOI： 10.1158/1538-7445.AM2012-1793 　

ISSN： 0008-5472

eISSN： 1538-7445
Molecular targeting agents for lung cancer

INOUE Akira

49　(1)　8-13　2012/01/25
Publisher: 日本老年医学会
ISSN： 0300-9173
General practice of adjuvant chemotherapy for lung cancer

104　808-813　2011/06
Publisher: 永井書店
ISSN： 0433-2644
LUX-LUNG 4: A PHASE II TRIAL OF AFATINIB (BIBW 2992) IN ADVANCED NSCLC PATIENTS PREVIOUSLY TREATED WITH ERLOTINIB OR GEFITINIB

Shinji Atagi, Nobuyuki Katakami, Toyoaki Hida, Koichi Goto, Takeshi Horai, Akira Inoue, Akiko Sarashina, Yoko Seki, Robert Lorence, Mehdi Shahidi, Nobuyuki Yamamoto

JOURNAL OF THORACIC ONCOLOGY　6　(6)　S360-S361　2011/06

ISSN： 1556-0864

eISSN： 1556-1380
RANDOMIZED PHASE II TRIAL OF URACIL/TEGAFUR (UFT) AND CISPLATIN VERSUS VINORELBINE AND CISPLATIN WITH CONCURRENT THORACIC RADIOTHERAPY FOR LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL-CELL LUNG CANCER: NJLCG 0601

Hiroshi Watanabe, Shunichi Sugawara, Makoto Maemondo, Motoko Tachihara, Tomohiro Sakakibara, Takashi Ishida, Akira Inoue, Kazuhiro Usui, Osamu Ishimoto, Nobumichi Matsubara, Yasuo Saijo, Toshihiro Nukiwa

JOURNAL OF THORACIC ONCOLOGY　6　(6)　S490-S491　2011/06

ISSN： 1556-0864

eISSN： 1556-1380
A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G)

N. Yamamoto, N. Katakami, S. Atagi, T. Hida, K. Goto, T. Horai, A. Inoue, Y. Ichinose, K. Kobayashi, K. Takeda, K. Kiura, H. Saka, T. Tamura, I. Okamoto, N. Nogami, R. Morinaga, K. Nishio, Y. Seki, R. M. Lorence, M. Shahidi

JOURNAL OF CLINICAL ONCOLOGY　29　(15)　2011/05

ISSN： 0732-183X

eISSN： 1527-7755
Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations

A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, Y. Saijo, H. Yoshizawa, S. Morita, K. Hagiwara, T. Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　29　(15)　2011/05

ISSN： 0732-183X

eISSN： 1527-7755
肺癌分子標的薬の感受性と耐性

宮内栄作, 井上彰

呼吸　30　(5)　444-450　2011/05
Publisher: (一社)呼吸研究
ISSN： 0286-9314
EGFR遺伝子変異を有する高齢者非小細胞肺癌に対する初回Gefitinib療法の第II相試験(NEJ003試験)

森川直人, 峯岸裕司, 井上彰, 前門戸任, 冲永壯治, 小林国彦, 原田真雄, 萩原弘一, 貫和敏博, 弦間昭彦

日本内科学会雑誌　100　(Suppl.)　189-189　2011
グラフ画像で見る肺癌分子標的薬EGFR-TKI治療の著効例(super-responder)

貫和敏博, 井上彰

日本医事新報　(4519)　69-72　2010/12/04
Publisher: 日本医事新報社
ISSN： 0385-9215
Molecular target therapy of lung cancer

54　(13)　1649-1654　2010/12
Publisher: 医学書院
ISSN： 0485-1420
QOL ANALYSIS FROM NEJ 002 STUDY COMPARING GEFITINIB TO CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER WITH MUTATED EGFR

H. Yoshizawa, K. Kobayashi, A. Inoue, M. Maemondo, S. Sugawara, S. Oizumi, A. Gemma, S. Morita, K. Hagiwara, T. Nukiwa

ANNALS OF ONCOLOGY　21　122-122　2010/10

ISSN： 0923-7534
RANDOMIZED PHASE II TRIAL OF URACIL/TEGAFUR (UFT) AND CISPLATIN VERSUS VINORELBINE AND CISPLATIN WITH CONCURRENT THORACIC RADIOTHERAPY FOR LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL-CELL LUNG CANCER: NJLCG 0601

M. Tachihara, S. Sugawara, M. Maemondo, T. Ishida, A. Inoue, K. Usui, O. Ishimoto, N. Matsubara, Y. Saijo, T. Nukiwa

ANNALS OF ONCOLOGY　21　136-136　2010/10

ISSN： 0923-7534
Interstitial Lung Disease and Gefitinib REPLY

Akira Inoue, Kunihiko Kobayashi, Toshihiro Nukiwa

NEW ENGLAND JOURNAL OF MEDICINE　363　(16)　1579-1580　2010/10

ISSN： 0028-4793

eISSN： 1533-4406
Randomized phase II trial of tegafur-uracil (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small cell lung cancer: NJLCG 0601

M. Maemondo, S. Sugawara, T. Ishida, A. Inoue, K. Usui, O. Ishimoto, N. Matsubara, M. Tachihara, Y. Saijo, T. Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　28　(15)　2010/05

ISSN： 0732-183X

eISSN： 1527-7755
The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002

A. Inoue, M. Maemondo, K. Kobayashi, S. Oizumi, H. Isobe, A. Gamma, Y. Saijo, K. Hagiwara, S. Morita, T. Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　28　(15)　2010/05

ISSN： 0732-183X

eISSN： 1527-7755
First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study)

Y. Minegishi, M. Maemondo, S. Okinaga, N. Morikawa, A. Inoue, K. Kobayashi, M. Harada, K. Hagiwara, T. Nukiwa, A. Gemma

JOURNAL OF CLINICAL ONCOLOGY　28　(15)　2010/05

ISSN： 0732-183X

eISSN： 1527-7755
腫瘍 EGFR変異陽性の進行非小細胞肺癌におけるゲフィチニブと化学療法の比較第3相試験(NEJ002)

原田眞雄, 井上彰, 小林国彦, 前門戸任, 菅原俊一, 大泉聡史, 西條康夫, 弦間昭彦, 磯部宏, 森田智視, 萩原弘一, 貫和敏博

日本呼吸器学会雑誌　48　(増刊)　113-113　2010
切除不能3B/4期非小細胞肺がんに対するゲムシタビン+カルボプラチン投与法別併用療法のRandomized Phase2STUDY(LC01)

野呂林太郎, 弦間昭彦, 吉村明修, 宝来威, 西尾誠人, 木村幸男, 井上彰, 大崎能伸, 池田徳彦, 坪井正博, 上野清伸, 今村文生

日本臨床腫瘍学会学術集会プログラム・抄録集　8th　203　2010
ゲフィチニブが奏効したEGFR遺伝子変異陰性非小細胞肺癌の一例~変異陰性例に対する前向き試験(HOT0702)より~

菊地英毅, 大泉聡史, 本村文宏, 井上彰, 大河内眞也, 小林国彦, 萩原弘一, 原田敏之, 秋田弘俊, 磯部宏, 西村正治

日本臨床腫瘍学会学術集会プログラム・抄録集　8th　209　2010
間質性肺炎と肺癌の合併に関する臨床的検討

宮内栄作, 太田洋充, 久田修, 大河内眞也, 井上彰, 海老名雅仁, 貫和敏博

肺癌　50　(5)　734-734　2010
意識消失で発見されたSIADH合併肺小細胞癌の1例

森戸正顕, 久田修, 阿部恭子, 玉田勉, 井上彰, 海老名雅仁, 貫和敏博

肺癌　49　(6)　962-962　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628
First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group

Y. Minegishi, A. Inoue, K. Kobayashi, A. Gemma, M. Maemondo, S. Oizumi, Y. Saijo, S. Morita, K. Hagiwara, T. Nukiwa

EJC SUPPLEMENTS　7　(4)　25-25　2009/10

ISSN： 1359-6349
A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, Y. Saijo, A. Genma, S. Morita, K. Hagiwara, T. Nukiwa

EJC SUPPLEMENTS　7　(3)　6-6　2009/09

ISSN： 1359-6349
Comparison and combination of the tumor markers for mesothelioma: N-ERC/mesothelin, Osteopontin, CA125, CYFRA21-1, Hyarulonic Acids

Kazu Shiomi, Motoki Sakuraba, Okio Hino, Kimihiko Masuda, Masashi Kobayashi, Masataka Hirabayashi, Atsuko Ishida, Takao Moroboshi, Takashi Yoshiyama, Akira Inoue, Hiroshi Izumi, Tatsuya Segawa, Masahiro Maeda, Kazuhisa Takahashi, Kenji Suzuki, Kazuya Miyashita, Tadasu Kohno, Yoshiaki Hagiwara

JOURNAL OF THORACIC ONCOLOGY　4　(9)　S775-S776　2009/09

ISSN： 1556-0864
A phase II study of a combination of carboplatin plus gemcitabine following a pretreatment of dexamethazone

Makoto Maemondo, Akira Inoue, Shunichi Sugawara, Mariko Kanbe, Kunihiko Kobayashi, Toshihiro Nukiwa, Yasuo Saijo

JOURNAL OF THORACIC ONCOLOGY　4　(9)　S697-S697　2009/09

ISSN： 1556-0864
First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group

K. Kobayashi, A. Inoue, M. Maemondo, S. Sugawara, H. Isobe, S. Oizumi, Y. Saijo, A. Gemma, S. Morita, K. Hagiwara, T. Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　27　(15)　2009/05

ISSN： 0732-183X
分子標的治療の基礎と臨床 Star Trials from Japan 1 EGFR遺伝子変異陽性の進行非小細胞肺癌における第三相試験(NEJ002)の中間解析結果

磯部宏, 井上彰, 小林国彦, 前門戸任, 菅原俊一, 大泉聡史, 西條康夫, 弦間昭彦, 森田智視, 萩原弘一, 貫和敏博

肺癌　49　(5)　563-563　2009
EGFR遺伝子変異陽性NSCLC症例に対するゲフィチニブ治療の第II相試験統合解析(I-CAMP study group)

杉尾賢二, 平島智徳, 樋田豊明, 萩原弘一, 砂長則明, 井上彰, 朝比奈肇, 森田智視, 光冨徹哉, 福岡正博, 貫和敏博, 安元公正

日本呼吸器学会雑誌　47　(増刊)　109-109　2009
3.Gefitinib治療中に微細粒状影を呈する脳転移を認めた1例(第47回日本肺癌学会東北支部会,東北支部,支部活動)

村上康司, 井上彰, 榊原智博, 貫和敏博

肺癌　48　(6)　792-792　2008/10/20
Publisher: 日本肺癌学会
ISSN： 0386-9628
P-271 根治的胸部放射線治療を施行した原発性肺癌患者における放射線肺臓炎の検討(放射線療法,第49回日本肺癌学会総会号)

中村敦, 井上彰, 太田洋充, 大河内眞也, 榊原智博, 福原達朗, 海老名雅仁, 貫和敏博

肺癌　48　(5)　557-557　2008/10/05
Publisher: 日本肺癌学会
ISSN： 0386-9628
WS4-3 ゲフィチニブ既治療進行非小細胞肺癌に対するゲフィチニブ再治療の第II相試験(分子標的治療2(臨床),第49回日本肺癌学会総会号)

朝比奈肇, 大泉聡史, 井上彰, 木下一郎, 石田卓, 藤田結花, 須甲憲明, 原田真雄, 前門戸任, 磯部宏, 西條康夫, 秋田弘俊, 貫和敏博, 西村正治

肺癌　48　(5)　421-421　2008/10/05
Publisher: 日本肺癌学会
ISSN： 0386-9628
COMPARISON OF THE EFFICACY BETWEEN CHEMOTHERAPY AND GEFITINIB AS 1ST LINE SETTING IN PATIENTS WITH EGFR MUTATION POSITIVE NSCLC

K. Yoshida, I. Okamoto, K. Kobayashi, N. Sunaga, K. Sugio, A. Inoue, K. Yamazaki, S. Morita, T. Nukiwa, M. Fukuoka

ANNALS OF ONCOLOGY　19　104-104　2008/09

ISSN： 0923-7534
GEFITINIB PROVIDES AN BENEFICIAL TREATMENT TO POOR PS OR SUPER-ELDERLY PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC (NORTH-EAST JAPAN GEFITINIB STUDY GROUP)

A. Inoue, K. Kobayashi, K. Usui, M. Maemondo, M. Ando, A. Gemma, S. Morita, T. Nukiwa, S. Okinaga, K. Hagiwara

ANNALS OF ONCOLOGY　19　106-106　2008/09

ISSN： 0923-7534
First-line gefitinib for poor PS patients with EGFR mutations

K. Kobayashi, A. Inoue, K. Usui, M. Maemondo, S. Okinaga, I. Mikami, M. Ando, A. Gemma, S. Morita, K. Hagiwara

JOURNAL OF CLINICAL ONCOLOGY　26　(15)　2008/05

ISSN： 0732-183X
Randomized, phase II trial comparing carboplatin (C) and tri-weekly paclitaxel (tP) with C and weekly paclitaxel (wP) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC)

M. Maemondo, A. Inoue, S. Sugawara, T. Ishida, K. Usui, T. Abe, M. Kanbe, H. Watanabe, Y. Saijo, T. Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　26　(15)　2008/05

ISSN： 0732-183X
Randomized, phase II trial comparing amrubicin with topotecan in patients (pts) with previously treated small cell lung cancer (SCLC)

S. Sugawara, A. Inoue, K. Yamazaki, Y. Saijo, K. Gomi, O. Ishimoto, F. Hommura, M. Maemondo, T. Suzuki, T. Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　26　(15)　2008/05

ISSN： 0732-183X
Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP)

S. Morita, T. Hirashima, K. Hagiwara, T. Hida, N. Sunaga, K. Sugio, A. Inoue, K. Yamazaki, T. Mitsudomi, T. Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　26　(15)　2008/05

ISSN： 0732-183X
Adjuvant chemotherapy for non-small-cell lung cancer

98　665-670　2008
Publisher: 永井書店
ISSN： 0433-2644
EGFR遺伝子変異を有するPS不良非小細胞肺癌(NSCLC)に対する救済初回ゲフィチニブ療法

臼井一裕, 井上彰, 小林国彦, 前門戸任, 冲永壮治, 植松和嗣, 安藤真弘, 山崎浩一, 西條康夫, 弦間昭彦, 貫和敏博, 萩原弘一

日本呼吸器学会雑誌　46　(増刊)　124-124　2008
EGFR遺伝子変異を有する進行非小細胞肺癌患者を対象としたgefitinib治療prospective試験統合解析

砂長則明, 柳谷典子, 山崎浩一, 朝比奈肇, 井上彰, 西條康夫, 萩原弘一, 小林国彦, 森田智視, 樋田豊明, 吉田公秀, 光富徹哉, 岡本勇, 平島智徳, 杉尾賢二, 貫和敏博, 福岡正博

肺癌　48　(5)　420-420　2008
7.EGFR遺伝子変異を有する進行非小細胞肺癌に対するゲフィチニブの臨床試験への取り組み(第33回日本肺癌学会北海道支部会,支部活動)

朝比奈肇, 山崎浩一, 大泉聡史, 西村正治, 木下一郎, 秋田弘俊, 井上彰, 西條康夫, 貫和敏博, 弦間昭彦, 小林国彦, 萩原弘一, 磯部宏, 朝比奈肇, 山崎浩一, 大泉聡史, 木下一郎, 秋田弘俊, 磯部宏, 西村正治, 朝比奈肇, 山崎浩一, 大泉聡史, 木下一郎, 井上彰, 西條康夫, 貫和敏博, 弦間昭彦, 小林国彦, 萩原弘一, 秋田弘俊, 磯部宏, 西村正治

肺癌　47　(7)　2007/12/20
Publisher: 日本肺癌学会
ISSN： 0386-9628
O-17 Gefinitibを投与したEGFR変異腸性非小細胞肺癌症例の耐性化に関する検討(一般演題(口演)3 分子標的治療,第48回日本肺癌学会総会号)

佐藤輝幸, 井上彰, 榊原智博, 福原達朗, 西條康夫, 貫和敏博

肺癌　47　(5)　483-483　2007/10/10
Publisher: 日本肺癌学会
ISSN： 0386-9628
P-12 蛋白分解酵素阻害物質Secretory leukoprotease inhibitor(SLPI)の肺癌における役割(一般演題(ポスター) 分子生物学,第48回日本肺癌学会総会)

福原達朗, 鈴木拓児, 榊原智博, 田原稔, 井上彰, 菊地利明, 西條康夫, 貫和敏博

肺癌　47　(5)　527-527　2007/10/10
Publisher: 日本肺癌学会
ISSN： 0386-9628
P-586 上皮成長因子受容体(EGFR)遺伝子変異を認めた肺癌の一家系(一般演題(ポスター) 症例11,第48回日本肺癌学会総会号)

榊原智博, 井上彰, 福原達朗, 菊地利明, 西條康夫, 貫和敏博, 石本修

肺癌　47　(5)　671-671　2007/10/10
Publisher: 日本肺癌学会
ISSN： 0386-9628
非小細胞肺癌の分子標的治療 EGFR遺伝子変異を有するPS不良非小細胞肺癌(NSCLC)に対する救済初回ゲフィチニブ療法

冲永壮治, 井上彰, 宇田川清司, 臼井一裕, 前門戸任, 植松和嗣, 安藤真弘, 弦間昭彦, 山崎浩一, 西條康夫, 貫和敏博, 小林国彦, 萩原弘一, 北東日本ゲフィチニブ研究グループ

肺癌　47　(5)　463-463　2007
Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor.

Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H

Endocr Relat Cancer.　14　(2)　279-92.-292　2007

DOI： 10.1677/ERC-06-0005 　

ISSN： 1351-0088
16.Gefitinibの再投与が奏功した肺腺癌の1例(第45回日本肺癌学会東北支部会,東北支部,支部活動)

猪原拓, 西條康夫, 森川直人, 井上彰, 渡辺洋, 榊原智博, 貫和敏博

肺癌　46　(7)　884-885　2006/12/20
Publisher: 日本肺癌学会
ISSN： 0386-9628
15.GefitinibによるInterstitial Lung Disease (ILD)を発症した後,再投与が有効であったEGFR変異陽性肺腺癌の1例(第45回日本肺癌学会東北支部会,東北支部,支部活動)

酒谷俊雄, 森川直人, 井上彰, 五味和紀, 福原達郎, 榊原智博, 木村雄一郎, 西條康夫, 貫和敏博

肺癌　46　(7)　884-884　2006/12/20
Publisher: 日本肺癌学会
ISSN： 0386-9628
Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan.

N. Morikawa, A. Inoue, T. Suzuki, T. Fukuhara, S. Suzuki, T. Kondo, T. Moriya, Y. Saijo, T. Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　24　(18)　383S-383S　2006/06

ISSN： 0732-183X
非喫煙女性の肺腺癌症例のEGFR mutation と臨床的特徴の検討(12 分子標的治療1, 第46回日本肺癌学会総会)

森川直人, 井上彰, 福原達郎, 鈴木拓児, 前門戸任, 西條康夫, 貫和敏博

肺癌　45　(5)　555-555　2005/11/05
Publisher: 日本肺癌学会
ISSN： 0386-9628
A phase II trial of biweekly docetaxel combined with carboplatin for patients with advanced non-small cell lung cancer

O Ishimoto, S Sugawara, A Inoue, T Ishida, S Koinumaru, Y Hasegawa, T Suzuki, H Miki, Y Saijo, T Nukiwa

LUNG CANCER　49　S391-S391　2005/07

ISSN： 0169-5002
A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).

K Usui, A Inoue, O Ishimoto, M Tanaka, S Koinumaru, N Matsubara, M Kanbe, K Gomi, Y Saijo, T Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　23　(16)　682S-682S　2005/06

ISSN： 0732-183X

eISSN： 1527-7755
Gene mutations in lung cancer: Promising predictive factors for the success of molecular therapy

A Inoue, T Nukiwa

PLOS MEDICINE　2　(1)　20-22　2005/01

DOI： 10.1371/journal.pmed.0020013 　

ISSN： 1549-1277
3. 骨髄異形成症候群の経過中に発症した非小細胞肺癌に化学療法を施行した1例(第43回日本肺癌学会東北支部会)(支部活動)

中島祥文, 榊原智博, 菊地利明, 井上彰, 鈴木拓児, 田澤立之, 西條康夫, 貫和敏博, 亀岡淳一

肺癌　44　(6)　723-723　2004/10/20
Publisher: 日本肺癌学会
ISSN： 0386-9628
P1-35 胸部CT画像上短径1cm以下の縦隔リンパ節におけるFDG-PET陽性例の検討(ポスター総括1 : 診断1 FDG-PET診断)

小西一央, 前門戸任, 鈴木拓児, 井上彰, 井上健太郎, 西條康夫, 貫和敏博

肺癌　44　(5)　393-393　2004/10/01
Publisher: 日本肺癌学会
ISSN： 0386-9628
P1-51 内科的治療前後のFDG-PETの検討(ポスター総括1 : 診断1 FDG-PET治療効果)

鈴木拓児, 前門戸任, 井上彰, 木村雄一郎, 榊原智博, 菊地利明, 田澤立之, 井上健太郎, 西條康夫, 貫和敏博

肺癌　44　(5)　401-401　2004/10/01
Publisher: 日本肺癌学会
ISSN： 0386-9628
P7-43 高齢者非小細胞肺癌に対するカルボプラチンと少量分割パクリタキセル併用療法の第二相試験(ポスター総括7 : 内科2 Poor risk症例の化学療法)

井上彰, 臼井一裕, 石本修, 田中昌史, 五味和紀, 松原信行, 神部眞理子, 小犬丸貞裕, 西條康夫, 貫和敏博

肺癌　44　(5)　551-551　2004/10/01
Publisher: 日本肺癌学会
ISSN： 0386-9628
P7-16 進行非小細胞肺癌に対するカルボプラチン,隔週ドセタキセル併用療法の第1相試験(ポスター総括7 : 内科2 非小細胞癌・化学療法1)

菅原綾, 石田卓, 井上彰, 鈴木拓児, 木村雄一郎, 大河内眞也, 小犬丸貞裕, 菅原俊一, 西條康夫, 棟方充, 貫和敏博

肺癌　44　(5)　537-537　2004/10/01
Publisher: 日本肺癌学会
ISSN： 0386-9628
P7-14 進行非小細胞肺癌に対するカルボプラチン,隔週ドセタキセル併用療法第2相試験(ポスター総括7 : 内科2 非小細胞癌・化学療法1)

安藤みゆき, 小犬丸貞裕, 井上彰, 西條康夫, 貫和敏博, 菅原俊一, 石田卓, 鈴木俊郎, 長谷川幸裕, 武内健一

肺癌　44　(5)　536-536　2004/10/01
Publisher: 日本肺癌学会
ISSN： 0386-9628
Phase I trial of bi-weekly docetaxel combined with carboplatin for patients with non-small cell lung cancer.

A Inoue, T Ishida, Y Saijo, M Maemondo, T Suzuki, Y Kimura, S Ohkouchi, T Nukiwa

JOURNAL OF CLINICAL ONCOLOGY　22　(14)　676S-676S　2004/07

ISSN： 0732-183X
高齢者非小細胞肺癌に対するカルボプラチン,パクリタキセル(毎週投与)併用療法の第2相試験

井上彰, 臼井一裕, 西條康夫, 前門戸任, 小犬丸貞裕, 田中昌史, 石本修, 松原信行, 大河内庭也, 木村雄一郎, 太田洋充, 徳江豊, 貫和敏博

肺癌　43　(5)　610-610　2003/10/20
Publisher: 日本肺癌学会
ISSN： 0386-9628
Molecular Targeting Drugs for Lung Cancer : New horizon of lung cancer biology and clinic by gefitinib

51　(7)　685-694　2003/07
Publisher: 医学書院
ISSN： 0452-3458
Recent advances in the chemotherapy of non-small cell lung cancer

A Inoue, N Saijo

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　31　(7)　299-304　2001/07

ISSN： 0368-2811

Show all ︎Show first 5

Presentations 22

進行非小細胞肺癌三次治療におけるイリノテカン療法の第２相試験

井上彰

日本臨床腫瘍学会　2010/03/12
ゲフィチニブ既治療進行非小細胞肺癌に対するゲフィチニブ再治療の第？相試験

井上彰

日本呼吸器学会総会　2009/06/05
I-CAMP：EGFR遺伝子変異陽性NSCLCに対するゲフィチニブ治療の統合解析

井上彰, 朝比奈肇, 砂長則明, 須谷顕尚, 吉田公秀, 岡本勇, 杉尾賢二, 森田智視, 小林国彦, 貫和敏博, 福岡正博

第7回日本臨床腫瘍学会総会　2009/03/11
Prospective study of gefitinib for chemotherapy naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. International-presentation

Inoue A

JCA-AACR joint symposium　2007/11/14
Phase II study of 1st line gefitinib for > PS 3 patient with advanced NSCLC with EGFR mutations International-presentation

Inoue A

The Meeting of Reunion Franco-Japonese on Clinical Oncology　2007/09/14
肺腺癌EGFR活性型変異：基礎的意義と臨床試験での検証

井上彰

第47回日本呼吸器学会総会　2007/05/14
再発小細胞肺癌に対するアムルビシンとノギテカンの無作為化第？相試験．

井上彰

日本臨床腫瘍学会　2007/03/14
Prospective study of gefitinib for chemotherapy naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations International-presentation

井上彰

日本癌学会・米国癌学会合同シンポジウム　2007/03/04
EGFR遺伝子変異を有する進行非小細胞肺癌に対するゲフィチニブの初回治療

井上彰

日本肺癌学会総会　2006/12/14
A prospective phase II study of gefitinib for chemotherapy naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations International-presentation

井上彰

アジア太平洋呼吸器学会　2006/11/14
薬剤性肺障害の発症機序

井上彰

日本呼吸器学会総会　2006/06/14
カルボプラチン・隔週ドセタキセル併用療法の第？相試験

井上彰, 石本修, 貫和敏博ら

第46回日本肺癌学会総会　2005/11/14
EGF受容体チロシンキナーゼ阻害剤は？型肺胞上皮機能を低下させる

井上彰, 西條康夫ら

第64回日本癌学会総会　2005/09/14
A prospective study of 1st line gefitinib for non-small-cell lung cancer with EGFR mutations. International-presentation

Inoue A, Suzuki T, Nukiwa N

Franco-Japanese Meeting on Cancer Chemotherapy　2005/07/14
高齢者小細胞肺癌に対するアムルビシン、カルボプラチン併用第？相試験

井上彰, 山崎浩一, 貫和敏博ら

第45回日本呼吸器学会総会　2005/04/14
ゲフィチニブの前向き臨床試験

井上彰, 鈴木拓児, 貫和敏博ら

第3回日本臨床腫瘍学会　2005/03/14
高齢者進行非小細胞肺癌に対するカルボプラチン、パクリタキセル（毎週投与）併用療法の第２相試験

井上彰, 臼井一裕, 貫和敏博ら

第45回日本肺癌学会総会　2004/11/14
高齢者進行非小細胞肺癌に対するカルボプラチン、パクリタキセル（毎週投与）併用療法の第２相試験

井上彰, 臼井一裕, 貫和敏博ら

第44回日本呼吸器学会総会　2004/05/14
脳・脊髄の広範囲に多発性病変を示した神経サルコイドーシスの１例

井上彰, 菊地利明, 貫和敏博ら

第23回日本サルコイドーシス学会　2003/12/14
高齢者非小細胞肺癌に対するカルボプラチンと少量分割パクリタキセル併用化学療法の検討

井上彰, 臼井一裕, 貫和敏博ら

第44回日本肺癌学会総会　2003/11/14
血液透析施行中の小細胞肺癌患者におけるカルボプラチン・エトポシド併用療法の薬物動態学的検討

井上彰, 西條康夫, 貫和敏博ら

第43回日本呼吸器学会総会　2003/05/14
気管支中心性の浸潤陰影を呈した２例.

井上彰, 木村雄一郎

第43回日本呼吸器学会総会　2003/05/14

Show all Show first 5

Research Projects 12

がん免疫療法看護の質評価指標開発に向けた探索的研究

佐藤冨美子, 井上彰

Offer Organization: 日本学術振興会

System: 科学研究費助成事業

Category: 挑戦的研究(萌芽)

Institution: 東北大学

2019/06/28 - 2023/03/31

More details Close

本研究は、他のがん治療と比較して経験が少ないがん免疫療法看護の質評価指標開発に向けた探索的研究であり、面接調査(Phase1)で質評価指標原案を作成し、専門職者(phase2)およびがん看護スペシャリスト(Phase3)によって質評価指標原案の内容妥当性を検討し、段階的に指標を精選させていくことを目的とした。今年度は、質評価指標原案の6構成要素、67項目の構成要素・項目間の関連と内容および表現の妥当性、重要性、実行可能性を質問紙調査によって検討した。Phase2における妥当性と重要性は1項目、実行可能性は9項目を除いて採用基準0.78以上のI-CVIを確保した。6構成要素の妥当性、重要性は全て0.90以上のS-CVI/Aveを確保したが、4構成要素の実行可能性が0.86～0.89であった。妥当性、重要性、実行可能性が0.58～0.63だった1項目、実行可能性0.58だった1項目、自由記述で指摘を受けた1項目の計3項目について修正した。次いで、Phase3の調査における妥当性と重要性は全項目、実行可能性は1項目を除いて採用基準0.78以上のI-CVIを確保し、6構成要素の妥当性、重要性、実行可能性が0.90以上のS-CVI/Aveを確保した。本研究はPhase1～Phase3の段階的な調査によって、十分な内容妥当性を備えたがん免疫療法看護の質評価指標を開発した。最終的に作成した質評価指標は、【がん免疫療法を受ける意思決定プロセスに添う支援】【がん免疫療法の安全性を確保するために行う支援】【がん免疫療法を継続するための支援】【多様なirAEに対応できるセルフケア能力を獲得する支援】【治療の長期化に伴う心理的社会的苦悩を緩和する支援】【医療者とのパートナーシップを育む支援】の6の構成要素、17の上位項目、67項目で構成された。
Combined study of drug therapy for appetite loss and fatigue due to cancer cachexia

Inoue Akira

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2017/04/01 - 2021/03/31

More details Close

"Prospective intervention study comparing different dosages of steroid therapy" was conducted in a multicenter collaborative study group (UMIN000022448). Although progress was delayed due to the spread of COVID-19 infection, the trial is scheduled to be completed by the end of this year, and evidence of steroid treatment for anorexia will be established for the first time in Japan. On the other hand, large-scale nationwide registry studies have identified factors that can predict "time to incapacity" and "time to immobility" in end-of-life cancer patients, and research studies include loss of appetite. It was shown that high QOL can be obtained by setting individual goals for each patient and coping with them.
The multicenter research regarding cessation of anticancer treatment for advanced lung cancer patients

Inoue Akira

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Challenging Research (Exploratory)

Institution: Tohoku University

2017/06/30 - 2020/03/31

More details Close

That this problem cancels anticancer drug treatment appropriately didn't affect the convalescence of the patient and in fact made the thing which contributes to QOL improvement a hypothesis. An observation study by a multicenter joint research group is begun targeted for the progress lung cancer patient taking molecular target medicine as the last treatment, and a case beyond 100 examples is accumulated and is continuing for 200 examples of a target in the present. The calculation and kou by which which is the medical cost after convalescence bad factor arrival, oh, it's made basic data of the positive intervention study which analyzes treatment continuation including an economic impact, and is after that. On the other hand it was possible to indicate the patient crowd who can think it's useful to do a retrospective study about the treatment reality of the end terminal cancer patient apart from the above observation study and receive chemotherapy in spite of the end period.
Differantial Mechanism of Lung Cells induced by Mesenchymal Stem Cells and the Treatment of Intractable Respiratory Diseases

Ohkouchi Shinya, Kanehira Masahiko, Kikuchi Toshiaki, Irokawa Toshiya, Ogawa Hiromasa, Kurosawa Hajime, Yamada Mitsuhiro, Inoue Akira

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2015/04/01 - 2018/03/31

More details Close

We showed that stannniocalcin-1 (STC1) released from mesenchymal stem cells control the mitochondrial respiration and wound healing signals in alveolar macrophage and lung epithelial cells under oxidative and endoplasmic reticulum stresses. STC1 intra-tracheal injection ameliorate bleomycin induced pulmonary fibrosis in animal model. At this time, we report the metabolome analyses to elucidate the molecular mechanism of STC1 which ameliorate the fibrosis. The results showed that STC1 control the cysteine and methionine metabolism strongly. This pathway regulates the methylation and de-methyration of DNA and histone and the synthesis of DNA, reactive sulfur species (RSS) with redox activities, and manage the stress response of the organs. These things suggest new insights of pathology of pulmonary fibrosis to us.
Familial pathogenesis of lung cancer with the epidermal growth factor receptor (EGFR) gene mutation

KIKUCHI Toshiaki, MATSUBARA Yoichi, INOUE Akira, SAKAKIBARA Tomohiro, TODE Naoki, HIRANO Taizou

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Challenging Exploratory Research

Institution: Tohoku University

2012/04/01 - 2015/03/31

More details Close

Lung cancer is globally the leading cause of cancer death with the estimated number of the annual deaths as around 1.4 million. Cigarette smoking is a predominant etiological factor of lung carcinogenesis. Further attention has been paid to a growing number of lung carcinomas occurring in never-smokers, suggesting a biologically different disease with a genetic susceptibility. In this regard, the epidermal growth factor receptor (EGFR) gene mutation is more frequent in lung adenocarcinomas of never smokers. In this study, we acquired two 2-generational pedigrees containing more than 2 family members affected with lung adenocarcinoma with EGFR gene mutations, and performed exome capture and sequencing of whole-blood DNA. A de novo mutation was identified in lung cancer patients, but was not in two control subjects. The mutation alters the amino acid sequence, and confers dominant-negative activity that potentially underlies the pathogenesis of EGFR-mutated lung adenocarcinoma.
Individualized treatment of lung cancer based on the resistant mutation in EGFR gene from circulating tumor cells

INOUE Akira

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Young Scientists (B)

Institution: Tohoku University

2010 - 2012

More details Close

Prospective study of individualized treatment for lung cancer resistant to epidermal growth factor receptor tyrosine kinase based on the T790M resistant mutation status detected from DNA of circulating tumor cells (CTC) was conducted. At the point when 6 enrolled patients were analyzed, it was revealed that the positive rate of CTC was quite lower than expected and that obtained DNA of CTC was too small to detect the T790M mutation. Thus the study was terminated halfway.
Pathogenesis and control of circulating fibrocytes and miRNAs causing interstitial/airway fibrosis and initiating/promoting cancer in the lung

EBINA Masahito, KONDOH Takahshi, OKOUCHI Shinya, SATO Yasufumi, INOUE Akira, TAMADA Tsutomu, HISATA Shu, OHTA Hiromitsu

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2010 - 2012

More details Close

Although the circulating fibrocytes in the patients with progressive fibrosis have been supposed to cause progressive fibrosis, these cells obtained from patients with various stages of IPF became too differentiated to reveal the sensitivity or tolerance to drugs. Therefore, we examined the circulating micro-RNAs (miRNAs) which might effect on circulating fibrocytes in these severe patients. We compared the expression patterns of miRNAs on Days 0, 7, and 21 in the serum and lung tissues. We found miR-30d increased the most toward Day 21, followed by miR-122,-690, 1907, and 3096b-5p, none of which were increased in the lung tissues. Only miR-322 and miR-874 were moderately increased in both serum and lung tissues. These results suggested these circulating miRNAs as possible biomarkers for pulmonary fibrosis.
Biological background for non-smoker lung adenocarcinoma : Why do EGFR somatic mutations accumulate on lung adenocarcinoma and on Asian ethnics?

NUKIWA Toshihiro, EBINA Masahito, KIKUCHI Toshiaki, INOUE Akira, SAKAKIBARA Tomohiro, FUKUHARA Tatsurou, HAGIWARA Kouichi

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Scientific Research (A)

Institution: Tohoku University

2009 - 2011

More details Close

Therapy for lung cancer has been revolutionized in 21st century. The discovery of somatic EGF receptor mutation with high incidence among Asian ethnics led to the targeted therapy by oral TKI administration. To further understand the biological background of lung cancer we succeeded in slow growing xenograft formation with clinical relevant EGFR mutation using NOD-SCID mice. We have identified candidate genes that could relate to somatic EGFR mutation selection in lung cancer through whole genome SNP microarray analysis of patients harboring EGFR mutations, and exome analysis among patients of familial lung cancer members with EGFR mutations. These findings could provide better treatment and preventive applications in the future.
The analysis of mechanisms of interstitial lung disease induced by epidermal growth factor receptor inhibitor.

INOUE Akira

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Young Scientists (B)

Institution: Tohoku University

2007 - 2008
肺腺癌EGFRキナーゼ活性型変異株はなぜ蛋白分解酵素阻害物質SLPIを高産生するか

貫和敏博, 井上彰, 田原稔

Offer Organization: 日本学術振興会

System: 科学研究費助成事業

Category: 特定領域研究

Institution: 東北大学

2006 - 2007

More details Close

肺癌細胞株H1650,PC9は肺癌臨床において重要な意味をもつEGFR(epidermal growth factor receptor)のexon19の一部に欠失変異を持つ細胞株である。これらの細胞株はSLPIを高産生することから、SLPIとEGFRの関連およびSLPIの肺癌における作用機序を解析した。 SLPIノックアウトマウス肺においてマイクロアレイによる解析から、炎症時に上昇するMuc5ACやSerum Amyloid A3等の発現が上昇していることから、炎症と発癌の関連について解析した。SLPIノックアウトマウス肺を詳細に観察すると、通常の飼育環境においても細菌感染、肺炎、気管支炎を発生しやすい事が明らかとなった。さらに、無処置のSLPIノックアウトマウスの肺においても、炎症を制御する重要な転写因子であるNfkBが核内に移行しており、活性化状態にあることが明らかとなった。通常NfkBの活性化は発癌を促進する作用があると報告されており、NfkBの活性化が強いSLPIノックアウトマウスがウレタン発癌に対して抑制的に働いていることが明らかとなった。NfkB関連シグナルにSLPIが関与している可能性がある。さらにSLPIノックアウトマウスにおける化学発癌の抵抗性がウレタンのみのものであるか検討するため、ウレタン以外の化学発癌の実験系(methylcholanthrene/butylated hydroxytoluene)を施行した。その結果SLPIノックアウトマウスにおいては典型的な腫瘍を形成せず、特徴的な表現系が形成されることが明らかとなった。SLPIが発癌に重要な役割をもっていることが明らかとなったが、発癌物質の違いにより表現型が異なる機序については不明である。
Activation mutations in EGF receptor kinase have the advantages of cell physiology in the bronchiolar region : Implication of anti-apoptotic signals and lung tumorigenesis and metastasis.

NUKIWA Toshihiro, SUZUKI Takuji, INOUE Akira, FUKUHARA Tatsuro, NISHIO Kazuto, KANEHIRA Masahiko

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Scientific Research (B)

Institution: TOHOKU UNIVERSITY

2005 - 2006

More details Close

Backgrounds : The evolving concept of molecular targeting drugs has revolutionized the treatment of cancer. The first success of imatinib targeting the chimera protein of Bcr-abl in hematologic malignancies is followed by drugs for solid tumors, gefitinib or erlotinib, targeting the activation form of EGFR kinase (either deletion or L858R mutation). The latter is unique in facts that (1)Rthe mutation is specific for lung adenocarcinoma, (2)resulting in high affinity for ATP and anti-apoptosis, and (3) somatic but high incidence in far-east Orientals. We hypothesized that this specific EGFR mutation is selected because of the advantages in the respiratory bronchiolar regions. Methods : We used PC9 (EGFR deletion type), 11-18 (EGFR L858R) and A549 (EGFR wild type) cell lines and prepared COS-7 cells with EGFR/wt, EGFR/del, EGFR/L858R. Western blot analysis for in vitro signaling, and in vivo metastatic model using nude mice were performed. Expression microarray (Affymetrix U133 plus 2.0) analysis were conducted using 3 cell lines. Results : 1. In vitro signaling revealed that (1) while PC9 is constitutively active in usual FCS medium, 11-18 or COS-7 showed phosphorylation in Tyr1068 only after the addition of EGF after overnight starvation. (2) The pEGFR/Tyr1068 was detected in the order of COS-7/EGFR wt> COS-7/EGFR del>COS-7. 2. PC9 (1O'6 cells) administered in the cervical vein resulted in tumors only in the lung in 2 months. Micro-metastatic lesions in the bronchiolar region were found using PC9 labeled with Cell Tracker 1 week after administration. 3. Microarray expression analysis of PC9, 11-18, and A549 cell lines revealed two characteristic patterns: (1) PC9=11-18 > A549 (ARHGAP29 etc) or PC9=11-18 < A549 (DKK1 etc). (2) PC9 > 11-18=A549 (FOX03A etc) or PC9 < 11-18=A549 (catenin α 1 etc). Conclusion : Specific EGFR activation mutation showed distinct patterns of phosphrylation signaling. In vivo micro-metastasis was seen in the bronchiolar regions. Two characteristic patterns in the microarray expression analysis using PC9, 11-18, and A549 indicated the possible difference in the EGFR signaling and biological outcome.
NKG2Dリガンド遺伝子導入による抗腫瘍効果増強の検討

井上彰

Offer Organization: 日本学術振興会

System: 科学研究費助成事業

Category: 若手研究(B)

Institution: 東北大学

2004 - 2005

More details Close

肺癌に対するNK細胞などの自然免疫を介した抗腫瘍効果増強の検討を目的として、我々はNK細胞膜表面上に発現するNKG2D受容体のリガンドであるretinoic acid inducible early transcript-1β(RAE-1β)のcDNAを組み込んだRAE-1発現アデノウイルスベクター(AdRAE-1)を作製し実験を行った。 AdRAE-1をRAE-1非発現腫瘍細胞株であるEL-4に感染させ、RAE-1に対するポリクローナル抗体を用いたFACSにてEL-4に新たにRAE-1の発現が得られることを確認した後、RAE-1発現EL-4をC57/BL6マウスに移植した。その結果、対照であるAdNull感染EL-4(RAE-1発現なし)では腫瘍の増大が認められたのに対し、AdRAE-1感染EL-4では、腫瘍は完全に拒絶された。さらに、EL-4が増大した状態のマウスに対して、AdRAE-1を1x10^9pfu投与したところ腫瘍増大の抑制効果が認められた(対照のAdNull群では腫瘍増大傾向に変化なし)。上記の結果に引き続いて、ヒト肺癌における臨床応用を鑑み、共感染させたE1A欠損アデノウイルスベクターをSLPI発現腫瘍内でのみ増殖させるAdSLPI.E1A(Cancer Res 2004:64;4611)をAdRAE-1と併用し、SLPIを発現しているヒト肺癌細胞A549に対する、NK細胞を介した抗腫瘍効果増強の検討を試みた。しかし、A549については移植マウスにおける腫瘍増大が抑制できなかった。上記の結果は、アデノウィルスによるNKG2Dリガンドの遺伝子導入が、自然免疫系を介した腫瘍制御の戦略として有用である可能性を示唆するものの、対象となる腫瘍細胞の特徴によってその効果が異なることも明らかとなり、その機序の解明にはさらなる研究が必要と考えられた。

Show all Show first 5

Other 1

バイオマーカーに基づいた肺癌個別化治療における分子標的治療薬の至適

More details Close

バイオマーカーに基づいた肺癌個別化治療における分子標的治療薬の至適